



(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2002/0164702 A1**

Valenzuela et al. (43) **Pub. Date: Nov. 7, 2002**

(54) **NOVEL TYROSINE KINASE RECEPTORS AND LIGANDS**

Publication Classification

(76) Inventors: **David M. Valenzuela**, Yorktown Heights, NY (US); **David J. Glass**, Cortlandt Manor, NY (US); **David C. Bowen**, Washington, DC (US); **George D. Yancopoulos**, Yorktown Heights, NY (US)

(51) **Int. Cl.⁷** **C12P 21/02**; C12N 5/06; C07H 21/04; C12N 9/00

(52) **U.S. Cl.** **435/69.1**; 435/183; 435/320.1; 435/325; 530/350; 536/23.2

Correspondence Address:

Linda O. Palladino
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 (US)

(57) **ABSTRACT**

The present invention provides for a gene, designated as musk, that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides for an isolated polypeptide which activates MuSK receptor. The invention further provides for a polypeptide which is functionally equivalent to the MuSK activating polypeptide. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the musk gene product. The present invention also provides for diagnostic and therapeutic methods based on molecules that activate MuSK.

(21) Appl. No.: **10/016,283**

(22) Filed: **Nov. 30, 2001**

Related U.S. Application Data

(62) Division of application No. 09/077,955, filed on Sep. 10, 1998, now Pat. No. 6,413,740.

```

ATG TCT GCA CTT CTG ATC CTA GCT CTT GTT GGA GCT GCA GTT GCT GAC
M S A L L I L A L V G A A V A D
TAC AAA GAC GAT GAC GAC AAG AAG AGC CCC TGC CAG CCC AAC CCC TGC
Y K D D D D K K S P C Q P N P C
CAT GGG GCG GCG CCC TGC CGT GTG CTG CCC GAG GGT GGT GCT CAG TGC
H G A A P C R V L P E G G A Q C
GAG TGC CCC CTG GGG CGT GAG GGC ACC TTC TGC CAG ACA GCC TCG GGG
E C P L G R E G T F C Q T A S G
CAG GAC GGC TCT GGG CCC TTC CTG GCT GAC TTC AAC GGC TTC TCC CAC
Q D G S G P F L A D F N G F S H
CTG GAG CTG AGA GGC CTG CAC ACC TTT GCA CGG GAC CTG GGG GAG AAG
L E L R G L H T F A R D L G E K
ATG GCG CTG GAG GTC GTG TTC CTG GCA CGA GGC CCC AGC GGC CTC CTG
M A L E V V F L A R G P S G L L
CTC TAC AAC GGG CAG AAG ACG GAC GGC AAG GGG GAC TTC GTG TCG CTG
L Y N G Q K T D G K G D F V S L
GCA CTG CGG GAC CCG CGC CTG GAG TTC CGC TAC GAC CTG GGC AAG GGG
A L R D R R L E F R Y D L G K G
GCA GCG GTC ATC AGG AGC AGG GAG CCA GTC ACC CTG GGA GCC TGG ACC
A A V I R S R E P V T L G A W T
AGG GTC TCA CTG GAG CGA AAC GGC CGC AAG GGT GCC CTG CGT GTG GGC
R V S L E R N G R K G A L R V G
GAC GGC CCC CGT GTG TTG GGG GAG TCC CCG AAA TCC CGC AAG GTT CCG
D G P R V L G E S P K S R K V P
CAC ACC GTC CTC AAC CTG AAG GAG CCG CTC TAC GTA GGG GGC GCT CCC
H T V L N L K E P L Y V G G A P
GAC TTC AGC AAG CTG GCC CGT GCT GCT GCC GTG TCC TCT GGC TTC GAC
D F S K L A R A A A V S S G F D
GGC GCC ATC CAG CTG GTC TCC CTC GGA GGC CGC CAG CTG CTG ACC CCG
G A I Q L V S L G G R Q L L T P
GAG CAC GTG CTG CGG CAG GTG GAC GTC ACG TCC TTT GCA GGT CAC CCC
E H V L R Q V D V T S F A G H P
TGC ACC CGG GCC TCA GGC CAC CCC TGC CTC AAT GGG GCC TCC TGC GTC
C T R A S G H P C L N G A S C V
CCG AGG GAG GCT GCC TAT GTG TGC CTG TGT CCC GGG GGA TTC TCA GGA
P R E A A Y V C L C P G G F S G
CCG CAC TGC GAG AAG GGG CTG GTG GAG AAG TCA GCC GGG GAC GTG GAT
P H C E K G L V E K S A G D V D

```

Fig. 1A

```

*5  10  15  20  25  30  35  40  45  50  55  60  65  70
*   *   *   *   *   *   *   *   *   *   *   *   *
GAATTOGGCA CGAGCAAACA GTCATTAGTG GACGACTCTA TTGTAATAAA CTGTGCTTTA AAATGTA AAC

75  80  85  90  95 100 105 110 115 120 125 130 135
*   *   *   *   *   *   *   *   *   *   *   *
CAGGGAGOGT TTTTITTOCT CACATTGTGC AGAAGCAAOC TTTCTTCTCG AGCCTGGATT AATC ATG
ID>

140 145 150 155 160 165 170 175 180 185 190
*   *   *   *   *   *   *   *   *   *   *
AGA GAG CTC GTC AAC ATT CCA CTG TTA CAG ATG CTC ACC CTG GTT GGC TTC AGC GGG
R E L V N I P L L Q H L T L V A F S G>

195 200 205 210 215 220 225 230 235 240 245 250
*   *   *   *   *   *   *   *   *   *   *
ACC GAG AAA CTT CCA AAA GGC CCT GTC ATC ACC ACG OCT CTT GAA ACT GTA GAT GGC
T E K L P K A P V I T T P L E T V D A>

255 260 265 270 275 280 285 290 295 300 305
*   *   *   *   *   *   *   *   *   *
TTA GTT GAA GAA GTG GCG ACT TTC ATG TGC GGC GTG GAA TCC TAC CCT CAG CCT GAA
L V E E V A T F M C A V E S Y P Q P E>

310 315 320 325 330 335 340 345 350 355 360 365
*   *   *   *   *   *   *   *   *   *   *
ATT TCT TGG ACC AGA AAT AAA ATT CTC ATC AAG CTG TTT GAC ACC GGC TAC AGC ATC
I S W T R N K I L I K L F D T R Y S I>

370 375 380 385 390 395 400 405 410 415 420
*   *   *   *   *   *   *   *   *   *
OGA GAG AAC GGT CAG CTC CTC ACC ATC CTG AGT GTG GAG GAC AGT GAT GAT GGC ATC
R E N G Q L L T I L S V E D S D D G I>

425 430 435 440 445 450 455 460 465 470 475
*   *   *   *   *   *   *   *   *   *
TAC TGC TGC ACA GGC AAC AAT GGA GTG GGA GGA GCG GTG GAA AGT TGT GGC GGC CTG
Y C C T A N N G V G G A V E S C G A L>

480 485 490 495 500 505 510 515 520 525 530 535
*   *   *   *   *   *   *   *   *   *
CAA GTG AAG ATG AAG OCT AAA ATA ACT CGT CCT CCC ATC AAT GTA AAA ATA ATT GAG
Q V K M K P K I T R P P I N V K I I E>

540 545 550 555 560 565 570 575 580 585 590
*   *   *   *   *   *   *   *   *   *
GGA TTG AAA GCA GTC CTA CCG TGC ACT ACG ATG GGT AAC CCC AAG CCA TCC GTG TCC
G L K A V L P C T T H G N P K P S V S>

595 600 605 610 615 620 625 630 635 640 645 650
*   *   *   *   *   *   *   *   *   *
TGG ATT AAG GGG GAC AGT GCT CTC AGG GAA AAT TCC AGG ATT GCA GTT CTT GAA TCT
W I K G D S A L R E N S R I A V L E S>

655 660 665 670 675 680 685 690 695 700 705
*   *   *   *   *   *   *   *   *   *
GGG AGT TTA AGG ATC CAT AAT GTG CAA AAG GAA GAC GCA GGA CAG TAC CGA TGT GTG
G S L R I H N V Q K E D A G Q Y R C V>

710 715 720 725 730 735 740 745 750 755 760
*   *   *   *   *   *   *   *   *   *
GCA AAA AAC AGC CTG GGC ACA GCT TAC TCC AAA CTG GTG AAG CTG GAA GTG GAG GTT
A K N S L G T A Y S K L V K L E V E V>

765 770 775 780 785 790 795 800 805 810 815 820
*   *   *   *   *   *   *   *   *   *
TTT GCA AGA ATC CTG GGT GCT OCT GAA TCC CAC AAT GTC ACC TTT GGT TCC TTT GTA
F A R I L R A P E S H N V T F G S F V>
    
```

Fig. 1B

```

825 830 835 840 845 850 855 860 865 870 875
* * * * *
ACC CTA CGC TGC ACA GCA ATA GGC ATG OCT GTC CCC AOC ATC AGC TGG ATT GAA AAC
T L R C T A I G M P V P T I S W I E N>

880 885 890 895 900 905 910 915 920 925 930 935
* * * * *
GGA AAT GCT GTT TCT TCA GGT TOC ATT CAA GAG AAT GTG AAA GAC CGA GTG ATT GAC
G N A V S S G S I Q E N V K D R V I D>

940 945 950 955 960 965 970 975 980 985 990
* * * * *
TCA AGA CTC CAG CTC TTT ATC ACA AAG OCA GGA CTC TAC ACA TGC ATA GCT ACC AAT
S R L Q L F I T K P G L Y T C I A T N>

995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045
* * * * *
AAG CAT GGA GAG AAA TTC AGT ACC GCA AAG GCT GCA GOC ACT GTC AGT ATA GCA GAA
K H G E K F S T A K A A A T V S I A E>

1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105
* * * * *
TGG AGC AAA TCA CAG AAA GAA AGC AAA GGC TAC TGT GOC CAG TAC AGA GGG GAG GTG
W S K S Q K E S K G Y C A Q Y R G E V>

1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160
* * * * *
TGT GAT GOC GTC CTG GTG AAA GAC TCT CTT GTC TTC TTC AAC ACC TOC TAT CCC GAC
C D A V L V K D S L V F F N T S Y P D>

1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220
* * * * *
OCT GAG GAG GOC CAA GAG CTG CTG ATC CAC ACT GOG TGG AAT GAA CTC AAG GCT GTG
P E E A Q E L L I H T A W N E L K A V>

1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275
* * * * *
AGC OCA CTC TGC OGA OCA GCT GCC GAG GCT CTG CTG TGT AAT CAC CTC TTC CAG GAG
S P L C R P A A E A L L C N H L F Q E>

1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330
* * * * *
TGC AGC OCT GGA GTG CTA CCT ACT OCT ATG CCC ATT TGC AGA GAG TAC TGC TTG GCA
C S P G V L P T P M P I C R E Y C L A>

1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390
* * * * *
GTA AAG GAG CTC TTC TGT GCA AAG GAA TGG CTG GCA ATG GAA GGG AAG ACC CAC CGC
V K E L F C A K E W L A M E G K T H R>

1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445
* * * * *
GGA CTC TAC AGA TOC GGG ATG CAT TTC CTC CCG GTC CCG GAG TGC AGC AAG CTT CCC
G L Y R S G M H F L P V P E C S K L P>

1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505
* * * * *
AGC ATG CAC CAG GAC CCC ACA GCC TGC ACA AGA-CTG CCG TAT TTA GAT TAT AAA AAA
S M H Q D P T A C T R L P Y L D Y K K>

1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560
* * * * *
GAA AAC ATA ACA ACA TTC CCG TOC ATA ACG TOC TOC AAG COG AGC GTG GAC ATT OCA
E N I T T F P S I T S S K P S V D I P>

1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615
* * * * *
AAC CTG OCT GCC TOC ACG TCT TOC TTC GCC GTC TOG CCT GOG TAC TOC ATG ACT GTC
N L P A S T S S F A V S P A Y S M T V>

```

Fig. 1C

```

1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675
* * * * *
ATC ATC TOC ATC ATG TOC TGC TTT GCG GTG TTT GCT CTC CTC AOC ATC ACT ACT CTC
I I S I M S C F A V F A L L T I T T L>

1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730
* * * * *
TAT TGC TGC OGA AGG AGG AGA GAG TGG AAA AAT AAG AAA AGA GAG TOG GCA GCG GTG
Y C C R R R R E W K N K K R E S A A V>

1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790
* * * * *
AOC CTC ACC ACA TTG OCT TOC GAG CTC CTG CTG GAC AGG CTG CAT CCC AAC OCC ATG
T L T T L P S E L L L D R L H P N P M>

1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845
* * * * *
TAC CAG AGG ATG OCA CTC CTT CTG AAT COC AAG TTG CTC AGC CTG GAG TAT COG AGG
Y Q R M P L L L N P K L L S L E Y P R>

1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900
* * * * *
AAT AAC ATC GAG TAT GTC AGA GAC ATC GGA GAG GGA GCG TTT GGA AGG GTC TTT CAA
N N I E Y V R D I G E G A F G R V F Q>

1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960
* * * * *
GCG AGG GOC OCA GGC TTG CTT OCT TAT GAA COC TTC ACT ATG GTG GCT GTG AAG ATG
A R A P G L L P Y E P F T M V A V K M>

1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015
* * * * *
CTG AAG GAG GAG GOC TCC GCA GAT ATG CAG GCA GAC TTT CAG AGG GAG GCA GOC CTC
L K E E A S A D M Q A D F Q R E A A L>

2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075
* * * * *
ATG GCG GAG TTT GAC AAC COC AAC ATT GTG AAG CTC TTA GGT GTG TGT GCT GTT GGG
M A E F D N P N I V K L L G V C A V G>

2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130
* * * * *
AAG OCA ATG TGC CTG CTC TTT GAA TAT ATG GOC TAT GGT GAC CTC AAT GAG TTC CTC
K P M C L L F E Y M A Y G D L N E F L>

2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185
* * * * *
OGA AGC ATG TOC OCT CAC ACT GTG TGC AGC CTC AGC CAC AGT GAC CTG TOC ACG AGG
R S M S P H T V C S L S H S D L S T R>

2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245
* * * * *
GCT CCG GTG TCC AGC OCT GGT OCT OCA COC CTG TCT TGT GCG GAA CAG CTC TGT ATT
A R V S S P G P P P L S C A E Q L C I>

2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300
* * * * *
GOC AGG CAA GTG GCA GCT GGC ATG GCC TAC CTG TOG GAG OGC AAG TTT GTC CAT OGG
A R Q V A A G M A Y L S E R K F V H R>

2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360
* * * * *
GAC TTA GCT ACC AGG AAC TGC CTG GTT GGA GAG AAC ATG GTG GTG AAA ATT GCA GAC
D L A T R N C L V G E N M V V K I A D>

2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415
* * * * *
TTT GGC CTC TCT AGG AAC ATC TAC TCC GCA GAC TAC TAC AAA GCT GAT GGA AAC GAT
F G L S R N I Y S A D Y Y K A D G N D>

```

Fig. 1D

2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470
* * * * *
GCT ATA OCT ATC OGC TGG ATG OCA OCC GAG TCT ATC TTC TAC AAC OGC TAC AOC ACG
A I P I R W H M P P E S I F Y N R Y T T>

2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530
* * * * *
GAG TCA GAT GTG TGG GCT TAT GGC GTG GTC CTC TGG GAG ATC TTC TCC TAT GGA CTG
E S D V W A Y G V V L W E I F S Y G L>

2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585
* * * * *
CAG OCC TAC TAT GGA ATG GCC CAT GAG GAG GTC ATT TAC TAT GTG AGA GAT GGT AAC
Q P Y Y G H A H E E V I Y Y V R D G H>

2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645
* * * * *
ATC CTT GCC TGC OCT GAG AAC TGT OCC TTG GAA CTG TAC AAC CTT ATG OGC CTA TGT
I L A C P E N C P L E L Y N L H R L C>

2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700
* * * * *
TGG AGC AAG CTG OCT GCA GAC AGA OCC AGC TTC TGC AGT ATC CAC OGC ATC CTG CAG
W S K L P A D R P S F C S I H R I L Q>

2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760
* * * * *
OGC ATG TGC GAG AGA GCA GAG GGA ACG GTA GGC GTC TAA GGTGAOCA TGCTCAAACA
R M C E R A E G T V G V *>

2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830
* * * * *
ACAOCAGGA GGATCTTTC AGACTGOGAG CTGGAGGGAT OCTAAAGCAG AGGGOGNATA AGTNCAGATA

2835 2840 2845 2850 2855 2860 2865
* * * * *
GGAAGAGTTT ATCTCAGGCA GCAOGTNCAG TTGGTTGTT

Fig.2.




Fig.3.




Fig. 4A

```

      10          20          30          40          50          60
      *          *          *          *          *          *
ATG AGA GAG CTC GTC AAC ATT OCA CTG GTA CAT ATT CTT ACT CTG GTT GGC TTC AGC GGA
K R E L V N I P L V H I L T L V A F S Q

      70          80          90          100          110          120
      *          *          *          *          *          *
ACT GAG AAA CTT OCA AAA GCT OCT GTC ATC ACC ACT OCT CTT GAA ACA GTG GAT GGC TTA
T E K L P K A P V I T T P L E T V D A L

      130          140          150          160          170          180
      *          *          *          *          *          *
GTT GAA GAA GTG GCT ACT TTC ATG TGT GCA GTG GAA TCC TAC CCC CAG OCT GAG ATT TCC
V E E V A T F H C A V E S Y P Q P E I S

      190          200          210          220          230          240
      *          *          *          *          *          *
TGG ACT AGA AAT AAA ATT CTC ATT AAA CTC TTT GAC ACC CCC TAC AGC ATC CGG GAG AAT
W T R N K I L I K L F D T R Y S I R E N

      250          260          270          280          290          300
      *          *          *          *          *          *
GGG CAG CTC CTC ACC ATC CTG AGT GTG GAA GAC AGT GAT GAT GGC ATT TAC TGC TGC AGC
G Q L L T I L S V E D S D D G I Y C C T

      310          320          330          340          350          360
      *          *          *          *          *          *
GCC AAC AAT GGT GTG GGA GGA GCT GTG GAG AGT TGT GGA GGC CTG CAA GTG AAG ATG AAA
A N N G V G G A V E S C G A L Q V K K K

      370          380          390          400          410          420
      *          *          *          *          *          *
OCT AAA ATA ACT CGC OCT CCC ATA AAT GTG AAA ATA ATA GAG GGA TTA AAA GCA GTC CTA
P K I T R P P I N V K I I E G L K A V L

      430          440          450          460          470          480
      *          *          *          *          *          *
OCA TGT ACT ACA ATG GGT AAT CCC AAA OCA TCA GTG TCT TGG ATA AAG GGA GAC AGC CCT
P C T T H G N P K P S V S W I K G D S P

      490          500          510          520          530          540
      *          *          *          *          *          *
CTC AGG GAA AAT TCC CGA ATT GCA GTT CTT GAA TCT GGG AGC TTG AGG ATT CAT AAC GTA
L R E N S R I A V L E S G S L R I H N V

      550          560          570          580          590          600
      *          *          *          *          *          *
CAA AAG GAA GAT GCA GGA CAG TAT CGA TGT GTG GCA AAA AAC AGC CTC GGG ACA GCA TAT
Q K E D A G Q Y R C V A K N S L G T A Y

      610          620          630          640          650          660
      *          *          *          *          *          *
TCC AAA GTG GTG AAG CTG GAA GTT GAG GTT TTT GCC AGG ATC CTG CGG GCT CCT GAA TCC
S K V V K L E V E V F A R I L R A P E S

      670          680          690          700          710          720
      *          *          *          *          *          *
CAC AAT GTC ACC TTT GGC TCC TTT GTG ACC CTG CAC TGT ACA GCA ACA GGC ATT CCT GTC
H N V T F G S F V T L H C T A T G I P V

```

Fig. 4B

```

      730          740          750          760          770          780
      *          *          *          *          *          *
    CCC ACC ATC ACC TGG ATT GAA AAC GGA AAT GCT GTT TCT TCT GGG TCC ATT CAA GAG AGT
      P  T  I  T  W  I  E  N  G  N  A  V  S  S  G  S  I  Q  E  S

      790          800          810          820          830          840
      *          *          *          *          *          *
    GTG AAA GAC CGA GTG ATT GAC TCA AGA CTG CAG CTG TTT ATC ACC AAG CCA GGA CTC TAC
      V  K  D  R  V  I  D  S  R  L  Q  L  F  I  T  K  P  G  L  Y

      850          860          870          880          890          900
      *          *          *          *          *          *
    ACA TGC ATA GCT ACC AAT AAG CAT GGG GAG AAG TTC AGT ACT GCC AAG GCT GCA GCC ACC
      T  C  I  A  T  N  K  H  G  E  K  F  S  T  A  K  A  A  A  T

      910          920          930          940          950          960
      *          *          *          *          *          *
    ATC AGC ATA GCA GAA TGG AGT AAA CCA CAG AAA GAT AAC AAA GGC TAC TGC GCC CAG TAC
      I  S  I  A  E  W  S  K  P  Q  K  D  N  K  G  Y  C  A  Q  Y

      970          980          990          1000          1010          1020
      *          *          *          *          *          *
    AGA GGG GAG GTG TGT AAT GCA GTC CTG GCA AAA GAT GCT CTT GTT TTT CTC AAC ACC TCC
      R  G  E  V  C  N  A  V  L  A  K  D  A  L  V  F  L  N  T  S

      1030          1040          1050          1060          1070          1080
      *          *          *          *          *          *
    TAT GCG GAC CCT GAG GAG GCC CAA GAG CTA CTG GTC CAC ACG GCC TGG AAT GAA CTG AAA
      Y  A  D  P  E  E  A  Q  E  L  L  V  H  T  A  W  N  E  L  K

      1090          1100          1110          1120          1130          1140
      *          *          *          *          *          *
    GTA GTG AGC CCA GTC TGC CCG CCA GCT GCT GAG GCT TTG TTG TGT AAC CAC ATC TTC CAG
      V  V  S  P  V  C  R  P  A  A  E  A  L  L  C  N  H  I  F  Q

      1150          1160          1170          1180          1190          1200
      *          *          *          *          *          *
    GAG TGC AGT CCT GGA GTA GTG OCT ACT CCT ATT CCC ATT TGC AGA GAG TAC TGC TTG GCA
      E  C  S  P  G  V  V  P  T  P  I  P  I  C  R  E  Y  C  L  A

      1210          1220          1230          1240          1250          1260
      *          *          *          *          *          *
    GTA AAG GAG CTC TTC TGC GCA AAA GAA TGG CTG GTA ATG GAA GAG AAG ACC CAC AGA GGA
      V  K  E  L  F  C  A  K  E  W  L  V  H  E  E  K  T  H  R  G

      1270          1280          1290          1300          1310          1320
      *          *          *          *          *          *
    CTC TAC AGA TCC GAG ATG CAT TTG CTG TCC GTG CCA GAA TGC AGC AAG CTT CCC AGC ATG
      L  Y  R  S  E  H  H  L  L  S  V  P  E  C  S  K  L  P  S  H

      1330          1340          1350          1360          1370          1380
      *          *          *          *          *          *
    CAT TGG GAC CCC ACG GCC TGT GCC AGA CTG CCA CAT CTA GAT TAT AAC AAA GAA AAC CTA
      H  W  D  P  T  A  C  A  R  L  P  H  L  D  Y  N  K  E  N  L

      1390          1400          1410          1420          1430          1440
      *          *          *          *          *          *
    AAA ACA TTC CCA CCA ATG ACG TCC TCA AAG CCA AGT GTG GAC ATT CCA AAT CTG CCT TCC
      K  T  F  P  P  H  T  S  S  K  P  S  V  D  I  P  N  L  P  S
  
```

Fig. 4C

1450 1460 1470 1480 1490 1500
* * * * * *
TCC TCC TCT TCT TCC TTC TCT GTC TCA CCT ACA TAC TCC ATG ACT GTA ATA ATC TCC ATC
S S S S S F S V S P T Y S N T V I I S I

1510 1520 1530 1540 1550 1560
* * * * * *
ATG TCC AGC TTT GCA ATA TTT GTG CTT CTT ACC ATA ACT ACT CTC TAT TGC TGC CGA AGA
M S S F A I F V L L T I T T L Y C C R R

1570 1580 1590 1600 1610 1620
* * * * * *
AGA AAA CAA TGG AAA AAT AAG AAA AGA GAA TCA GCA GCA GTA ACC CTC ACC ACA CTG CCT
R K Q W K N K K R E S A A V T L T T L P

1630 1640 1650 1660 1670 1680
* * * * * *
TCT GAG CTC TTA CTA GAT AGA CTT CAT CCC AAC CCC ATG TAC CAG AGG ATG CCG CTC CTT
S E L L L D R L H P N P K Y Q R K P L L

1690 1700 1710 1720 1730 1740
* * * * * *
CTG AAC CCC AAA TTG CTC AGC CTG GAG TAT CCA AGG AAT AAC ATT GAA TAT GTG AGA GAC
L N P K L L S L E Y P R N N I E Y V R D

1750 1760 1770 1780 1790 1800
* * * * * *
ATC GGA GAG GGA GCG TTT GGA AGG GTG TTT CAA GCA AGG GCA CCA GGC TTA CTT CCC TAT
I G E G A F G R V F Q A R A P G L L P Y

1810 1820 1830 1840 1850 1860
* * * * * *
GAA CCT TTC ACT ATG GTG GCA GTA AAG ATG CTC AAA GAA GAA GCC TCG GCA GAT ATG CAA
E P F T H V A V K H L K E E A S A D H Q

1870 1880 1890 1900 1910 1920
* * * * * *
GCG GAC TTT CAG AGG GAG GCA GCC CTC ATG GCA GAA TTT GAC AAC OCT AAC ATT GTG AAG
A D F Q R E A A L H A E F D N P N I V K

1930 1940 1950 1960 1970 1980
* * * * * *
CTA TTA GGA GTG TGT GCT GTC GGG AAG CCA ATG TGC CTG CTC TTT GAA TAC ATG GCC TAT
L L G V C A V G K P H C L L F E Y H A Y

1990 2000 2010 2020 2030 2040
* * * * * *
GGT GAC CTC AAT GAG TTC CTC CGC AGC ATG TCC CCT CAC ACC GTG TGC AGC CTC AGT CAC
G D L N E F L R S H S P H T V C S L S H

2050 2060 2070 2080 2090 2100
* * * * * *
AGT GAC TTG TCT ATG AGG GCT CAG GTC TCC AGC CCT GGG CCC CCA CCC CTC TCC TGT GCT
S D L S H R A Q V S S P G P P P L S C A

2110 2120 2130 2140 2150 2160
* * * * * *
GAG CAG CTT TGC ATT GCC AGG CAG GTG GCA GCT GGC ATG GCT TAC CTC TCA GAA CGT AAG
E Q L C I A R Q V A A G H A Y L S E R K

Fig. 4D

```

      2170      2180      2190      2200      2210      2220
      *         *         *         *         *         *
TTT GTT CAC CGA GAT TTA GCC ACC AGG AAC TGC CTG GTG GGC GAG AAC ATG GTG CTG AAA
F V H R D L A T R N C L V G E N H V V K

      2230      2240      2250      2260      2270      2280
      *         *         *         *         *         *
ATT GCC GAC TTT GGC CTC TCC AGG AAC ATC TAC TCA GCA GAC TAC TAC AAA GCT AAT GAA
I A D F G L S R N I Y S A D Y Y K A N E

      2290      2300      2310      2320      2330      2340
      *         *         *         *         *         *
AAC GAC GCT ATC CCT ATC CGT TGG ATG CCA CCA GAG TCC ATT TTT TAT AAC CGC TAC ACT
N D A I P I R W H K P P E S I F Y N R Y T

      2350      2360      2370      2380      2390      2400
      *         *         *         *         *         *
ACA GAG TCT GAT GTG TGG GCC TAT GGC GTG GTC CTC TGG GAG ATC TTC TCC TAT GGC CTG
T E S D V W A Y G V V L W E I F S Y G L

      2410      2420      2430      2440      2450      2460
      *         *         *         *         *         *
CAG CCC TAC TAT GGG ATG GCC CAT GAG GAG GTC ATT TAC TAC GTG CGA GAT GGC AAC ATC
Q P Y Y G H A H E E V I Y Y V R D G N I

      2470      2480      2490      2500      2510      2520
      *         *         *         *         *         *
CTC TCC TGC OCT GAG AAC TGC CCC GTG GAG CTG TAC AAT CTC ATG CGT CTA TGT TGG AGC
L S C P E N C P V E L Y N L H R L C W S

      2530      2540      2550      2560      2570      2580
      *         *         *         *         *         *
AAG CTG OCT GCA GAC AGA CCC AGT TTC ACC AGT ATT CAC CGA ATT CTG GAA CGC ATG TGT
K L P A D R P S F T S I H R I L E R H C

      2590      2600      2610
      *         *         *
GAG AGG GCA GAG GGA ACT GTG AGT GTC TAA
E R A E G T V S V *
    
```

Fig. 5.




Fig. 6.




Fig. 7B.





Fig. 7A.



Fig. 7D.








Fig. 7C.



CONTROL

MuSK -/-








Fig. 10B:




Fig. 11.





Fig. 12.


A. Formation of CNTF Receptor Complex



B. CNTF Receptor Complex With Soluble β Components



C. Formation of Receptor Complex For Agrin







Fig. 13C.




Fig. 14A

10	20	30	40	50	60
* *	* *	* *	* *	* *	* *
MPPLPLEHRP	RQEPGASMLV	RYFMIPCNIC	LILLATSTLG	FAVLLEFLSNY	KPGIHFTPAP
70	80	90	100	110	120
* *	* *	* *	* *	* *	* *
PTPPDVCRGM	LCGFGAVCEP	SVEDPGRASC	VCKKNACPAT	VAPVCGSDAS	TYSNECELQR
130	140	150	160	170	180
* *	* *	* *	* *	* *	* *
AQCNQRRIR	LLRQGPGSR	DPCANVTCSE	GSTCVPSADG	QTASCLCPTT	CFGAPDGTVC
190	200	210	220	230	240
* *	* *	* *	* *	* *	* *
GSDGVDYPSE	CQLLSHACAS	QEHIFKFFNG	PCDPCQGSMS	DLNHICRVNP	RTRHPEMLLR
250	260	270	280	290	300
* *	* *	* *	* *	* *	* *
PENCPAQHTP	ICGDDGVTYE	NDCVMSRIGA	TRGLLLQKVR	SGQCQTRDQC	PETCQFNSVC
310	320	330	340	350	360
* *	* *	* *	* *	* *	* *
LSRRGRPHCS	CDRVTCDSY	RPVCAQDGH	YNNDCWRQQA	ECRQORAIPP	KHQGPCDQTP
370	380	390	400	410	420
* *	* *	* *	* *	* *	* *
SPCHGVQCAF	GAVCTVKNGK	AECECQRVCS	GIYDFVCGSD	GVTYGSVCEL	ESMACTLGRE
430	440	450	460	470	480
* *	* *	* *	* *	* *	* *
IQVARRGPCD	PCGQCRFGSL	CEVETGRCVC	PSECVESAQP	VCGSDGHTYA	SECELHVHAC
490	500	510	520	530	540
* *	* *	* *	* *	* *	* *
THQISLYVAS	AGHCQTCGEK	VCTFGAVCSA	GQCVCPRCEH	PPPGPVCSD	GVTYLSACEL
550	560	570	580	590	600
* *	* *	* *	* *	* *	* *
REAACQQQVQ	IEEAHAGPCE	PAECGSGGSG	SGEDDECEQE	LCRQRGGIWD	EDSEDGPCVC
610	620	630	640	650	660
* *	* *	* *	* *	* *	* *
DFSCQSVPRS	PVCGSDGVTY	GTECDLKKAR	CESQQELYVA	AQGACRGPTL	APLLPVAFPH
670	680	690	700	710	720
* *	* *	* *	* *	* *	* *
CAQTFYGCCQ	DNFTAAQGVG	LAGCPSTCHC	NPHGSYSGTC	DPATGQCSCR	PGVGGRLRCDR
730	740	750	760	770	780
* *	* *	* *	* *	* *	* *
CEPGFWNFRG	IVTDGHSCT	PCSCDPRGAV	RDDCEQMTGL	CSCRPGVAGP	KCGQCPDQVQ
790	800	810	820	830	840
* *	* *	* *	* *	* *	* *
LGHLCCEADP	MTPVTCVEIH	CEFGASCVEK	AGFAQCICPT	LTCPEANSTK	VCGSDGVTYG

Fig. 14B

850	860	870	880	890	900
* *	* *	* *	* *	* *	* *
NECQLKAIAC	RQRLDISTQS	LGPCQESVTP	GASPTSASMT	TPRHILSKTL	PFPHNSLPLS
910	920	930	940	950	960
* *	* *	* *	* *	* *	* *
PGSTTHDWPT	PLPISPHTTV	SIPRSTAWPV	LTVPPTAAS	DVTSLATSIF	SESGSANGSG
970	980	990	1000	1010	1020
* *	* *	* *	* *	* *	* *
DEELSGDEEA	SGGGSGGLEP	FVGSIVVTHG	PPIERASCYN	SPLGCCSDGK	TPSLDSEGSN
1030	1040	1050	1060	1070	1080
* *	* *	* *	* *	* *	* *
CPATKAFQGV	LELEGVEGQE	LFYTPEMADP	KSELFGETAR	SIESTLDDLF	RNSDVKKDFW
1090	1100	1110	1120	1130	1140
* *	* *	* *	* *	* *	* *
SVRLRELPGP	KLVRAIVDVH	FDPTTAFQAS	DVGQALLRQI	QVSRPWALAV	RRPLQEHVRF
1150	1160	1170	1180	1190	1200
* *	* *	* *	* *	* *	* *
LDFDWFPTFF	TGAATGTAA	MATARATTVS	RLPASSVTPR	VYPSHTSRPV	GRTTAPPTTR
1210	1220	1230	1240	1250	1260
* *	* *	* *	* *	* *	* *
RPPTTATNMD	RPRTPGHQQP	SKSCDSQPCL	HGGTCQDQDS	GKGFTCSCTA	GRGGSVCEKV
1270	1280	1290	1300	1310	1320
* *	* *	* *	* *	* *	* *
QPPSMPAFKG	HSFLAFPTLR	AYHTLRLALE	FRALETEGLL	LYNGNARGKD	FLALALLDGR
1330	1340	1350	1360	1370	1380
* *	* *	* *	* *	* *	* *
VQFRFDTGSG	PAVLTSLVVPV	EPGRWHRLEL	SRHWRQGTLS	VDGETPVVGE	SPSGTDGLNL
1390	1400	1410	1420	1430	1440
* *	* *	* *	* *	* *	* *
DTNLVYGGIP	EEQVAMVLDR	TSVGVGLKGC	IRMLDINNQQ	LELSDWQRAA	VQSSGVGECG
1450	1460	1470	1480	1490	1500
* *	* *	* *	* *	* *	* *
DHPCLPNPCH	GGALCQALEA	GMFLCQCPPG	RFGPTCADEK	SPCQPNPCHG	AAPCRVLSSG
1510	1520	1530	1540	1550	1560
* *	* *	* *	* *	* *	* *
GAKCECPLGR	SGTFCQTVLE	TAGSRPFLAD	FNGFSYLELK	GLHTFERDLG	EKMALEMVFL
1570	1580	1590	1600	1610	1620
* *	* *	* *	* *	* *	* *
ARGPSGLLLY	NGQKTGKGD	FVSLALHNRH	LEFCYDLGKG	AAVIRSKEPI	ALGTWVRVFL
1630	1640	1650	1660	1670	1680
* *	* *	* *	* *	* *	* *
ERNRKGALQ	VGDGPRVLGE	SPKSRKVPHT	MLNLKEPLYI	GGAPDFSKLA	RGAAVSSGFS

▲
Y-site

Fig. 14C

1690	1700	1710	1720	1730	1740
* * * *	* * * *	* * * *	* * * *	* * * *	* * * *
GVIQLVSLRG	HQLLTQEHVL	RAVDVSPFAD	HPCTQALGNP	CLNGGSCVPR	EATYECLCPG
1750	1760	1770	1780	1790	1800
* * * *	* * * *	* * * *	* * * *	* * * *	* * * *
GFSGLHCEKG	LVEKSVGDL E	TLAFDGRTYI	EYLN AVIESE	KALQSNHFEL	SLRTEATQGL
			▲ Z-site		
1810	1820	1830	1840	1850	1860
* * * *	* * * *	* * * *	* * * *	* * * *	* * * *
VLWIGKAAER	ADYMALAIVD	GHLQLSYDLG	SQPVVLRSTV	KVNTNRWLRI	RAHREHREGS
1870	1880	1890	1900	1910	1920
* * * *	* * * *	* * * *	* * * *	* * * *	* * * *
LQVGNEAPVT	GSSPLGATQL	DTDGALWLGG	LQKLPVGQAL	PKAYGTGFVG	CLRDVVVGHR
1930	1940				
* * * *	* * * *				
QLHLL EDAVT	KPELRPCPTP	*			

Fig. 15A

```

ATG TCT GCA CTT CTG ATC CTA GCT CTT GTT GGA GCT GCA GTT GCT GAC
M S A L L I L A L V G A A V A D
TAC AAA GAC GAT GAC GAC AAG AAG AGC CCC TGC CAG CCC AAC CCC TGC
Y K D D D D K K S P C Q P N P C
CAT GGG GCG GCG CCC TGC CGT GTG CTG CCC GAG GGT GGT GCT CAG TGC
H G A A P C R V L P E G G A Q C
GAG TGC CCC CTG GGG CGT GAG GGC ACC TTC TGC CAG ACA GCC TCG GGG
E C P L G R E G T F C Q T A S G
CAG GAC GGC TCT GGG CCC TTC CTG GCT GAC TTC AAC GGC TTC TCC CAC
Q D G S G P F L A D F N G F S H
CTG GAG CTG AGA GGC CTG CAC ACC TTT GCA CGG GAC CTG GGG GAG AAG
L E L R G L H T F A R D L G E K
ATG GCG CTG GAG GTC GTG TTC CTG GCA CGA GGC CCC AGC GGC CTC CTG
M A L E V V F L A R G P S G L L
CTC TAC AAC GGG CAG AAG ACG GAC GGC AAG GGG GAC TTC GTG TCG CTG
L Y N G Q K T D G K G D F V S L
GCA CTG CGG GAC CGC CGC CTG GAG TTC CGC TAC GAC CTG GGC AAG GGG
A L R D R R L E F R Y D L G K G
GCA GCG GTC ATC AGG AGC AGG GAG CCA GTC ACC CTG GGA GCC TGG ACC
A A V I R S R E P V T L G A W T
AGG GTC TCA CTG GAG CGA AAC GGC CGC AAG GGT GCC CTG CGT GTG GGC
R V S L E R N G R K G A L R V G
GAC GGC CCC CGT GTG TTG GGG GAG TCC CCG AAA TCC CGC AAG GTT CCG
D G P R V L G E S P K S R K V P
CAC ACC GTC CTC AAC CTG AAG GAG CCG CTC TAC GTA GGG GGC GCT CCC
H T V L N L K E P L Y V G G A P
GAC TTC AGC AAG CTG GCC CGT GCT GCT GCC GTG TCC TCT GGC TTC GAC
D F S K L A R A A A V S S G F D
GGC GCC ATC CAG CTG GTC TCC CTC GGA GGC CGC CAG CTG CTG ACC CCG
G A I Q L V S L G G R Q L L T P
GAG CAC GTG CTG CGG CAG GTG GAC GTC ACG TCC TTT GCA GGT CAC CCC
E H V L R Q V D V T S F A G H P
TGC ACC CGG GCC TCA GGC CAC CCC TGC CTC AAT GGG GCC TCC TGC GTC
C T R A S G H P C L N G A S C V
CCG AGG GAG GCT GCC TAT GTG TGC CTG TGT CCC GGG GGA TTC TCA GGA
P R E A A Y V C L C P G G F S G
CCG CAC TGC GAG AAG GGG CTG GTG GAG AAG TCA GCG GGG GAC GTG GAT
P H C E K G L V E K S A G D V D
  
```

Fig. 15B

```

ACC TTG GCC TTT GAC GGG CGG ACC TTT GTC GAG TAC CTC AAC GCT GTG
T L A F D G R T F V E Y L N A V

ACC GAG AGC GAA CTG GCC AAT GAG ATC CCC GTC GAG AAG GCA CTG CAG
T E S E L A N E I P V E K A L Q
Z-insert

AGC AAC CAC TTT GAA CTG AGC CTG CGC ACT GAG GCC ACG CAG GGG CTG
S N H F E L S L R T E A T Q G L

GTG CTC TGG AGT GGC AAG GCC ACG GAG CGG GCA GAC TAT GTG GCA CTG
V L W S G K A T E R A D Y V A L

GCC ATT GTG GAC GGG CAC CTG CAA CTG AGC TAC AAC CTG GGC TCC CAG
A I V D G H L Q L S Y N L G S Q

CCC GTG GTG CTG CGT TCC ACC GTG CCC GTC AAC ACC AAC CGC TGG TTG
P V V L R S T V P V N T N R W L

CGG GTC GTG GCA CAT AGG GAG CAG AGG GAA GGT TCC CTG CAG GTG GGC
R V V A H R E Q R E G S L Q V G

AAT GAG GCC CCT GTG ACC GGC TCC TCC CCG CTG GGC GCC ACG CAG CTG
N E A P V T G S S P L G A T Q L

GAC ACT GAT GGA GCC CTG TGG CTT GGG GGC CTG CCG GAG CTG CCC GTG
D T D G A L W L G G L P E L P V

GGC CCA GCA CTG CCC AAG GCC TAC GGC ACA GGC TTT GTG GGC TGC TTG
G P A L P K A Y G T G F V G C L

CGG GAC GTG GTG GTG GGC CGG CAC CCG CTG CAC CTG CTG GAG GAC GCC
R D V V V G R H P L H L L E D A

GTC ACC AAG CCA GAG CTG CGG CCC TGC CCC ACC CCA TGA
V T K P E L R P C P T P *
    
```

Fig.16.





Fig.17.



NOVEL TYROSINE KINASE RECEPTORS AND LIGANDS

[0001] This application claims priority of U.S. application Ser. No. 08/644,271 filed May 10, 1996 and of U.S. Provisional Application No. 60/008,657 filed Dec. 15, 1995, each of which is incorporated by reference herein.

[0002] Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application.

INTRODUCTION

[0003] The present invention provides for a novel receptor molecule, a novel molecule capable of activating the receptor, and methods of making and use thereof.

BACKGROUND OF THE INVENTION

[0004] The ability of polypeptide ligands to bind cells and thereby elicit a phenotypic response such as cell growth, survival or differentiation in such cells is often mediated through receptor tyrosine kinases. The extracellular portion of each receptor tyrosine kinase (RTK) is generally the most distinctive portion of the molecule, as it provides the protein with its ligand-recognizing characteristic. Binding of a ligand to the extracellular domain results in signal transduction via an intracellular tyrosine kinase catalytic domain which transmits a biological signal to intracellular target proteins. The particular array of sequence motifs of this cytoplasmic, catalytic domain determines its access to potential kinase substrates (Mohammadi, et al., 1990, Mol. Cell. Biol., 11: 5068-5078; Fantl, et al., 1992, Cell, 69:413-413).

[0005] The tissue distribution of a particular tyrosine kinase receptor within higher organisms provides relevant data as to the biological function of the receptor. For example, the localization of a Trk family receptor, TrkB, in tissue provided some insight into the potential biological role of this receptor, as well as the ligands that bind this receptor (referred to herein as cognates). Thus, for example, in adult mice, trkB was found to be preferentially expressed in brain tissue, although significant levels of trkB mRNAs were also observed in lung, muscle, and ovaries. Further, trkB transcripts were detected in mid and late gestation embryos. In situ hybridization analysis of 14 and 18 day old mouse embryos indicated that trkB transcripts were localized in the central and peripheral nervous systems, including brain, spinal cord, spinal and cranial ganglia, paravertebral trunk of the sympathetic nervous system and various innervation pathways, suggesting that the trkB gene product may be a receptor involved in neurogenesis and early neural development as well as play a role in the adult nervous system.

[0006] The cellular environment in which an RTK is expressed may influence the biological response exhibited upon binding of a ligand to the receptor. Thus, for example, when a neuronal cell expressing a Trk receptor is exposed to a neurotrophin which binds that receptor, neuronal survival and differentiation results. When the same receptor is expressed by a fibroblast, exposure to the neurotrophin results in proliferation of the fibroblast (Glass, et al., 1991, Cell 66:405-413). Thus, it appears that the extracellular

domain provides the determining factor as to the ligand specificity, and once signal transduction is initiated the cellular environment will determine the phenotypic outcome of that signal transduction.

[0007] A number of RTK families have been identified based on sequence homologies of their intracellular domains. For example, two members of the TIE (tyrosine kinase with immunoglobulin and EGF homology domains) family, known as TIE-1 and TIE-2, have 79% sequence homology in their intracellular region (Maisonpierre, et al., 1993, Oncogene 8:1631-1637). Although these receptors share similar motifs in their extracellular domain, only 32% of the sequences are identical.

[0008] A receptor having a kinase domain that is related to the Trk family has been identified in the electric ray *Torpedo californica* and may play a role in motor neuron induced synapses on muscle fibers. Jennings, et al. Proc. Natl. Acad. Sci. USA 90: 2895-2899 (1993). This kinase was isolated from the electric organ, a tissue which is a specialized form of skeletal muscle. The tyrosine kinase domain of this protein is related to the Trk family, while the extracellular domain is somewhat divergent from the Trks. The protein was found to be expressed at high levels in Torpedo skeletal muscle, and at much lower levels in adult Torpedo brain, spinal cord, heart, liver and testis.

[0009] Often such novel RTKs are identified and isolated by searching for additional members of known families of tyrosine kinase receptors using, for example, PCR-based screens involving known regions of homology among Trk family members. (See, for example, Maisonpierre, et al., 1993, Oncogene 8: 1631-1637). Isolation of such so called "orphan" tyrosine kinase receptors, for which no ligand is known, and subsequent determination of the tissues in which such receptors are expressed, provides insight into the regulation of the growth, proliferation and regeneration of cells in target tissues. The identification and isolation of novel RTKs may be used as a means of identifying new ligands or activating molecules that may then be used to regulate the survival, growth, differentiation and/or regeneration of cells expressing the receptors. Further, because RTKs appear to mediate a number of important functions during development, the identification and isolation of such receptors, ligands and activating molecules enhances our understanding of developmental processes and may improve our ability to diagnose or treat abnormal conditions.

[0010] For example, the above described methods may be used to study an event that occurs during development of the neuromuscular junction (NMJ)—the localization of acetylcholine receptors at the synapse. It has long been known that important signals are exchanged across the NMJ (Nitkin et al., 1987, J.Cell.Biol. 105: 2471-2478; Hall, Z. W. and Sanes, J. R., 1993, Cell/Neuron (Suppl.) 72/10: 99-121; Bowe, M. A. and Fallon, J. R., 1995, Ann. Rev. Neurosci. 18: 443-462; Sanes, J. R., 1995, Devel. Biol. 6: 163-173; Burden, S. J., et al., 1995, Devel. Biol. 6: 59-65). These signals include the chemical transmitter, acetylcholine, which is released from vesicles in the nerve terminal, recognized by acetylcholine receptors (AChRs) on the muscle, and ultimately results in electrical activation and contraction of the muscle.

[0011] Muscle also provides neurotrophic factors that support survival of motor neurons (DeChiara, T. et al., 1995,

Cell 83: 313-322), and the nerve may in turn provide myotrophic factors that maintain muscle mass (Helgren, M. E., et al., 1994, *Cell* 76: 493-504). Reciprocal signaling interactions are also critical both for the formation and maintenance of the neuromuscular junction itself. Such signals regulate recognition of nerve-to-muscle contact, arrest the growth of the incoming nerve ending, and induce formation of a highly specialized nerve terminal marked by a polarized arrangement of synaptic vesicles and active zones. Simultaneously, precisely juxtaposed with respect to the nerve terminal, a complex molecular apparatus forms on the muscle membrane. This specialized postsynaptic structure, termed the motor endplate, comprises a tiny patch on the muscle membrane which is characterized by a dense clustering of particular proteins; some of these may receive nerve-derived signals, as AChRs are known to do, while others may be involved in creating the molecular scaffold for this post-synaptic specialization.

[0012] Signals produced by the nerve induce postsynaptic clusters by at least two mechanisms. First, these signals can induce redistribution of pre-existing molecules that are initially expressed throughout the myofiber, and second, they can induce localized transcription of specific genes only by subsynaptic nuclei underlying the NMJ. Between the nerve terminal and the motor endplate is a narrow synaptic cleft containing a complex basal lamina. This basal lamina is distinguished from the adjacent extracellular matrix by the accumulation of a number of proteins, such as acetylcholinesterase and s-laminin. The synaptic basal lamina also serves as a reservoir for signaling molecules exchanged between nerve and muscle.

[0013] While the reciprocal interactions between nerve and muscle have been intensively explored for decades, many questions still remain concerning the precise nature of the signals involved in formation of the NMJ. The realization that empty sheaths of the synaptic basal lamina could induce formation of both nerve terminal specializations and motor endplates suggested that key signaling molecules might be embedded in the extracellular matrix (Sanes, J. R. et al., 1978, *J.Cell. Biol.* 78: 176-198; Burden, S. J., et al., 1979, *J.Cell. Biol.* 82: 412-425; McMahan, U. J. and Slater, C. R., 1984, *J.Cell. Biol.* 98: 1453-1473; Kuffler, D. P., 1986, *J.Comp. Neurol.* 250: 228-235). Indeed, recent findings indicate that a protein discovered for its AChR-inducing activity and thus termed ARIA (Jessell, T. M., et al., 1979, *PNAS (USA)* 76: 5397-5401; Falls, D. L., et al., 1990, *Cold Spring Harbor Symp. Quant. Biol.* 55: 397-406; Falls, D. L., et al., 1993, *Cell* 72: 801-815) which can increase the expression of several of the AChR subunit genes (Harris, D. A., 1989, et al., *Nature* 337: 173-176; Martinou, J.-C., et al., 1991, *PNAS (USA)* 88: 7669-7673; Jo, S. A., et al., 1995, *Nature* 373: 158-161; Chu, G. C., et al., 1995, *Neuron* 14: 329-339), is localized to the synaptic basal lamina (Jo, S. A., et al., 1995, *Nature* 373: 158-161; Goodearl, A. D., et al., 1995, *J.Cell. Biol.* 130: 1423-1434). Molecular cloning has revealed that ARIA corresponds to a factor alternatively referred to as neuregulin, NDF, heregulin or glia growth factor, and binds to the erbB family of RTKs (Carraway, K. L. and Burden, S. J., 1995, *Curr. Opin. Neurobiol.* 5: 606-612). Interestingly, neuregulin production has been demonstrated in motor neurons and neuregulin receptors, erbB3 and erbB4, have recently been localized to the motor endplate, supporting the idea that nerve-derived neuregulin provides an important signal to muscle that regulates tran-

scription from subsynaptic nuclei (Altiok, N., et al., 1995, *EMBO J.* 14: 4258-4266; Moscoso, L. M., et al., 1995, *Dev. Biol.* 172: 158-169; Zhu, X., et al., 1995, *EMBO J.* 14: 5842-5848).

[0014] Another protein, known as agrin, was isolated from the synaptic basal lamina based on its ability to cause redistribution of pre-existing AChRs into clusters on the surface of cultured myotubes (Godfrey, E. W., et al., 1984, *J.Cell. Biol.* 99: 615-627; Rupp, F., et al., 1991, *Neuron* 6: 811-823; Tsim, K. W., et al., 1992, *Neuron* 8: 677-689). In contrast to neuregulin, agrin does not appear to regulate AChR expression. However, agrin causes the clustering of a number of synaptic components, along with AChRs, in cultured myotubes (Wallace, B. G., 1989, *J.Neurosci.* 9: 1294-1302).

[0015] A variety of data are consistent with the notion that agrin also acts *in vivo* to induce and maintain the postsynaptic membrane specialization. Most important among these are the findings that the most active forms of agrin are exclusively made by neurons and are deposited in the synaptic basal lamina (Ruegg, M. A., et al., 1992, *Neuron* 8: 691-699; Ferns, M., et al., 1993, *Neuron* 11: 491-502; Hoch, W., et al., 1993, *Neuron* 11: 479-490), and that antibodies to agrin block nerve-induced clustering of AChRs on cultured myotubes (Reist, N. E., et al., 1992, *Neuron* 8: 865-868).

[0016] The precise mechanism of action of agrin remains a mystery (Sealock, R. and Froehner, S. C., 1994, *Cell* 77: 617-619). Agrin is known to induce tyrosine phosphorylation of AChRs, and inhibitors of tyrosine phosphorylation block agrin-mediated clustering (Wallace, B. G., et al., 1991, *Neuron* 6: 869-878; Wallace, B. G., 1994, *J.Cell. Biol.* 125: 661-668; Qu, Z. and Haganir, R. L., 1994, *J.Neurosci.* 14: 6834-6841; Wallace, B. G., 1995, *J.Cell. Biol.* 128: 1121-1129).

[0017] Intriguing recent findings have revealed that agrin can directly bind to α -dystroglycan, an extrinsic peripheral membrane protein that is attached to the cell surface by covalent linkage to β -dystroglycan, which in turn couples to the intracellular cytoskeletal scaffold via an associated protein complex (Bowe, M. A., et al., 1994, *Neuron* 12: 1173-1180; Campanelli, J. T., et al., 1994, *Cell.* 77: 673-674; Gee, S. H., et al., 1994, *Cell* 77: 675-686; Sugiyama, J., et al., 1994, *Neuron* 13: 103-115; Sealock, R. and Froehner, S. C., 1994, *Cell* 77: 617-619).

[0018] Extrasynaptically, the dystroglycan complex binds laminin on its extracellular face, and couples to the actin scaffold via a spectrin-like molecule known as dystrophin. At the synapse however, agrin (via its own laminin-like domains) may be able to substitute for laminin, whereas utrophin (a dystrophin related protein) replaces dystrophin as the link to actin (reviewed in (Bowe, M. A. and Fallon, J. R., 1995, *Ann. Rev. Neurosci.* 18: 443-462)). The dystroglycan complex co-clusters with AChRs in response to agrin *in vitro* and components of this complex are concentrated at the endplate *in vivo* (reviewed in (Bowe, M. A. and Fallon, J. R., 1995, *Ann. Rev. Neurosci.* 18: 443-462)).

[0019] Recent evidence suggests that a 43 kD cytoplasmic protein, known as rapsyn, anchors AChRs to a sub-synaptic cytoskeleton complex, probably via interactions with the dystroglycan complex (Cartaud, J. and Changeux, J. P., 1993, *Eur. J. Neurosci.* 5: 191-202; Apel, E. D., et al., 1995,

Neuron 15: 115-126). Gene disruption studies reveal that rapsyn is absolutely necessary for clustering of AChRs, as well as of the dystroglycan complex. However, other aspects of NMJ formation, involving presynaptic differentiation and synapse-specific transcription, are seen in mice lacking rapsyn (Gautam, M., et al., 1995, Nature 377: 232-236).

[0020] Despite the findings that agrin can bind directly to α -dystroglycan, and that AChRs and the dystroglycan complex are linked and co-cluster in response to agrin, the role of dystroglycan as an agrin receptor remains unclear (Sealock, R. and Froehner, S. C., 1994, Cell 77: 617-619; Ferns, M., et al., 1996, J. Cell Biol. 132: 937-944). It has recently been reported that a 21kD fragment of chick agrin is sufficient to induce AChR aggregation (Gesemann, M., et al., 1995, J. Cell. Biol. 128: 625-636). Dystroglycan could be directly involved in activating signaling pathways that appear to be required for clustering, such as those involving tyrosine phosphorylation, by an unknown mechanism (for example, via association with a cytoplasmic tyrosine kinase).

[0021] Alternatively, dystroglycan could be involved in couplings of agrin not only to AChRs but to a novel signaling receptor. It also remains possible that dystroglycan does not play an active or required role in initiating clustering, and is merely among an assortment of post-synaptic molecules that undergo clustering. Recent evidence indicates that the agrin fragment that is active in inducing AChR aggregation does not bind to α -dystroglycan and a structural role in aggregation, rather than a signal transfer role, has been proposed for the binding of agrin to α -dystroglycan (Gesemann, M., et al., 1996, Neuron 16: 755-767).

SUMMARY OF THE INVENTION

[0022] The present invention provides for a novel tyrosine kinase, termed "MuSK" for "muscle specific kinase," that is expressed in normal and denervated muscle, as well as other tissues including heart, spleen, ovary or retina (See Valenzuela, D., et al., 1995, Neuron 15: 573-584). The novel tyrosine kinase has alternatively been referred to as "Dmk" for "denervated muscle kinase." (See PCT International Application No. PCT/US94/08039 published Feb. 1, 1996 as WO 96/02643 entitled Denervated Muscle Kinase (DMK), A Receptor Of The Tyrosine Kinase Superfamily). Thus, the terms MuSK and Dmk may be used interchangeably. The protein appears to be related to the Trk family of tyrosine kinases.

[0023] The present invention further provides for an isolated nucleic acid molecule encoding MuSK.

[0024] The present invention also provides for a protein or peptide that comprises the extracellular domain of MuSK and the nucleic acid which encodes such extracellular domain. The invention further provides for vectors comprising an isolated nucleic acid molecule encoding MuSK or its extracellular domain, which can be used to express MuSK in bacteria, yeast and mammalian cells.

[0025] The present invention also provides for use of the MuSK receptor or its extracellular or intracellular domain to screen for drugs that interact with or activate MuSK. Novel agents that bind to and/or activate the receptor described herein may mediate survival, proliferation and differentiation in cells naturally expressing the receptor, but also may

mediate survival, proliferation or differentiation when used to treat cells engineered to express the receptor.

[0026] In particular embodiments, the extracellular domain (soluble receptor) of MuSK is utilized in screens for cognate ligands and activating molecules. For example, the MuSK receptor activating molecule described herein may be used in a competition assay to identify agents capable of acting as receptor agonists or antagonists by competing the agents with MuSK activating molecule for phosphorylation of the MuSK receptor. Specifically, the active portion of human agrin described herein may be used as the MuSK activating molecule in a competition assay to screen for agents capable of acting as receptor agonists or antagonists.

[0027] The term "MuSK activating molecule" as used herein refers to a molecule which is capable of inducing phosphorylation of the MuSK receptor in the context of a differentiated muscle cell. One such activating molecule is agrin as described in the Examples set forth herein.

[0028] The present invention also provides for nucleic acid probes, capable of hybridizing with a sequence included within the nucleotide sequence encoding human MuSK or its activating molecule, useful for the detection of MuSK expressing tissue or MuSK activating molecule-expressing tissue in humans and animals. The invention further provides for antibodies capable of specifically binding MuSK or MuSK activating molecule. The antibodies may be polyclonal or monoclonal.

[0029] The present invention also has diagnostic and therapeutic utilities. In particular embodiments of the invention, methods of detecting aberrancies in the function or expression of the receptor described herein may be used in the diagnosis of muscular or other disorders. In other embodiments, manipulation of the receptor, agonists which bind this receptor, or receptor activating molecules may be used in the treatment of neurological diseases or diseases of muscle or neuromuscular unit disorders, including, but not limited to, muscular dystrophy and muscle atrophy. In further embodiments, the extracellular domain of the receptor is utilized as a blocking agent.

[0030] The present invention also provides for an isolated and purified polypeptide which activates MuSK receptor. In one embodiment, the polypeptide of the invention is encoded by a nucleotide sequence comprising the coding region of the active portion of human agrin contained in the vector designated as pBluescript human Agrin-1 (pBL-hAgrin1) that was deposited with the American Type Culture Collection on Dec. 12, 1995 under ATCC Accession No. 97378. The present invention further provides for an isolated polypeptide which is functionally equivalent to this polypeptide.

[0031] The invention further provides for an isolated and purified nucleic acid molecule comprising a nucleotide sequence encoding the active portion of human agrin, wherein the nucleotide sequence is selected from the group consisting of:

[0032] (a) the nucleotide sequence comprising the coding region of the active portion of human agrin contained in the vector designated as pBL-hAgrin 1 (ATCC Accession No. 97378);

[0033] (b) a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of (a) and which encodes the active portion of human agrin; and

[0034] (c) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a) or (b) and which encodes the active portion of human agrin.

[0035] The invention also provides for the above-described nucleic acid molecule which additionally contains a nucleotide sequence so that the encoded polypeptide contains the eight amino acids ELANEIPV at the position corresponding to amino acid position 1780 as shown in FIG. 14.

[0036] The invention also provides for a method of promoting the growth, survival or differentiation of a MuSK receptor expressing cell comprising administering to the MuSK receptor expressing cell an effective amount of agrin or a derivative of agrin. The method may be practiced in vitro or in vivo. In one embodiment of this method, the agrin is human agrin. In another embodiment of this method, the MuSK receptor expressing cell is a cell which is normally found in the heart, spleen, ovary, retina or skeletal muscle. In another embodiment, the MuSK receptor expressing cell is a cell which has been genetically engineered to express the MuSK receptor.

[0037] The present invention also includes a method of treating a patient suffering from a muscle disease or neuromuscular disorder comprising administering to the patient an effective amount of agrin or a derivative thereof. By way of non-limiting example, the agrin may be human agrin and the derivative may be the active portion of the human agrin molecule.

[0038] The present invention also includes an antibody capable of specifically binding human agrin. More specifically, the invention includes an antibody capable of specifically binding the active portion of human agrin. The antibody may be monoclonal or polyclonal. The invention further provides a method of detecting the presence of human agrin in a sample comprising:

[0039] a) reacting the sample with an antibody capable of specifically binding human agrin under conditions whereby the antibody binds to human agrin present in the sample; and

[0040] b) detecting the bound antibody, thereby detecting the presence of human agrin in the sample.

[0041] The antibody used may be monoclonal or polyclonal. The sample may be biological tissue or body fluid. The biological tissue may be brain, muscle, or spinal cord. The body fluid may be cerebrospinal fluid, urine, saliva, blood, or a blood fraction such as serum or plasma.

[0042] The invention further provides for an isolated and purified nucleic acid molecule comprising a nucleotide sequence encoding human muscle specific kinase (MuSK) receptor, wherein the nucleotide sequence is selected from the group consisting of:

[0043] (a) the nucleotide sequence comprising the coding region of the human MuSK receptor as set forth in FIG. 4;

[0044] (b) a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of (a) and which encodes a human MuSK receptor; and

[0045] (c) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a) or (b) and which encodes a human MuSK receptor.

BRIEF DESCRIPTION OF THE FIGURES

[0046] FIG. 1—Nucleotide and deduced amino acid (single letter code) sequences of rat musk. The nucleotide sequence encoding mature MuSK begins around nucleotide 192.

[0047] FIG. 2—Northern blot showing distribution of musk in the rat during early development. Lane 1: Total embryo E9; Lane 2: Total embryo E11; Lane 3: Placenta E11; Lane 4: Embryo head E12; Lane 5: Embryo body E12; Lane 6: Embryo spinal cord E12; Lane 7: Placenta E12; Lane 8: Embryo head E13; Lane 9: Embryo body E13; Lane 10: Embryo brain E17; Lane 11: Embryo brain P1; Lane 12: Embryo brain P10; Lane 13: Embryo brain P19; Lane 14: Adult brain; Lane 15: Adult muscle; Lane 16: Adult denervated muscle; where day of sperm positivity is designated as day E1, and day of birth is designated as day P1.

[0048] FIG. 3—Northern blot showing distribution of musk in adult rat tissues. Lane 1: Brain; Lane 2: Olfactory bulb; Lane 3: Cortex; Lane 4: Hippocampus; Lane 5: Thalamus/hypothalamus; Lane 6: Midbrain; Lane 7: Hindbrain; Lane 8: Cerebellum; Lane 9: Spinal Cord; Lane 10: Thymus; Lane 11: Spleen; Lane 12: Liver; Lane 13: Kidney; Lane 14: Lung; Lane 15: Sciatic Nerve; Lane 16: Retina; Lane 17: Heart; Lane 18: Ovary; Lane 19: Muscle; Lane 20: Denervated muscle.

[0049] FIG. 4—Nucleotide and deduced amino acid (single letter code) sequences of human MuSK receptor.

[0050] FIG. 5—Schematic representation of genomic DNA encompassing the three kinase domain exons of the mouse MuSK gene, of the targeting vector constructed, and of a mutant locus following successful targeting. The three exons of the MuSK kinase domain are indicated as black boxes, containing the indicated kinase subdomains (SD). The PGK-neo and MC1-tk cassettes are indicated as open boxes. The novel EcoRI (R) and NcoI (N) fragments generated following successful targeting are labeled. The 5' EcoRI/HpaI probe used to detect the endogenous and mutant EcoRI fragments was derived from genomic DNA not included in the targeting construct. B, BamHI; Hp, HpaI; S, SpeI (sites included within parentheses are destroyed in the cloning process).

[0051] FIG. 6—MuSK Knockout Mice—Southern blot of tail DNA from wild-type, heterozygous and homozygous F2 progeny showing the endogenous and mutant EcoRI fragments detected by the 5' RI/HpaI probe, as well as the endogenous NcoI fragments detected by the kinase region probe, which are absent in the homozygous mutant.

[0052] FIGS. 7A-7D—Post-mortem histological analysis of lung demonstrating that the alveoli air sacs in the MuSK^{-/-} newborn are not expanded (FIG. 7A) as they are in the lung of the control littermate (FIG. 7B), indicating

that mutant pups do not take a single breath. Post-mortem histological analysis of hindlimb musculature reveals that $\text{MuSK}^{-/-}$ mice (**FIG. 7C**) possess grossly normal muscle architecture similar to that of control mice (**FIG. 7D**).

[0053] **FIGS. 8A-8C**—Agrin induces AChR clustering in myotubes from control but not $\text{MuSK}^{-/-}$ mice. Myotubes derived from control and $\text{MuSK}^{-/-}$ mice were treated overnight with varying concentrations of agrin_{4,8}, stained with rhodamine-conjugated α -bungarotoxin (α -BGT) to label surface AChRs, and then either photographed at 64 \times magnification under rhodamine optics (**FIG. 8A**, challenge with 100 nM agrin depicted) or subjected to AChR cluster quantitation (**FIG. 8B**, each point represents the mean \pm SEM of forty myotube segments). Total AChRs on the myotubes before agrin treatment was determined by binding with ¹²⁵I- α -BGT (**FIG. 8C**, each bar represents the mean \pm SEM CPM bound per μ g of total cell protein (control: N=6; $\text{MuSK}^{-/-}$: N=5).

[0054] **FIGS. 9A-9D**—c-agrin_{4,8} and c-agrin_{0,8} specifically induce rapid tyrosine phosphorylation of MuSK receptors. C2C12 and primary rat myoblasts were differentiated into myotubes and stimulated with conditioned media from COS cells transfected with a plasmid control (Mock) or plasmids encoding the various forms of soluble agrin, with conditioned media containing neuregulin, or with purified bFGF or insulin, as labelled. Stimulations were for ten minutes using 10 nM concentrations of the various factors, except as indicated in **FIGS. 9C and 9D**. Following factor challenges, the cells were lysed and subjected to immunoprecipitations (I.P.) for either the MuSK or ErbB3 receptors as indicated, then immunoblotted for phosphotyrosine levels. Only agrins containing the eight amino acid insert at the Z position, but not other factors, could induce MuSK phosphorylation (**FIG. 9A**). Agrin could not induce phosphorylation of another muscle receptor, ErbB3 (**FIG. 9B**). MuSK phosphorylation occurred at low agrin concentrations (**FIG. 9C**) and very rapidly in response to agrin (**FIG. 9D**).

[0055] **FIGS. 10A & 10B**—Agrin can not detectably bind to the isolated ectodomain of MuSK. Agrin was assayed for its binding to immobilized MuSK-Fc or to an immobilized agrin-specific monoclonal antibody (mAb), each coupled to a BIAcore sensorchip surface (**FIG. 10A**); bindings to the MuSK-Fc surface were also done in the presence 2 mM Ca⁺⁺ or heparin (0.01 mg/ml), as indicated, while bindings to the antibody surface were also competed with excess soluble monoclonal antibody or MuSK-Fc (each at 25 μ g/ml), as indicated. Reciprocally, binding of soluble MuSK-Fc or monoclonal antibody to immobilized agrin was assayed by first binding conditioned media transfected with a plasmid control (Mock) or a plasmid encoding c-agrin_{4,8} (cAg_{4,8}) to nitrocellulose, followed by detection using either the soluble MuSK-Fc or the agrin-specific monoclonal antibody, as indicated (**FIG. 10B**); TrkB-Fc detection of nitrocellulose-immobilized BDNF served as an additional control.

[0056] **FIG. 11**—Agrin can only induce MuSK phosphorylation in the context of a differentiated myotube: evidence for a myotube-specific accessory component. Agrin-inducible phosphorylation of an introduced chick MuSK receptor was evaluated in a clone of C2C12 myoblasts stably transfected with a chick MuSK expression vector. The introduced chick MuSK is expressed regardless of whether this C2C12

clone is undifferentiated (“Undif”) or differentiated into myotubes (“Dif”) (middle panel), in contrast to the endogenous mouse MuSK, which is only expressed in differentiated cells (bottom panel). However, the chick MuSK can only be inducibly phosphorylated in response to agrin when it is assayed in differentiated myotubes (top panel). The chick MuSK displays the same specificity for activation by the various agrin isoforms (each at 10 nM for ten minutes) as does the endogenous mouse MuSK (compare transfected chick MuSK and endogenous mouse MuSK in upper panel).

[0057] **FIGS. 12A-12C**. Relevant models for the agrin/MuSK receptor complex. **FIG. 12A**—Schematic representation depicting the step-wise assembly of the multi-component receptor complex for ciliary neurotrophic factor (CNTF); b1, gp130; b2, LIFRb. **FIG. 12B**—Schematic depiction of the use of soluble b receptor components (Fc-tagged) to build a CNTF receptor complex attached to the cell surface via only one of its components, the non-signaling a component; surface binding of the soluble b components can be detected using antibodies recognizing the Fc tag. **FIG. 12C**—Schematic representation of one of several possible models of the MuSK receptor complex for agrin, depicting requirement for a myotube-associated specificity component (M.A.S.C.) and possible interactions to additional components that may be required for signaling or coupling to various effectors or substrates; these couplings may be mediated extracellularly (for example via agrin binding to the dystroglycan complex) or intracellularly (for example via interactions of SH2 domain-containing proteins to phosphorylated tyrosines on MuSK).

[0058] **FIGS. 13A-13C**. Evidence for an agrin/MuSK receptor complex utilizing a myotube-specific accessory component. **FIG. 13A**—Formation of agrin/MuSK complexes on the surface of myotubes: undifferentiated (Undif.) or myotube-differentiated (Dif) C2C12 cells were assayed for their ability to bind either MuSK-Fc or a control receptor-Fc fusion (TrkB-Fc), in the absence or presence of various agrin isoforms (provided in conditioned media from transient COS transfections); specific binding of MuSK-Fc to the myotube surface, which is enhanced by exogenously provided agrin, is suggested to involve complexes analogous to those depicted in **FIG. 12B**. **FIG. 13B**—Direct binding of agrin to MuSK is demonstrated by cross-linking analysis. Radiolabelled agrin (a recombinant c-terminal fragment (or portion) of human agrin, termed hAgrin_{4,8}) at 1 nM was chemically cross-linked to the surface of myotubes. Following cross-linking, lysates were immunoprecipitated with a MuSK-specific antibody (lane 1). The cross-linking was also done in the presence of excess (150 nM) unlabelled agrin (lane 2), while the immunoprecipitation was also done in the presence of excess peptide (corresponding to that used to generate the antibody) to block the MuSK precipitation; positions of the agrin/MuSK complex, as well as of various forms of unbound monomeric and dimeric agrin (see text), are indicated. **FIG. 13C**—Inhibition of agrin-induced AChR clustering by MuSK-Fc: agrin-induced AChR-clustering (using 10 nM c-agrin_{4,8}) was performed on C2C12 myotube cultures in the presence of varying concentrations of soluble MuSK-Fc or a control receptor-Fc fusion (Ret-Fc); the soluble MuSK-Fc specifically inhibits, presumably by forming inactive complexes on the cell surface with agrin and the myotube-specific accessory component.

[0059] **FIG. 14**—Amino acid (single letter code) sequence of rat agrin indicating Y and Z sites of amino acid inserts found in splice variants.

[0060] **FIG. 15**—Nucleotide and amino acid (single letter code) sequences of human agrin expression construct including the signal peptide and fig tag (FLAG tag). The start of the coding region for the active C-terminal fragment (portion) of human agrin 4-8 is indicated. Also indicated are the position Y and position Z insert sites at which the 4 and 8 amino acid inserts are located. Throughout this application, references to human agrin 4,8; c-agrin 4,8; or human c-agrin 4,8 indicate the active C-terminal fragment (portion) of human agrin 4-8 as set forth in the Figure.

[0061] **FIG. 16**—Results of phosphorylation assay showing that the active C-terminal 50 kD portion of human agrin 4,8 and the truncated delta 9 portion of human agrin can each induce phosphorylation of the MuSK receptor.

[0062] **FIG. 17**—Results of pharmacokinetic study comparing serum half-lives of active C-terminal 50 kD portion of human agrin 4,8 (c-agrin 4,8) with active C-terminal 50 kD portion of human agrin 4,8 that has been modified by covalent addition of polyethylene glycol.

DETAILED DESCRIPTION OF THE INVENTION

[0063] The present invention provides for a novel tyrosine kinase molecule that is related to the trk family of tyrosine kinases. The sequence of the protein is set forth in **FIG. 1** as SEQ. ID NO: 1. The coding region of the mature protein is believed to begin on or around the serine-glycine-threonine on or around position 20 of the coded region.

[0064] The novel tyrosine kinase described herein has been found to be induced in denervated skeletal muscle. Accordingly, it has been designated as MuSK (muscle specific kinase). It has also been referred to previously as Dmk (denervated muscle kinase). In addition to being found in skeletal muscle, both normal and denervated, MuSK has also been found to be present in, but not be limited to, the spleen, ovary and retina. It appears to be present during early development, but is also found in adult tissue.

[0065] MuSK may be related to the Torpedo RTK identified by Jennings, et al. supra. However, MuSK differs in that it appears to be induced in denervated muscle, whereas no such induction has been reported with regard to the Torpedo RTK. Furthermore, the Torpedo RTK has an extracellular kringle domain, whereas MuSK does not. However, these kinases may be members of the same or related families.

[0066] The gene encoding rat MuSK has been cloned and the DNA sequence determined (**FIG. 1**; SEQ ID NO: 2). The extracellular domain of the mature protein is believed to be encoded by the nucleotide sequence beginning on or around position 192 and ending on or around position 1610. The transmembrane portion of the protein is believed to be encoded by the nucleotide sequence beginning on or around position 1611 and ending on or around position 1697. The intracellular domain is believed to be encoded by the nucleotide sequence beginning on or around position 1698 and ending on or around position 2738. A cDNA clone encoding Dmk (MuSK) was deposited with the American Type Culture Collection on Jul. 13, 1993 and accorded an accession number of ATCC No. 75498.

[0067] The present invention also provides for a protein or peptide that comprises the extracellular domain of MuSK as well as the sequence of nucleotides which encode this extracellular domain. The extracellular domain of the protein is believed to be comprised of the amino acids at or around positions 20 through 492 of the coding region set forth as SEQ ID NO: 1.

[0068] The similarity between MuSK and the Torpedo RTK suggests the utilization of regions of sequence homologies within these genes to develop primers useful for searching for additional, related RTKs.

[0069] Accordingly, the invention provides for nucleic acids, or oligonucleotides greater than about 10 bases in length, that hybridize to the nucleic acid sequences described herein and that remain stably bound under stringent conditions. Stringent conditions as used herein are those which (1) employ low ionic strength and high temperature for washing, for example, 0.15 M NaCl/0.015 M sodium citrate/0.1% NaDodSO₄ at 50° C., or (2) use during hybridization of a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42° C.

[0070] The present invention further provides for an isolated and purified nucleic acid molecule comprising a nucleotide sequence encoding human muscle specific kinase (MuSK) receptor, wherein the nucleotide sequence is selected from the group consisting of:

[0071] (a) the nucleotide sequence comprising the coding region of the human MuSK receptor as set forth in **FIG. 4**;

[0072] (b) a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of (a) and which encodes a human MuSK receptor; and

[0073] (c) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a) or (b) and which encodes a human MuSK receptor.

[0074] The invention further provides for isolated and purified human MuSK receptor encoded by the coding region of the human MuSK receptor nucleotide sequence as set forth above. The invention also provides for a vector which comprises the isolated nucleic acid molecule described. In one embodiment, the vector is an expression vector wherein the DNA molecule is operatively linked to an expression control sequence. In a further embodiment, the expression vector comprises an immediate early gene promoter. In a still further embodiment, the expression vector of the invention comprises the fos promoter or the jun promoter as the early gene promoter.

[0075] The invention further contemplates a host-vector system for the production of a polypeptide having the biological activity of a human MuSK receptor which comprises the vector described above in a suitable host cell. By way of nonlimiting example, a suitable host cell may be a C2C12 cell or an NIH3T3 cell. The invention further provides for a method of producing a polypeptide having the biological activity of human MuSK receptor which com-

prises growing cells of the above-described host-vector system under conditions permitting production of the polypeptide and recovering the polypeptide so produced.

[0076] In addition, the invention provides for a therapeutic composition comprising the MuSK receptor activating molecule in a pharmaceutically acceptable vehicle.

[0077] The invention also provides for an antibody which specifically binds the above-described MuSK receptor. The antibody of the invention may be a polyclonal or monoclonal antibody.

[0078] The invention further provides for a MuSK receptorbody comprising the extracellular portion of the above-described MuSK receptor, fused to an immunoglobulin constant region. In a preferred embodiment, the constant region of the receptorbody is the human immunoglobulin gamma-1 constant region (MuSK-IgG1 receptorbody).

[0079] The invention further provides a method of detecting the presence of MuSK ligand in a sample comprising:

[0080] a) reacting the sample with a MuSK receptorbody capable of specifically binding MuSK ligand under conditions whereby the MuSK receptorbody binds to MuSK ligand present in the sample; and

[0081] b) detecting the bound MuSK receptorbody, thereby detecting the presence of MuSK ligand in the sample.

[0082] The MuSK receptorbody used is most preferably MuSK-IgG1 receptorbody. The sample may be biological tissue or body fluid. The biological tissue may be muscle, heart, spleen or ovary. The body fluid may be cerebrospinal fluid, urine, saliva, blood, or a blood fraction such as serum or plasma.

[0083] The invention also provides for a fibroblast cell line that is growth factor dependent in serum-free medium and that comprises a nucleic acid molecule encoding the human MuSK receptor as described above.

[0084] When using nucleotide sequences coding for part or all of MuSK in accordance with this invention to isolate new family members or MuSK from other species, the length of the sequence should be at least sufficient to be capable of hybridizing with endogenous mRNA from the vertebrate's own musk. Typically, sufficient sequence size will be about 15 consecutive bases (DNA or RNA).

[0085] Strategies for identifying novel RTKs using degenerate oligodeoxyribonucleotide primers corresponding to protein regions surrounding amino acids conserved in tyrosine kinases have been previously described (Wilks, et al., 1989, Proc. Natl. Acad. Sci. U.S.A., 86:1603-1607, Partanen, J. et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87: 8913-8917; Lai and Lemke, 1991, Neuron 6: 691-704; Masiakowski and Carroll, 1992, J. Biol. Chem. 267: 26181-26190). The discovery by applicants of the relationship between MuSK and the Torpedo RTK has led to the identification of heretofore unknown homology regions which may be used in screening strategies.

[0086] The following primer, based on the amino acid homology domain Asp-Val-Trp-Ala-Tyr-Gly (SEQ ID NO: 3) between MuSK and the Torpedo RTK, may be used in combination with additional primers that correspond to known homology regions characteristic of RTKs, to isolate

related tyrosine kinases, e.g. other family members [all codes used herein representing amino acids and nucleotides are as set forth in 37 C.F.R. §1.822(b)]:

[0087] 5'-GAATTCGAGCTCCCRWANGC-
CCANACRTC-3' (SEQ ID NO:4)

[0088] The additional primers that correspond to known homology regions characteristic of RTKs include the following:

5'
1) Asp-Leu-Ala-Thr-Arg-Asn (SEQ ID NO: 5)
5'-TCTTGACTCGAGAYYTNGCNACNMGNA (SEQ ID NO: 6)
A-3'

2) Asp-Leu-Ala-Ala-Arg-Asn (SEQ ID NO: 7)
5'-TCTTGACTCGAGAYYTNGCNGCNMGNA (SEQ ID NO: 8)
A-3'

3'
1) Asp-Val-Trp-Ser-Leu-Gly (SEQ ID NO: 9)
3'-CTRCANACCWSNATRCCTCGAGCTTA (SEQ ID NO: 10)
AG-5'

2) Asp-Val-Trp-Ser-Phe-Gly (SEQ ID NO: 11)
3'-CTRCANACCWSNAARCCCTCGAGCTTA (SEQ ID NO: 12)
AG-5'

3) Asp-Val-Trp-Ser-Tyr-Gly (SEQ ID NO: 13)
3'-CTRCANACCWSNRANCCCTCGAGCTTA (SEQ ID NO: 14)
AG-5'

[0089] Alternatively, regions of homology shared by MuSK and members of related families, such as the Trk family, may be used in strategies designed to isolate novel RTKs.

[0090] The present invention further provides for substantially purified protein molecules comprising the amino acid sequence substantially as set forth in FIG. 1 for MuSK (SEQ ID NO: 1) or functionally equivalent molecules. Functionally equivalent molecules include derivatives in which amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Also included within the scope of the invention are proteins or fragments (portions) or derivatives thereof which are differentially modified during or after translation, e.g., by glycosylation, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc.

[0091] The invention further contemplates the isolation of proteins that have substantial similarity to the MuSK protein described herein. Substantial similarity, as used herein, refers to proteins that are from different species or are family members within a species and are identical in at least 40%

of positions. Substantial similarity at the protein level includes the ability of a subject protein to compete with MuSK for binding to monoclonal antibodies raised against MuSK epitopes.

[0092] The MuSK protein described herein is useful in 1) screening strategies, 2) purification strategies and 3) diagnostic uses. With respect to screening strategies, expression cloning strategies based on cell survival and proliferation assays provide a method of screening for cognate ligands (Glass, et al. (1991) *Cell* 66:405-413). Since ligands that bind MuSK may be membrane bound, other strategies for identification of such receptors may be more well suited (Armitage, et al. 1992, *Nature* 357:80-82; Smith, et al. 1993, *Cell* 73:1349-1360). In preferred embodiments, the extracellular domain of MuSK is fused to a marker to create a chimeric protein which enables identification and purification of the extracellular domain when bound to a cognate.

[0093] If, for example, the cognate ligand is membrane bound, as described in Smith, et al. supra, the extracellular portion of MuSK may be fused to truncated immunoglobulin heavy chains (Fc). The fusion product may then be used to identify cells expressing surface ligand that binds the receptor by, for example, flow cytometry. Alternatively, other tags, such as myc used to tag the extracellular domain of MuSK, may also be useful for the screening and purification of MuSK-binding ligands (Davis, et al. 1991, *Science* 253:59-63; Squinto, et al., 1990, *Neuron* 5:757-766).

[0094] In other embodiments, the extracellular portion of RTKs that bind known ligands are replaced with the extracellular portion of MuSK. Measurable effects, such as changes in phenotype or induction of early response genes, normally associated with binding of the known ligand to the receptor, can be used to screen for cognate ligands that induce comparable effects.

[0095] For example, a cell line bearing the introduced MuSK receptor or a chimeric protein comprising the extracellular domain of MuSK fused to the transmembrane domain and intracellular domain of another RTK (MuSK-chimeric receptor), as well as the parental cell line without the receptor can be exposed to any potential source of an agent that might work through the receptor. Any specific effects (e.g. on cell survival or proliferation) on the cell line bearing the receptor or chimera can be used to identify and eventually purify agents acting on that receptor. Once a particular receptor/ligand system is defined, a variety of additional specific assay systems can be utilized, for example, to search for additional agonists or antagonists of MuSK.

[0096] According to the invention, MuSK or a MuSK-RTK chimeric receptor, when introduced into cells that do not normally express this receptor, can be used to identify ligands that bind the receptor based on the distinguishable response of the cell. The present invention contemplates that the type of response elicited depends on the cell utilized, and not the specific receptor introduced into the cell. Thus, for example, expression of the MuSK receptor in PC12 pheochromocytoma cells may result in the differentiation of the PC12 cells upon exposure to a ligand that binds the receptor, whereas the same receptor in fibroblasts may mediate both survival and proliferation in response to a MuSK binding ligand. Appropriate cell lines can be chosen to yield a response of the greatest utility for the assay, as well as

discovery of agents that can act on tyrosine kinase receptors. "Agents" refers to any molecule(s), including but not limited to peptide and non-peptide molecules, that will act in systems to be described in a receptor dependent manner.

[0097] One of the more useful systems to be exploited involves the introduction of the desired receptor into a growth factor dependent fibroblast cell line. Such a receptor which does not normally mediate proliferative responses may, following introduction into fibroblasts, nonetheless be assayed by a variety of well established methods used to quantitate effects of fibroblast growth factors (e.g. thymidine incorporation or other types of proliferation assays; see van Zoelen, 1990, "The Use of Biological Assays For Detection Of Polypeptide Growth Factors" in *Progress in Factor Research*, Vol. 2, pp. 131-152; Zhan and M. Goldfarb, 1986, *Mol. Cell. Biol.*, Vol. 6, pp. 3541-3544). These assays have the added advantage that any preparation can be assayed both on the cell line having the introduced receptor as well as the parental cell line lacking the receptor. Only specific effects on the cell line with the receptor would be judged as being mediated through the introduced receptor.

[0098] A cell that expresses a receptor described herein may either naturally express the receptor or be genetically engineered to do so. For example, nucleotide sequences obtained as described herein may be introduced into a cell by transfection, transduction, microinjection, electroporation, via a transgenic animal, etc., using any method known in the art.

[0099] The specific binding of test agent to the receptor may be measured in a number of ways. For example, the binding of test agent to cells may be detected or measured, by detecting or measuring (i) test agent bound to the surface of intact cells; (ii) test agent cross-linked to receptor protein in cell lysates; or (iii) test agent bound to receptor in vitro. The specific interaction between test agent and the receptor may be evaluated by using reagents that demonstrate the unique properties of that interaction.

[0100] Alternatively, the specific activity of test agent on the receptor may be measured by evaluating the secondary biological effects of that activity, including, but not limited to, the induction of neurite sprouting, immediate early gene expression or phosphorylation of the receptor. For example, the ability of the test agent to induce neurite sprouting can be tested in cells that lack the receptor and in comparable cells that express, for example, a chimeric receptor comprising the MuSK extracellular domain and the intracellular domain of a member of the Trk family (such as TrkA, TrkB or TrkC); neurite sprouting in receptor-expressing cells but not in comparable cells that lack the receptor would be indicative of a specific test agent/receptor interaction. A similar analysis could be performed by detecting immediate early gene (e.g. fos and jun) induction in receptor-minus and receptor-plus cells, or by detecting phosphorylation of the receptor protein using standard phosphorylation assays known in the art.

[0101] Similarly, the present invention provides for a method of identifying an agent that has signal transducing activity comprising (i) exposing a cell that expresses a tyrosine kinase receptor as described herein to a test agent and (ii) detecting the activity of the test agent to the receptor, in which activity positively correlates with signal transducing activity. Activity may be detected by either assaying for

direct binding or the secondary biological effects of binding, as discussed supra. Such a method may be particularly useful in identifying new neurotrophic factors or factors having other pharmaceutical activity such as cardioprotective activity, or may be useful in screening a large array of peptide and non-peptide agents (e.g., peptidomimetics) for such activities.

[0102] In a preferred, specific, nonlimiting embodiment of the invention, a large grid of culture wells may be prepared that contain, in alternate rows, PC12 (or fibroblasts, see infra) cells that are either receptor-minus or engineered to be receptor-plus. A variety of test agents may then be added such that each column of the grid, or a portion thereof, contains a different test agent. Each well could then be scored for the presence or absence of neurite sprouting. An extremely large number of test agents could be screened for signal transducing activity in this manner.

[0103] The present invention also provides for assay systems that may be used according to the methods described supra. Such assay systems may comprise in vitro preparations of receptor, e.g. affixed to a solid support, or may preferably comprise cells that express receptor proteins described herein.

[0104] The present invention further provides for host cells and microorganisms and vectors that carry the recombinant nucleic acid molecules described supra. Cells that express receptor protein may be genetically engineered to produce receptor as described supra, by transfection, transduction, electroporation, or microinjection of nucleic acid encoding MuSK in a suitable expression vector. In one embodiment, the host cell carrying the recombinant nucleic acid is an animal cell, such as COS. In another embodiment, the host cell is a bacterium, preferably *Escherichia coli*.

[0105] Any of the methods known to one skilled in the art for the insertion of DNA fragments into a vector may be used to construct expression vectors encoding receptor. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinations (genetic recombination). Expression of nucleotide sequence encoding the receptor protein or peptide fragment may be regulated by a second nucleotide sequence so that the receptor protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of receptor may be controlled by any promoter/enhancer element known in the art. Promoters which can be used to control receptor expression include, but are not limited to the long terminal repeat as described in Squinto et al., (1991, Cell 65:1-20);

[0106] the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the CMV promoter, the M-MuLV 5' terminal repeat the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:144-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25). See also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast

or other fungi such as the Gal 4 promoter, the ADH (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology Z:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58); alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94); myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

[0107] Expression vectors containing receptor-encoding gene inserts can be identified by three general approaches: (a) DNA-DNA hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising sequences that are homologous to an inserted gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the receptor-encoding gene is inserted within the marker gene sequence of the vector, recombinants containing the gene insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant vector. Such assays can be based, for example, on the physical or functional properties of the receptor-encoding gene product, for example, by binding of the receptor to neurotrophic factor or to an antibody which directly recognizes the receptor. Cells of the present invention may transiently or, preferably, constitutively and permanently express receptors or portions thereof.

[0108] In preferred embodiments, the present invention provides for cells that express receptors described herein or portions thereof and that also contain recombinant nucleic acid comprising an immediate early gene promoter [e.g. the

fos or jun promoters (Gilman et al., 1986, Mol. Cell. Biol. 6:4305-4316)]. When such a cell is exposed to a ligand that binds to the receptor, the binding secondarily induces transcription off the immediate early promoter. Such a cell may be used to detect receptor/ligand binding by measuring the transcriptional activity of the immediate early gene promoter, for example, by nuclear run-off analysis, Northern blot analysis, or by measuring levels of a gene controlled by the promoter. The immediate early promoter may be used to control the expression of fos or jun or any detectable gene product, including, but not limited to, any of the known reporter genes, such as a gene that confers hygromycin resistance (Murphy and Efstratiadis, 1987, Proc. Natl. Acad. Sci. U.S.A. 84:8277-8281) chloramphenicol acetyltransferase (CAT), neomycin phosphotransferase (neo), beta-galactosidase beta-glucuronidase, beta-galactosidase, etc. of detecting or measuring neurotrophin activity.

[0109] Furthermore, the cells used in the assay systems of the invention may or may not be cells of the nervous system. For example, in a specific, nonlimiting embodiment of the invention, growth-factor dependent fibroblasts may be used as the basis for a signal transducing assay system. A fibroblast cell line that is growth factor dependent in serum-free media (e.g. as described in Zham and Goldfarb, 1986, Mol. Cell. Biol. 6:3541-3544) may be transfected with a receptor-encoding gene, for instance by using a CaPO₄ transfection protocol with micrograms of DNA of CMV-promoter-based expression vector comprising the musk gene and one microgram of hygromycin-resistance gene-containing expression vector. After about 48 hours, the cells may then be selected for hygromycin resistance to identify positive transfectants. The cells may then be cultured for about three weeks in the presence of hygromycin, and then resistant colonies may be pooled. These cells may then be plated on tissue culture plates coated with poly-D-lysine and human fibronectin, and allowed to grow in DMEM plus 10% bovine calf serum for about four hours to allow the cells to bind to the plates. The serum-containing media may then be aspirated and the cells may be washed about three times with PBS to remove any residual serum. The cells may then be taken up with either serum free defined media (a 3:1 mixture of DMEM and Hams F12, supplemented with 8 mM sodium bicarbonate, 15 mM HEPES, 4×10⁻⁶M MnCl₂, 3 mM histidine, 10⁻⁵M ethanolamine, 10⁻⁷M sodium selenite, 5 mg transferrin per liter, 200 mg bovine serum albumin-linoleic acid complex per liter gentamicin, penicillin, and streptomycin, 20 mM L-glutamine). Cells produced in this manner, then incubated with a factor capable of binding to MuSK may, after about 5 days in culture (replacing media and growth factors every 48 hours), be expected to be growing and proliferating; cells treated with an unrelated ligand at 100 ng/ml or in serum free-medium should not, however, proliferate.

[0110] Further insight into the physiological role of MuSK will come from the further definition of the activating molecule of the present invention. The kinase domain of the MuSK receptor appears to be related to other receptor tyrosine kinases, thus it is likely that the MuSK receptor is involved in signal transduction in cells in which it is expressed. Accordingly, the MuSK activating molecule of the present invention may be used to induce signal transduction not only in naturally occurring MuSK-expressing cells, which include cells found in the muscle tissue, heart, spleen, ovaries and retina, but also in cells engineered to

express the MuSK receptor. The MuSK activating molecule of the present invention may be used to promote the growth or survival of such cells.

[0111] The term “MuSK activating molecule” as used herein refers to a molecule which is capable of inducing phosphorylation of the MuSK receptor in the context of a differentiated muscle cell. One such activating molecule is agrin as described in the Examples set forth herein.

[0112] As used herein, the term “MuSK activating molecule” includes the isolated and purified MuSK receptor activating polypeptides described herein, as well as functionally equivalent molecules in which amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Also included within the scope of the invention are proteins or fragments (portions) or derivatives thereof which exhibit the same or similar biological activity and derivatives which are differentially modified during or after translation, e.g., by glycosylation, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc.

[0113] The present invention also provides for use of the MuSK receptor or its extracellular or intracellular domain to screen for drugs that interact with or activate MuSK. Novel agents that bind to and/or activate the receptor described herein may mediate survival, proliferation and differentiation in cells naturally expressing the receptor, but also may mediate survival, proliferation or differentiation when used to treat cells engineered to express the receptor.

[0114] In particular embodiments, the extracellular domain (soluble receptor) of MuSK is utilized in screens for cognate ligands and activating molecules. For example, the MuSK receptor activating molecule described herein may be used in a competition assay to identify agents capable of acting as receptor agonists or antagonists by competing the agents with MuSK activating molecule for phosphorylation of the MuSK receptor. Specifically, the active portion of human agrin described herein may be used as the MuSK activating molecule in a competition assay to screen for agents capable of acting as receptor agonists or antagonists.

[0115] The present invention also provides for nucleic acid probes, capable of hybridizing with a sequence included within the nucleotide sequence encoding human MuSK or its activating molecule, useful for the detection of MuSK expressing tissue or MuSK activating molecule-expressing tissue in humans and animals. The invention further provides for antibodies capable of specifically binding MuSK or MuSK activating molecule. The antibodies may be polyclonal or monoclonal.

[0116] The present invention also has diagnostic and therapeutic utilities. In particular embodiments of the inven-

tion, methods of detecting aberrancies in the function or expression of the receptor described herein may be used in the diagnosis of muscular or other disorders. In other embodiments, manipulation of the receptor, agonists which bind this receptor, or receptor activating molecules may be used in the treatment of neurological diseases or diseases of muscle or neuromuscular unit disorders, including, but not limited to, muscular dystrophy and muscle atrophy. In further embodiments, the extracellular domain of the receptor is utilized as a blocking agent.

[0117] The present invention also provides for an isolated and purified polypeptide which activates MuSK receptor. In one embodiment, the polypeptide of the invention is encoded by a nucleotide sequence comprising the coding region of the active portion of human agrin contained in the vector designated as pBluescript human Agrin-1 (pBL-hAgrin1) that was deposited with the American Type Culture Collection on Dec. 12, 1995 under ATCC Accession No. 97378. The present invention further provides for an isolated polypeptide which is functionally equivalent to this polypeptide.

[0118] The invention further provides for an isolated and purified nucleic acid molecule comprising a nucleotide sequence encoding the active portion of human agrin, wherein the nucleotide sequence is selected from the group consisting of:

[0119] (a) the nucleotide sequence comprising the coding region of the active portion of human agrin contained in the vector designated as pBL-hAgrin 1 (ATCC Accession No. 97378);

[0120] (b) a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of (a) and which encodes the active portion of human agrin; and

[0121] (c) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a) or (b) and which encodes the active portion of human agrin.

[0122] The invention also provides for the above-described nucleic acid molecule which additionally contains a nucleotide sequence so that the encoded polypeptide contains the eight amino acids ELANEIPV at the position corresponding to amino acid position 1780 as shown in FIG. 14.

[0123] The invention further provides for an isolated and purified nucleic acid molecule comprising a nucleotide sequence encoding the active portion of human agrin, wherein the nucleotide sequence is selected from the group consisting of:

[0124] (a) the nucleotide sequence comprising the coding region of the active portion of human agrin as set forth in FIG. 15;

[0125] (b) a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of (a) and which encodes the active portion of human agrin; and

[0126] (c) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from the

nucleotide sequence of (a) or (b) and which encodes the active portion of human agrin.

[0127] The invention further provides for an isolated nucleic acid molecule comprising a nucleotide sequence encoding the active portion of human agrin, wherein the nucleotide sequence is selected from the group consisting of:

[0128] (a) the nucleotide sequence as set forth in FIG. 15;

[0129] (b) the nucleotide sequence encoding amino acids 24 to 492 as set forth in FIG. 15;

[0130] (c) the nucleotide sequence encoding amino acids 60 to 492 as set forth in FIG. 15;

[0131] (d) the nucleotide sequence encoding amino acids 76 to 492 as set forth in FIG. 15;

[0132] (e) the nucleotide sequence encoding amino acids 126 to 492 as set forth in FIG. 15;

[0133] (f) the nucleotide sequence encoding amino acids 178 to 492 as set forth in FIG. 15;

[0134] (g) the nucleotide sequence encoding amino acids 222 to 492 as set forth in FIG. 15;

[0135] (h) the nucleotide sequence encoding amino acids 260 to 492 as set forth in FIG. 15;

[0136] (i) the nucleotide sequence encoding amino acids 300 to 492 as set forth in FIG. 15;

[0137] (j) a nucleotide sequence that hybridizes under stringent conditions to any of the nucleotide sequences of (a) through (i) and which encodes the active portion of human agrin; and

[0138] (k) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from any of the nucleotide sequences of (a) through (j) and which encodes the active portion of human agrin.

[0139] A further embodiment of the invention is an isolated and purified nucleic acid molecule encoding agrin 0-8 comprising a nucleotide sequence encoding the active portion of human agrin, wherein the nucleotide sequence is as set forth in FIG. 15 with the exception that there is no insert at position Y. Another embodiment of the invention is an isolated and purified nucleic acid molecule encoding agrin 4-0 comprising a nucleotide sequence encoding the active portion of human agrin, wherein the nucleotide sequence is as set forth in FIG. 15 with the exception that there is no insert at position Z.

[0140] The present invention provides for an isolated polypeptide encoded by any one of the nucleic acid molecules of the invention as set forth herein. Furthermore, the present invention provides for said polypeptides modified by covalent attachment of a polyethylene glycol molecule.

[0141] Thus, the present invention provides truncated forms of the human agrin polypeptide which retain one or more of the biological activities of human agrin. As set forth herein, the invention also provides nucleic acid sequences encoding such truncated forms. These truncated forms retain, for example, the ability to induce phosphorylation of the MuSK receptor. The truncated forms may be of any suitable length, as long as they retain one or more of the

biological activities of human agrin. Truncated forms including the C-terminal of human agrin are preferred.

[0142] Referring to FIG. 15, starting at the N-terminal end (amino acid 24—KSPC) these truncated forms of human agrin preferably have deletions of up to 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350 or 400 amino acids. Particularly preferred truncated forms are described herein as delta 3 through delta 9.

[0143] The invention also provides for a method of promoting the growth or survival of a MuSK receptor expressing cell in culture comprising administering to the MuSK receptor expressing cell an effective amount of agrin or a derivative of agrin. In one embodiment of this method, the agrin is human agrin. In another embodiment of this method, the MuSK receptor expressing cell is a cell which is normally found in the heart, spleen, ovary or retina. In another embodiment, the MuSK receptor expressing cell is a cell which has been genetically engineered to express the MuSK receptor.

[0144] The present invention also includes a method of treating a patient suffering from a muscle disease or neuromuscular disorder comprising administering to the patient an effective amount of agrin or a derivative thereof. By way of non-limiting example, the agrin may be human agrin and the derivative may be the active portion of the human agrin molecule. The active portion of the human agrin molecule may be any one of the truncated fragments' (portions) of human agrin as described herein that is capable of inducing phosphorylation of the MuSK receptor.

[0145] The present invention also includes a method of treating a patient suffering from a muscle disease or neuromuscular disorder comprising administering to the patient an effective amount of agrin or a portion or derivative thereof in combination with Ciliary Neurotrophic Factor (CNTF) or Modified Ciliary Neurotrophic Factor as described in U.S. Pat. No. 5,349,056 issued Sep. 20, 1994 to Panayotatos.

[0146] The present invention also includes an antibody capable of specifically binding human agrin. More specifically, the invention includes an antibody capable of specifically binding the active portion of human agrin. The antibody may be monoclonal or polyclonal. The invention further provides a method of detecting the presence of human agrin in a sample comprising:

[0147] a) reacting the sample with an antibody capable of specifically binding human agrin under conditions whereby the antibody binds to human agrin present in the sample; and

[0148] b) detecting the bound antibody, thereby detecting the presence of human agrin in the sample.

[0149] The antibody used may be monoclonal or polyclonal. The sample may be biological tissue or body fluid. The biological tissue may be brain, muscle, or spinal cord. The body fluid may be cerebrospinal fluid, urine, saliva, blood, or a blood fraction such as serum or plasma.

[0150] The cDNA clone encoding the active portion of human agrin described herein will facilitate screening of cDNA and genomic libraries in order to clone the full length sequence coding for the entire human agrin molecule. Cells may be genetically engineered to produce the active portion or the full length agrin molecule by, e.g., transfection,

transduction, electroporation, microinjection, via a transgenic animal, of a nucleotide sequence encoding the active portion or the full length agrin molecule in a suitable expression vector. The invention also provides for a vector comprising an isolated nucleic acid molecule encoding an active portion or the full length human agrin molecule.

[0151] The invention further provides for a host-vector system for the production in a suitable host cell of a polypeptide having the biological activity of human agrin. The suitable host cell may be a bacterial cell such as *E. coli.*, a yeast cell such as *Pichia pastoris*, an insect cell such as *Spodoptera frugiperda* or a mammalian cell such as a COS or CHO cell. The invention also provides for a method of producing a polypeptide having the biological activity of human agrin which comprises growing cells of the host-vector system under conditions permitting production of the polypeptide and recovering the polypeptide so produced.

[0152] The invention further provides for an expression vector comprising a nucleic acid molecule encoding human agrin or a portion thereof, wherein the nucleic acid molecule is operatively linked to an expression control sequence. The invention also provides a host-vector system for the production of a polypeptide having the biological activity of human agrin which comprises the expression vector of the invention in a suitable host cell. The suitable host cell may be a bacterial cell such as *E. coli.*, a yeast cell such as *Pichia pastoris*, an insect cell such as *Spodoptera frugiperda* or a mammalian cell such as a COS or CHO cell. The invention further provides for a method of producing a polypeptide having the biological activity of human agrin which comprises growing cells of the host-vector system of the invention, under conditions permitting production of the polypeptide and recovering the polypeptide so produced.

[0153] As described above, the present invention relates to a tyrosine kinase receptor that appears to be expressed in denervated muscle. According to the present invention, probes capable of recognizing these receptors may be used to identify diseases or disorders by measuring altered levels of the receptor in cells and tissues. Such diseases or disorders may, in turn, be treatable using the activating molecule disclosed herein. Such disorders include but are not limited to those in which atrophic or dystrophic change of muscle is the fundamental pathological finding. For example, muscle atrophy can result from denervation (loss of contact by the muscle with its nerve) due to nerve trauma; degenerative, metabolic or inflammatory neuropathy (e.g. Guillian-Barre syndrome), peripheral neuropathy, or damage to nerves caused by environmental toxins or drugs. In another embodiment, the muscle atrophy results from denervation due to a motor neuronopathy. Such motor neuronopathies include, but are not limited to: adult motor neuron disease, including Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease); infantile and juvenile spinal muscular atrophies, and autoimmune motor neuropathy with multifocal conduction block. In another embodiment, the muscle atrophy results from chronic disuse. Such disuse atrophy may stem from conditions including, but not limited to: paralysis due to stroke, spinal cord injury; skeletal immobilization due to trauma (such as fracture, sprain or dislocation) or prolonged bed rest. In yet another embodiment, the muscle atrophy results from metabolic stress or nutritional insufficiency, including, but not limited to, the cachexia of cancer and other chronic illnesses, fasting or rhabdomyolysis, endo-

crine disorders such as, but not limited to, disorders of the thyroid gland and diabetes. The muscle atrophy can also be due to a muscular dystrophy syndrome, including but not limited to the Duchenne, Becker, myotonic, Fascioscapulo-humeral, Emery-Dreifuss, oculopharyngeal, scapulo-humeral, limb girdle, and congenital types, and the dystrophy known as Hereditary Distal Myopathy. In a further embodiment, the muscle atrophy is due to a congenital myopathy, including, but not limited to Benign Congenital Hypotonia, Central Core disease, Nemaline Myopathy, and Myotubular (centronuclear) myopathy. In addition, MuSK and its associated ligand may be of use in the treatment of acquired (toxic or inflammatory) myopathies. Myopathies which occur as a consequence of an inflammatory disease of muscle, include, but not limited to polymyositis and dermatomyositis. Toxic myopathies may be due to agents, including, but are not limited to adiodarone, chloroquine, clofibrate, colchicine, doxorubicin, ethanol, hydroxychloroquine, organophosphates, perhexiline, and vincristine.

[0154] Although not wishing to be bound by theory, preliminary mapping of musk in the mouse has revealed that the gene is localized to mouse chromosome 4 in a region of homology with human chromosome 9q. Mutations in mice that are associated with this region of chromosome 4 include the "wi" mutation (whirler), which results in symptoms of the shaker syndrome, including deafness, head-tossing, circling and hyperactivity (Lane, P. W., 1963, *J. Hered.* 54:263-266). Another mutation in mice that is associated with this region of chromosome 4 is the "vc" mutation (vacillans) which is associated with the symptoms of violent tremor when walking and with swaying of the hindquarters (Sirlin, J. L., 1956, *J. Genet.* 54:42-48).

[0155] In humans, the disease known as idiopathic torsion dystonia (ITD) is associated with a gene that has been mapped, through linkage analysis to human chromosome 9q band 34. This disease is characterized by sustained, involuntary muscle contractions, frequently causing twisting and repetitive movements or abnormal postures.

[0156] Assuming a defect in musk to be associated with these diseases, the present invention may be used in gene therapy for the replacement of such gene in situ. Alternatively, probes utilizing a unique segment of the musk gene may prove useful as a diagnostic for such disorders. The present invention may also be used, where indicated, in gene therapy for the replacement of the human agrin gene in situ.

[0157] Any of the methods known to one skilled in the art of transferring genes into skeletal muscle tissue may be used in MuSK or agrin gene therapy protocols. By way of non-limiting example, one skilled in the art may utilize direct injection of naked DNA into muscle tissue, adenovirus-associated gene transfer, primary myoblast transplantation, or cationic liposome: DNA complex gene transfer.

[0158] For example, direct injection of DNA into muscle may be employed to optimize vector construction as described by Manthorpe et al., (1993, *Hum. Gene Ther.* 4: 419-431) in which covalently closed circular plasmid DNA encoding the firefly luciferase reporter gene was injected into adult murine skeletal muscle for the purpose of evaluating the efficacy of various regulatory elements contained in the DNA expression vector. In a biological study, the systemic immunological effects of cytokine genes were evaluated using direct injection into muscle of DNA encod-

ing the genes for IL-2, IL-4, or TGF- β -1 (Raz, et al., 1993, *Proc. Natl. Acad. Sci. USA* 90: 4523-7). Another study tested the ability of the human kallikrein gene product to reduce blood pressure in spontaneously hypertensive rats following direct DNA injection of the human kallikrein gene into murine skeletal muscle (Xiong, et al., 1995, *Hypertension* 25: 715-719). In studies aimed at evaluating the expression of muscle-specific proteins following direct injection of DNA various deletion-containing dystrophin gene mutant DNA constructs were injected into mdx mouse skeletal muscle and expression patterns and colocalization studies were performed to investigate dystrophin function (Fritz, et al., 1995, *Pediatr. Res.* 37: 693-700). Many investigators believe that it may be not only important but advantageous to regulate the timing and level of gene expression following gene transfer through direct DNA injection. For example, Dhawan et al., (1995, *Somat. Cell. Mol. Genet.* 21: 233-240) have tested a tetracycline-responsive promoter system in which orally or parenterally administered tetracycline can regulate reporter gene expression in mouse skeletal muscle following direct injection of DNA.

[0159] Adenovirus-mediated in vivo gene transfer has been studied extensively as a possible method for delivering genes for gene therapy. Recombinant adenovirus vectors containing exogenous genes for transfer are derived from adenovirus type 5 and are rendered replication-deficient by deletion of the E1 region of the viral genome (Brody & Crystal, 1994, *Ann. N. Y. Acad. Sci.* 716: 90-101). Huard et al., (1995, *Gene Ther.* 2:107-115) have evaluated the efficiency of viral transduction into rat tissues following various routes of administration (intra-arterial, intravenous, gastric-rectal, intraperitoneal, and intracardiac). The investigators report that route of administration is a major determinant of the transduction efficiency of rat tissue by adenovirus recombinants. In addition to route of administration preferences, it has been shown that vectors carrying U3 region viral long terminal repeats (LTRs) modified in the enhancer region may be used to target tissue- and differentiation-specific gene expression into skeletal muscle (Ferrari et al., 1995, *Hum. Gene Ther.* 6: 733-742). Many studies have been performed (Ragot, et al., 1993, *Nature* 361: 647-50; Petrof, et al., 1995, *Am. J. Respir. Cell. Mol. Biol.* 13: 508-17; Phelps, et al., 1995, *Hum. Mol. Genet.* 4: 1251-1258; Kochanek, et al., 1996, *Proc. Natl. Acad. Sci. USA* 93: 5731-36) which have tested adenovirus-mediated transfer of full length and truncated forms of the dystrophin gene into muscle of normal and mdx mice.

[0160] Transplantation into skeletal muscle tissue of retrovirally transformed primary myoblasts expressing recombinant genes has also been extensively studied as a possible approach to gene therapy for muscle as well as non-muscle diseases. It is known that the success of myoblast transplantation for correction of intrinsic muscle defects is dependent on the ability of the transplanted myoblasts to fuse to the host myofibers. To address this issue, Rando & Blau (1994, *J. Cell. Biol.* 125:1275-87) developed a novel culture system for isolating enriched and clonal populations of primary myoblasts. Myoblasts isolated by this technique were shown to efficiently fuse to host myofibers to form hybrid myofibers persisting for up to six months as evidenced by β -galactosidase reporter gene expression. Because immunorejection of transplanted myoblasts is a potential problem in this gene therapy approach, it has been addressed in studies comparing autologous versus heterologous myoblasts for transplan-

tation (Huard, et al., 1994, Hum. Gene Ther. 5: 949-58) and with Cyclosporin A-induced immunosuppression in adult mice receiving myoblast transplants following muscle injury (Irintchev et al., 1995, J. Neurocytol. 24: 319-331). Representative disease targets for gene therapy using myoblast transplantation include hemophilia B in which circulating human or canine factor IX has been measured in the plasma of mice following transplantation of recombinant myoblasts into skeletal muscles of normal and SCID mice (Roman, et al., 1992, Somat. Cell. Mol. Genet. 18: 247-58; Dai, et al., 1992, Proc. Natl. Acad. Sci. USA 89: 10892-5; Yao, et al., Proc. Natl. Acad. Sci. USA 89: 3357-61; Yao, et al., 1994, Gene Ther. 1: 99-107) and primary myopathies such as Duchenne muscular dystrophy where myoblasts expressing the dystrophin gene have been transplanted into normal and mdx mice (Partridge, et al., Nature 337: 176-9; Sopper, et al., 1994, Gene Ther. 1: 108-113).

[0161] Plasmid DNA complexed with cationic lipids has been evaluated for its ability to deliver genes into muscle tissue as well. Trivedi, et al., (1995, J. Neurochem. 64: 2230-38) carried out in vitro studies that utilized polycationic liposomes to successfully deliver the reporter gene LacZ into the cultured mouse myoblast cell line C2C12 and into primary mouse myoblasts derived from normal and mdx mice, forming the basis for adaptation to in vivo gene therapy.

[0162] The present invention provides for a method of diagnosing a neurological or other disorder in a patient comprising comparing the levels of expression of MuSK in a patient sample with the levels of expression of MuSK in a comparable sample from a healthy person, in which a difference in the levels of expression of MuSK in the patient compared to the healthy person indicates that a disorder in the patient may be primarily or secondarily related to MuSK metabolism. A patient sample may be any cell, tissue, or body fluid but is preferably muscle tissue, cerebrospinal fluid, blood, or a blood fraction such as serum or plasma.

[0163] One variety of probe which may be used is anti-MuSK antibody or fragments thereof containing the binding domain of the antibody.

[0164] According to the invention, MuSK protein, or fragments or derivatives thereof, may be used as an immunogen to generate anti-MuSK antibodies. By providing for the production of relatively abundant amounts of MuSK protein using recombinant techniques for protein synthesis (based upon the MuSK nucleotide sequences of the invention), the problem of limited quantities of MuSK has been obviated.

[0165] To further improve the likelihood of producing an anti-MuSK immune response, the amino acid sequence of MuSK may be analyzed in order to identify portions of the molecule which may be associated with increased immunogenicity. For example, the amino acid sequence may be subjected to computer analysis to identify surface epitopes which present computer-generated plots of hydrophilicity, surface probability, flexibility, antigenic index, amphiphilic helix, amphiphilic sheet, and secondary structure of MuSK. Alternatively, the deduced amino acid sequences of MuSK from different species could be compared, and relatively non-homologous regions identified; these non-homologous regions would be more likely to be immunogenic across various species.

[0166] For preparation of monoclonal antibodies directed toward MuSK, or its activating molecule, any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used. For example, the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in "Monoclonal Antibodies and Cancer Therapy," Alan R. Liss, Inc. pp. 77-96) and the like are within the scope of the present invention.

[0167] The monoclonal antibodies for therapeutic use may be human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies. Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:7308-7312; Kozbor et al., 1983, Immunology Today 4:72-79; Olsson et al., 1982, Meth. Enzymol. 92:3-16). Chimeric antibody molecules may be prepared containing a mouse antigen-binding domain with human constant regions (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851, Takeda et al., 1985, Nature 314:452).

[0168] Various procedures known in the art may be used for the production of polyclonal antibodies to epitopes of MuSK. For the production of antibody, various host animals can be immunized by injection with MuSK protein, or a fragment or derivative thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*Bacille Calmette-Guerin*) and *Corynebacterium parvum*.

[0169] A molecular clone of an antibody to a MuSK epitope can be prepared by known techniques. Recombinant DNA methodology (see e.g., Maniatis et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) may be used to construct nucleotide sequences which encode a monoclonal antibody molecule, or antigen binding region thereof.

[0170] Antibody molecules may be purified by known techniques, e.g., immunoabsorption or immunoaffinity chromatography, chromatographic methods such as HPLC (high performance liquid chromatography), or a combination thereof, etc.

[0171] The present invention provides for antibody molecules as well as fragments of such antibody molecules. Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

[0172] The above mentioned probes may be used experimentally to identify cells or tissues which hitherto had not

been shown to express musk. Furthermore, these methods may be used to identify the expression of musk by aberrant tissues, such as malignancies. In additional embodiments, these methods may be used diagnostically to compare the expression of musk in cells, fluids, or tissue from a patient suffering from a disorder with comparable cells, fluid, or tissue from a healthy person. Fluid is construed to refer to any body fluid, but particularly blood, including blood fractions such as serum or plasma, or cerebrospinal fluid. A difference in the levels of expression of musk in the patient compared to a healthy person may indicate that the patient's disorder may be primarily or secondarily related to MuSK metabolism. An increase in levels of MuSK, for example, could either indicate that the patient's disorder is associated with an increased sensitivity to normal levels of MuSK-binding ligand or, alternatively, may suggest that the patient's MuSK-binding ligand levels are low such that the number of receptors is increased by way of compensation.

[0173] The present invention further provides for the use of soluble receptor (the extracellular domain) to counter the effect of ligand on MuSK expressing cells.

EXAMPLE 1

Cloning of the cDNA Encoding MuSK

[0174] Tyrosine kinase homology domains were identified based on the alignments by Hanks et al. (1988) Science 241, 42-52. Highly conserved regions Asp-Leu-Ala-Ala-Arg-Asn (SEQ ID NO: 7) AND Asp-Val-Trp-Ser-Tyr-Gly (SEQ ID NO: 13) were used in designing the following degenerate oligonucleotide primers:

[0175] 5'-TCTTGACTCGAGAYYTNGCNGCN-MGNAA-3' (SEQ ID NO: 8)

[0176] 5'-GAATTCGAGCTCCCRTANSWCCANACRTC-3' (SEQ ID NO: 15)

[0177] with which to prime PCR reactions using denervated muscle cDNAs. Resulting amplified DNA fragments were cloned by insertion into plasmids, sequenced and the DNA sequences were compared with those of all known tyrosine kinases. cDNA templates were generated by reverse transcription of denervated muscle tissue RNAs using oligo d(T) primers. PCR reactions were done at primer annealing temperatures of 40° C. Aliquots of the PCR reactions were subjected to electrophoresis on an agarose gel.

[0178] Size-selected amplified DNA fragments from these PCR reactions were cloned into plasmids as follows: Each PCR reaction was reamplified as described above, digested with XhoI and SacI to cleave sites in the termini of the primers (see below). XhoI/SacI-cut DNAs were purified by Magic PCR kit (from Promega) and cloned into compatible XhoI/SacI sites in the Bluescript II SK(+) plasmid, introduced into DH10B *E. coli* by electroporation, followed by plating of transformants on selective agar. Ampicillin-resistant bacterial colonies from PCR transformation were inoculated into 96-well microtiter plates and used for PCR using vector primers (T3 and T7) flanking the tyrosine kinase insert and these PCR fragments were analyzed by sequencing.

[0179] One of the cloned fragment sequences contained a segment of a novel tyrosine kinase domain, which was designated as MuSK. The sequence of the PCR-derived

fragment corresponding to MuSK was used to generate PCR primers to obtain longer MuSK specific fragments by the RACE procedure. These longer MuSK probes were used as a hybridization probe to obtain full length MuSK cDNA clones from a rat denervated skeletal muscle cDNA library. DNA was sequenced by using the ABI 373A DNA sequencer and Taq Dyedeoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, Calif.). The sequence of MuSK (FIG. 1; SEQ ID NO:1) has a high degree of homology to members of the trk family of proteins. It was also found to be similar to the Jennings, et al. Torpedo RTK found in muscle.

[0180] Oligonucleotide primers corresponding to conserved regions of known tyrosine kinase molecules were used to amplify and clone DNA sequences encoding novel orphan tyrosine kinase receptor molecules. The amino acid sequences of representatives from branches of the tyrosine kinase family and regions of homology within the catalytic domain of these proteins were used to design degenerate oligonucleotide primers. These primers were then used to prime PCR reactions using as template a rat denervated muscle cDNA library. Resulting amplified DNA fragments were then cloned into Bluescript II SK(+) plasmid, sequenced, and the DNA sequences compared with those of known tyrosine kinases. The sequence of a PCR fragment encoding a novel tyrosine kinase named MuSK was used to obtain more adjoining DNA sequence. A DNA fragment containing MuSK sequences was used as a probe to obtain a cDNA clone from a denervated skeletal muscle library. This clone encodes a novel tyrosine kinase receptor with a high degree of homology to members of the trk family of proteins. It was also found to be homologous to the Jennings, et al. Torpedo RTK. FIG. 1 presents the nucleotide sequence (SEQ ID NO: 2) of the musk clone.

EXAMPLE 2

Identification of Additional Tyrosine Kinases

[0181] The novel MuSK sequence is used to obtain homology segments among receptor tyrosine kinases which can be used in combination with other homology segments. For example, an alignment of the Torpedo trk-related kinase with MuSK shows the following conserved protein segment:

[0182] Asp-Val-Trp-Ala-Tyr-Gly (SEQ ID NO: 3)

[0183] This homology "box" is not present in any other mammalian tyrosine kinase receptor. Degenerated oligonucleotides essentially based on this "box" in combination with either previously known or novel tyrosine kinase homology segments can be used to identify new tyrosine kinase receptors.

[0184] The highly conserved regions between MuSK and Torpedo TRK Asp-Val-Trp-Ala-Tyr-Gly (SEQ ID NO: 3) as well as additional primers based on known regions of homology, such as SEQ ID NOS. 5, 7, 9 OR 11, are used in designing degenerate oligonucleotide primers with which to prime PCR reactions using cDNAs. cDNA templates are generated by reverse transcription of tissue RNAs using oligo d(T) or other appropriate primers. Aliquots of the PCR reactions are subjected to electrophoresis on an agarose gel. Resulting amplified DNA fragments are cloned by insertion into plasmids, sequenced and the DNA sequences are compared with those of all known tyrosine kinases.

[0185] Size-selected amplified DNA fragments from these PCR reactions are cloned into plasmids as follows. Each PCR reaction is reamplified as described above in Example 1, digested with XhoI and SacI to cleave sites in the termini of the primers (see below). XhoI/SacI-cut DNAs are cloned into compatible XhoI/SacI sites in a plasmid, introduced into *E. coli* by electroporation, followed by plating of transformants on selective agar. Ampicillin-resistant bacterial colonies from PCR transformation are inoculated into 96-well microtiter plates and individual colonies from these PCR clones are analyzed by sequencing of plasmid DNAs that are purified by standard plasmid miniprep procedures.

[0186] Cloned fragments containing a segment of a novel tyrosine kinase domain are used as hybridization probes to obtain full length cDNA clones from a cDNA library.

EXAMPLE 3

Tissue Specific Expression of MuSK

[0187] A 680 nts fragment, containing the tyrosine kinase domain of MuSK, was radiolabeled and utilized in Northern analysis of various rat tissue specific RNAs. The rat tissue specific RNAs were fractionated by electrophoresis through a 1% agarose-formaldehyde gel followed by capillary transfer to a nylon membrane with 10×SSC. The RNAs were cross-linked to the membranes by exposure to ultraviolet light and hybridized at 65° C. to the radiolabeled MuSK probe in the presence of 0.5M NaPO₄ (pH 7), 1% bovine serum albumin (Fraction V, Sigma), 7% SDS, 1 mM EDTA and 100 ng/ml sonicated, denatured salmon sperm DNA. The filter was washed at 65° C. with 2×SSC, 0.1% SDS and subjected to autoradiography for 5 days with one intensifying screen and X-ray film at -70° C. Ethidium bromide staining of the gel demonstrated that equivalent levels of total RNA were being assayed for the different samples.

[0188] The MuSK probe hybridized strongly in adult rat tissue (FIG. 3) to a 7 kb transcript from denervated skeletal muscle, and weakly to normal muscle, retina, ovary, heart and spleen. Weaker levels of expression could also be found in liver, kidney and lung. It also hybridizes weakly to a shorter MuSK transcript of about 6 kb in brain, spinal cord and cerebellum.

[0189] In embryonic tissue (FIG. 2), MuSK transcripts can be found in body, spinal cord, placenta and head at E12 and E 13.

[0190] The high expression of MuSK in muscle and neural tissue suggests that the present invention may be utilized to treat disorders of the nervous system, specifically the wide array of neurological disorders affecting motor neurons (see discussion, supra) and the neuromuscular junction. Additionally, high expression of MuSK in heart tissue suggests that the present invention may be utilized to treat heart disease, and may, for example, have prophylactic use in preventing muscle loss during or following a cardiac event. (see discussion, supra). Expression of MuSK in retinal tissue suggests that the present invention may be utilized to treat retina related disorders, including but not limited to retinitis pigmentosa. Expression of MuSK in ovaries suggests that MuSK or the ligand associated with MuSK may be useful in the treatment of diseases or disorders involving the ovaries. Finally, expression of MuSK in spleen suggests that MuSK

or the ligand associated with MuSK may be useful in the treatment of diseases or disorders involving the spleen.

EXAMPLE 4

Cloning and Expression of MuSK Receptorbody for Affinity-Based Study of MuSK Ligand Interactions

[0191] An expression construct was created that would yield a secreted protein consisting of the entire extracellular portion of the rat MuSK receptor fused to the human immunoglobulin gamma-1 constant region (IgG1 Fc). This fusion protein is called a Dmk or MuSK "receptorbody" (RB), and would be normally expected to exist as a dimer in solution based on formation of disulfide linkages between individual IgG1 Fc tails. The Fc portion of the MuSK RB was prepared as follows. A DNA fragment encoding the Fc portion of human IgG1 that spans from the hinge region to the carboxy-terminus of the protein, was amplified from human placental cDNA by PCR with oligonucleotides corresponding to the published sequence of human IgG1; the resulting DNA fragment was cloned in a plasmid vector. Appropriate DNA restriction fragments from a plasmid encoding MuSK receptor and from the human IgG1 Fc plasmid were ligated on either side of a short PCR-derived fragment that was designed so as to fuse, in-frame, the MuSK and human IgG1 Fc protein-coding sequences. Thus, the resulting MuSK ectodomain-Fc fusion protein precisely substituted the IgG1 Fc in place of the region spanning the MuSK transmembrane and cytoplasmic domains. An alternative method of preparing receptorbodies is described in Goodwin, et. al. Cell 73: 447-456 (1993).

[0192] Milligram quantities of MuSK RB were obtained by cloning the MuSK RB DNA fragment into the pVL1393 baculovirus vector and subsequently infecting the *Spodoptera frugiperda* SF-21AE insect cell line. Alternatively, the cell line SF-9 (ATCC Accession No. CRL-1711) or the cell line BTI-TN-5b1-4 may be used. DNA encoding the MuSK RB was cloned as an Eco RI-NotI fragment into the baculovirus transfer plasmid pVL1393. Plasmid DNA purified by cesium chloride density gradient centrifugation was recombined into viral DNA by mixing 3 mg of plasmid DNA with 0.5 mg of Baculo-Gold DNA (Pharminigen), followed by introduction into liposomes using 30 mg Lipofectin (GIBCO-BRL). DNA-liposome mixtures were added to SF-21AE cells (2×10⁶ cells/60 mm dish) in TMN-FH medium (Modified Grace's Insect Cell Medium (GIBCO-BRL) for 5 hours at 27° C., followed by incubation at 27° C. for 5 days in TMN-FH medium supplemented with 5% fetal calf serum. Tissue culture medium was harvested for plaque purification of recombinant viruses, which was carried out using methods previously described (O'Reilly, D. R., L. K. Miller, and V. A. Luckow, Baculovirus Expression Vectors—A Laboratory Manual. 1992, New York: W. H. Freeman) except that the agarose overlay contained 125 mg/mL X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside; GIBCO-BRL). After 5 days of incubation at 27° C., non-recombinant plaques were scored by positive chromogenic reaction to the X-gal substrate, and their positions marked. Recombinant plaques were then visualized by addition of a second overlay containing 100 mg/mL MTT (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide; Sigma). Putative recombinant virus plaques were

picked by plug aspiration, and purified by multiple rounds of plaque isolation to assure homogeneity. Virus stocks were generated by serial, low-multiplicity passage of plaque-purified virus. Low passage stocks of one virus clone (vMuSK receptor body) were produced.

[0193] SF-21AE cells were cultured in serum free medium (SF-900 II, Gibco BRL) containing 1x antibiotic/antimycotic solution (Gibco BRL) and 25 mg/L Gentamycin (Gibco BRL). Pluronic F-68 was added as a surfactant to a final concentration of 1 g/L. Cultures (4 L) were raised in a bioreactor (Artisan Cell Station System) for at least three days prior to infection. Cells were grown at 27° C., with gassing to 50% dissolved oxygen, at a gas flow rate of 80 mL/min (aeration at a sparge ring). Agitation was by means of a marine impeller at a rate of 100 rpm. Cells were harvested in mid-logarithmic growth phase ($\sim 2 \times 10^6$ cells per mL), concentrated by centrifugation, and infected with 5 plaque forming units of vMuSK Receptor Body per cell. Cells and inoculum were brought to 400 mL with fresh medium, and virus was adsorbed for 2 hours at 27° C. in a spinner flask. The culture was then resuspended in a final volume of 8 L with fresh serum-free medium, and the cells incubated in the bioreactor using the previously described conditions.

[0194] Culture medium from vMuSK Receptor Body-infected SF21AE cells were collected by centrifugation (500xg, 10 minutes) at 72 hours post-infection. Cell supernatants were brought to pH 8 with NaOH. EDTA was added to a final concentration of 10 mM and the supernatant pH was readjusted to 8. Supernatants were filtered (0.45 mm, Millipore) and loaded on a protein A column (protein A sepharose 4 fast flow or HiTrap protein A, both from Pharmacia). The column was washed with PBS containing 0.5 M NaCl until the absorbance at 280 nm decreased to baseline. The column was washed in PBS and eluted with 0.5 M acetic acid. Column fractions were immediately neutralized by eluting into tubes containing 1 M Tris pH 9. The peak fractions containing the MuSK RB were pooled and dialyzed versus PBS. Recombinant *Autographa californica* baculovirus encoding the Dmk (MuSK) RB was designated "vDmk receptorbody" and deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852 on May 16, 1995 under ATCC Accession No. VR-2507.

EXAMPLE 5

Sequencing of Human MuSK Receptor

[0195] In order to obtain the full coding sequence of the human MuSK receptor, oligonucleotides based on the rat sequence were utilized as PCR primers to amplify cDNA from a human muscle biopsy. The PCR fragment so produced was then sequenced and the resulting new sequence corresponded to a partial sequence of the human MuSK receptor. The novel partial human MuSK receptor sequence was then used to obtain further sequence through successive rounds of the RACE procedure. (Frohman, M. A. (1990), RACE: Rapid amplification of cDNA ends. in PCR Protocols, Innis, M. A. Gelfand, D. H., Sninsky, J. J., and White, T. J. eds. Academic Press. San Diego).

[0196] This process was complemented by obtaining human genomic clones of MuSK and using the coding

sequence of the genomic MuSK to design oligonucleotide primers used to amplify the biopsy cDNA. Stretches of the human MuSK cDNA sequence which were difficult to sequence, absent or presenting some ambiguity were confirmed, corrected or added from the human genomic MuSK sequence. MuSK cDNA variants produced by alternative splicing of MuSK transcripts may be obtained by using this sequence to obtain MuSK cDNA from human sources. The deduced amino acid sequence of the human MuSK receptor and the nucleotide sequence encoding it is set forth in FIG. 4. One of skill in the art will readily recognize that this sequence may be used to clone full length, naturally occurring cDNA sequences encoding the human MuSK receptor, which may vary slightly from the sequence set forth in FIG. 4.

EXAMPLE 6

Homologous Recombination to Disrupt the MuSK Gene

[0197] The tyrosine kinase domain of MuSK is comprised of 11 subdomains that are divided among three coding exons. Subdomain I encoding the ATP-binding domain is located on the first kinase exon, while subdomains 5-11 encoding the catalytic region are located on the third kinase exon (FIG. 5). To disrupt MuSK tyrosine kinase activity, a targeting vector was designed that would delete most of the third kinase exon upon homologous recombination into the endogenous mouse MuSK locus (FIG. 5); this targeting vector contained a total of 3.8 kb of homology with the mouse MuSK gene.

[0198] The MuSK gene targeting vector was constructed from mouse genomic DNA fragments isolated from a lambda FIX II phage library prepared with 129 strain mouse genomic DNA (Stratagene). The 1.7 kb SpeI fragment depicted in FIG. 5 was ligated into the compatible ends of a unique XbaI site upstream of the PGK-neo cassette (destroying the SpeI and XbaI sites), while the 2.1 kb BamHI DNA fragment depicted in FIG. 5 was blunt-end ligated into the unique HindIII site between the PGK-neo cassette and MC1-tk expression cassettes (destroying the BamHI and HindIII sites). The targeting vector was linearized by digestion with NotI and then electroporated into E14.1 embryonic stem cells, which were subjected to a double selection protocol (gancyclovir addition resulted in a 5-10 fold enrichment compared with selection in G418 alone) and then used to generate chimeric mice as previously described (Conover et al., 1995; DeChiara et al., 1995).

[0199] Successful gene targeting using this construct was predicted to result in the generation of a novel 3.8 kb EcoRI fragment from the targeted allele as detected by a 5' probe, as well as loss of two NcoI fragments hybridizing to a kinase probe (FIG. 5). Southern blot screening for these fragments revealed that successful targeting of the mouse MuSK gene was achieved in four of approximately 400 embryonic stem (ES) cell clones obtained using a double selection scheme intended to enhance for selection of targeted clones; the ES cells were derived from the 129 strain of mice. Male chimeras derived from all four of these targeted clones were bred with C57BL/6 females. Chimeras from two of the targeted clones transmitted the mutant allele to the F1 generation. The resulting F1 progeny heterozygous for the MuSK mutation were viable and appeared normal and fertile.

EXAMPLE 7

MuSK Gene Disruption Results in Perinatal Lethality

[0200] The heterozygous F1 progeny were interbred to generate mice homozygous for the MuSK gene disruption (designated MuSK^{-/-} mice). Among the F2 litters derived from these crosses were newborn mice that died perinatally. Genotype analysis of tail DNA mice revealed that the dead pups were homozygous for the mutant MuSK allele (FIG. 6); significantly, not a single mouse homozygous for the mutation survived the perinatal period (37 homozygotes were noted among the first 138 pups that were genotyped, corresponding to a 26.8% frequency of homozygotes).

[0201] To determine the phenotype of the MuSK^{-/-} newborns immediately at birth, applicants were careful to observe the births of several litters derived from heterozygote crosses. Though normal in their gross anatomy and body weight, the MuSK^{-/-} pups differed in several striking ways from their littermate controls. First, they showed no spontaneous movement and did not respond to a mild tail or leg pinch. Only a strong tail pinch was able to elicit a weak uncoordinated movement. By contrast, littermate controls showed extensive movement and responded vigorously to a mild tail pinch. Second, the MuSK^{-/-} pups were cyanotic at birth and appeared not to breathe, although their hearts continued to beat for a short time after birth. To determine whether the MuSK^{-/-} pups had ever taken a breath, applicants examined the lungs histologically. Lung alveoli are collapsed in utero, and expand with the first breath of life; even if respiration is then terminated, the alveoli remain expanded.

[0202] Histological examination (FIG. 7A) revealed that the alveoli of MuSK^{-/-} pups were not expanded, indicating that the pups had never taken a breath. In contrast, the lungs of the littermate controls displayed expanded alveoli (FIG. 7B).

EXAMPLE 8

Normal Skeletal Muscle in MuSK^{-/-} Mice

[0203] Because MuSK is localized to synaptic sites in skeletal muscle (Valenzuela, D., et al., 1995, Neuron 15: 573-584) and because MuSK^{-/-} mutant mice are immobile at birth and die shortly thereafter, applicants reasoned that neuromuscular synapse formation might be aberrant in MuSK^{-/-} mutants. Applicants first examined the diaphragm muscle because its simple organization and thin structure allows synaptic sites to be visualized in whole-mount preparations. The diaphragm muscle is innervated by the phrenic nerve, which normally enters near the center of the diaphragm muscle. The main intramuscular nerve is oriented perpendicular to the long axis of the muscle fibers and extends through the central region of the muscle.

[0204] For whole-mount diaphragm preparations newborn mice were fixed in 1% paraformaldehyde in phosphate-buffered saline (PBS) at 4° C. for several hours and then rinsed briefly in PBS. Diaphragm muscles were dissected out, washed twice for 10 minutes in PBS, incubated in 0.1M glycine in PBS for 15 minutes, rinsed for 5 minutes in PBS, and permeabilized with 0.5% Triton X-100 in PBS (PBT) for 5 minutes. The muscles were then incubated with rabbit

antibodies to synaptophysin (kindly provided by Dr. R. Jahn, Yale University Medical School), which were diluted 1/1000 in PBT with 2% BSA, overnight at 4° C., subsequently rinsed for 5 minutes in PBT, washed three times for one hour in PBT and then incubated, simultaneously with fluorescein-conjugated sheep anti-rabbit IgG (Boehringer Mannheim) and tetramethylrhodamine-conjugated α -bungarotoxin (α -BGT) (Molecular Probes, Oregon) overnight at 4° C. The tissues were then washed three times for 1 hour with PBT, rinsed once with PBS for 5 minutes, fixed in 100% methanol at -20° C. and mounted in 90% glycerol, 0.1 M Tris, pH 7.5 with 1 mg/ml p-phenylenediamine. The whole-mounts were viewed with epifluorescence and filters that were selective for rhodamine or fluorescein, and images were recorded either on film or on a CCD camera (Princeton Instruments).

[0205] The arrangement and gross structure of the muscle fibers (compare FIGS. 7C and 7D), as well as of the main intramuscular nerve, appeared to be unaltered in MuSK^{-/-} mutant mice. Thus, although the onset of MuSK expression occurs at about embryonic day 11 in developing mouse somites (within the presumptive myotome), MuSK does not appear to be essential for the generation, proliferation and fusion of myoblasts, or for the growth of motor axons from spinal cord to muscle.

EXAMPLE 9

Agrin Fails to Induce AChR Clustering in Myotubes Lacking MuSK

[0206] The localization of MuSK to the NMJ inspired us to ask whether MuSK is required for responsiveness to agrin. To test this, applicants first isolated myoblasts from newborn MuSK^{-/-} mice or from control pups, attempted to differentiate them into myotubes in culture, and then assayed for their responsiveness to agrin.

[0207] Primary myoblast cultures were established from hind limb musculature of newborn MuSK^{-/-} or littermate control pups. This tissue was treated sequentially with collagenase and trypsin, then plated onto plastic tissue culture dishes. After 1 hour, non-adherent cells (principally myoblasts) were removed and plated onto chamber slides coated with poly-D-lysine and fibronectin. Myoblast cultures were maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 25% fetal calf serum, 10% horse serum, and 50 μ g/ml gentamycin. To induce myotube formation, cultures were switched to a medium consisting of DMEM containing 5% horse serum, L-glutamine and gentamycin to which 20 μ M cytosine arabinoside was added after 24 hr. After an additional 2-3 days, contractile myotubes had formed abundantly in cultures from both MuSK^{-/-} and control pups. C2C12 cells were maintained and caused to differentiate in a serum-poor medium as previously described (Ferns, M., et al., 1993, Neuron 11: 491-502).

[0208] For agrin-mediated AChR clustering assays on primary myotubes, cultures on chamber slides were treated overnight with c-agrin4,8 at 0.01-100 nM; for evaluating MuSK-Fc as an inhibitor of clustering, differentiated C2C12 cells, on chamber slides coated with fibronectin and poly-D-lysine, were pretreated with MuSK-Fc or a control receptor-body for 1 hr at 37° C. before addition of approximately 10 nM agrin4,8 for overnight incubation. Following over-

night treatments with agrin, the cells were next incubated in rhodamine-conjugated α -bungarotoxin to label AChRs, then fixed and mounted for fluorescence microscopy. To quantify the extent of AChR clustering, randomly selected myotubes were viewed under fluorescein optics, then switched to rhodamine optics and the number of AChR clusters within a reticule grid aligned along the long axis of the myotube were counted. AChRs on the surface of cultured primary myotubes were quantitated by incubating live cultures with 25 mCi 125I- α -BGT for 1 hr at room temperature, washing, and then lysing the cells in 0.1 N NaOH. The protein concentration in aliquots of each extract was determined using a BCA protein assay kit (Pierce), while the remainder of the extract was counted in a gamma counter.

[0209] Myoblasts from both the control and MuSK^{-/-} mice were able to fuse and form long, twitching myotubes in culture. Together with the observation that skeletal muscle appears rather normal in MuSK^{-/-} mice, these findings indicate that MuSK is not critical for early muscle development and myoblast fusion. On the other hand, MuSK appeared to be absolutely required for AChR clustering in response to agrin. After stimulation with the most active form of c-agrin, containing both the four and eight amino acid insertions (c-agrin_{4,8}), AChR clusters were evident only in the myotubes from control mice (FIG. 8A). While clusters were induced in normal myotubes with as little as 1 nM c-agrin_{4,8}, no clustering was observed in MuSK^{-/-} myotubes even after increasing the concentration of c-agrin_{4,8} to as high as 100 nM (FIG. 8B). Lack of detectable clustering was not due to the absence of AChRs, since myotubes from MuSK^{-/-} mice expressed similar numbers of AChR on their surface as did myotubes from control mice (FIG. 8C). Thus MuSK appeared to be absolutely required for AChR clustering in response to agrin.

EXAMPLE 10

Agrin Induces Prominent and Rapid Tyrosine Phosphorylation of MuSK

[0210] The inability of agrin to induce AChR clustering in myotubes from MuSK^{-/-} mice demonstrates that MuSK is required for agrin responsiveness, and is consistent with the possibility that MuSK serves as the functional agrin receptor. However, since clustering occurs over a period of hours, these results are also consistent with the possibility that MuSK acts much further downstream in the agrin signaling pathway. To begin to distinguish between these possibilities, applicants took advantage of the fact that RTKs become rapidly autophosphorylated on tyrosine upon challenge with their cognate ligand. Applicants decided to assay four of the known forms of soluble agrin—which exhibit differing AChR clustering activities (Ruegg, M. A. et al., 1992, Neuron 8: 691-699; Ferns, M., et al., 1992, Neuron 8: 1079-1086; Ferns, M., et al., 1993, Neuron 11: 491-502; Hoch, W. et al., 1994, EMBO J. 13: 2814-2821)—for their ability to induce phosphorylation of the MuSK receptor.

[0211] The ability of various agrins and growth factors to induce MuSK or ErbB3 tyrosine phosphorylation, for the indicated times and at the indicated concentrations, was evaluated in primary rat myoblasts and in either untransfected C2C12 myoblasts, or in C2C12 myoblasts stably transfected with a chick MuSK-expressing plasmid. The cells were challenged at confluence in an undifferentiated

state, or approximately 4-5 days after being induced to differentiate into myotubes in serum-poor media. After challenge, the cells were lysed, the extracts subjected to immunoprecipitation with receptor-specific antibodies, and then immunoblotted with either receptor-specific or phosphotyrosine-specific antibodies, using methods previously described (Stitt, T., et al., 1995, Cell 80: 661-670). Polyclonal antibodies for MuSK were generated as follows: for rat MuSK, rabbits were immunized with a peptide corresponding to the carboxy-terminal 20 amino acids of the rat MuSK protein (Valenzuela, D., et al., 1995, Neuron 15: 573-584; the nomenclature for this antibody is: 41101K); for chick MuSK, rabbits were immunized with a peptide corresponding to the first 19 amino acids of the chick MuSK cytoplasmic domain (Peptide: TLPSELLLDRLHPNPMYQ; the nomenclature for this antibody is 52307K). The specificity of the antibodies was determined on Cos-cell expressed MuSK proteins, by both immune-precipitation and Western, comparing untransfected Cos cell lysates to lysates from rat and chicken-MuSK transfected Cos cells. 41101K immune precipitates and Westerns rodent MuSK, but does not recognize chicken MuSK. 52307 immune precipitates and Westerns chicken MuSK. Antibodies to ErbB3 were obtained from Santa Cruz Biotechnology, Inc.

[0212] Cultures of confluent C2C12 cells, either undifferentiated or differentiated in serum-poor media for four to five days as described above, were transferred to 4° C. and incubated for 90 minutes with either MuSK-Fc or TrkB-Fc (at 5 mg/ml), each in the presence of the indicated mock or agrin-containing conditioned media (with 10 nM agrin). Agrin levels were determined by Western analysis of the conditioned media with a rat agrin antibody (131, from StressGen, Inc.), using a purified agrin control of known concentration. Following these incubations, the cells were washed four times with PBS containing calcium and magnesium, and then incubated for an additional hour with radio-iodinated goat anti-human IgG (NEN/Dupont; 1 mCi/ml in PBS) to detect surface-bound receptor-Fc. After four additional washes, cells were solubilized in 0.1N NaOH, and bound radioactivity was determined. The assay is similar to that described elsewhere (Davis, S., et al., 1994, Science 266: 816-819).

[0213] Transient transfections using either previously described agrin constructs (Ferns, M., et al., 1993, Neuron 11: 491-502) or empty vector controls, or stable transfections of a chick MuSK-expression construct, were performed as described (Glass, D., et al., 1991, Cell 66: 405-413; Ip, N.Y., et al., 1992, PNAS (USA) 89: 3060-3064). Agrin concentrations in conditioned media derived from transient transfections were estimated by immunoblot comparisons with purified agrin of known concentration.

[0214] Phosphorylation was assessed on the endogenous MuSK receptor that is highly expressed in myotube cultures, obtained by differentiating either the C2C12 mouse myoblast cell line (Valenzuela, D., et al., 1995, Neuron 15: 573-584) or primary rat myoblasts. Strikingly, soluble agrins containing the eight amino acid insert at position Z (c-agrin_{4,8} and c-agrin_{0,8}), which are the forms capable of inducing AChR clustering, were also the forms that induced prominent tyrosine phosphorylation of MuSK (FIG. 9A). The agrin most active in clustering (c-agrin_{4,8}) was also most active in inducing MuSK phosphorylation (FIG. 9A). In contrast, the soluble agrins lacking the eight amino acid

insert (c-agrin_{4,0} and c-agrin_{0,0}), which cannot induce AChR clustering, also could not induce MuSK phosphorylation (FIG. 9A).

[0215] The specificity of action of agrin was further explored by comparing its activity to growth factors known to have receptors on muscle. Of the several such factors tested, including insulin, fibroblast growth factor (FGF) and ARIA/neuregulin, only agrin could induce phosphorylation of MuSK (FIG. 9A); since FGF also induces AChR clustering on myotubes (Peng, H. B., et al., 1991, *Neuron* 6: 237-246), these results also indicate that MuSK phosphorylation is specific to agrin responses and not just to agents capable of inducing clustering. Furthermore, while such factors could be shown to induce phosphorylation of their own RTKs on myotubes (e.g., neuregulin induces phosphorylation of its cognate RTK, erbB3), agrin could only activate MuSK and not other RTKs (FIG. 9B).

[0216] The activation of a RTK by its cognate ligand typically tends to occur rapidly, and applicants could demonstrate that agrin induces tyrosine phosphorylation of MuSK with kinetics similar to those seen for well-characterized RTK/ligand systems (e.g. Kaplan, D. R., et al., 1991, *Nature* 350: 158-160); induction was detectable by one minute, peaked within the first five minutes, and remained elevated for over an hour (FIG. 9D). The tyrosine phosphorylation of MuSK also occurred using agrin at concentrations similar to those noted for other ligands that act on RTKs (Ip, N.Y., et al., 1993, *Neuron* 10: 137-149), with phosphorylation detectable using 1 nM agrin (FIG. 9C).

[0217] The requirement of MuSK for agrin responsiveness, the ability of agrin to induce rapid and prominent MuSK phosphorylation, the specificity of agrin for MuSK as compared to other factors tested, and the precise correlation of agrin forms active in AChR clustering assays and in MuSK phosphorylation assays, together continue to support the notion that MuSK serves as the functional agrin receptor.

EXAMPLE 11

Agrin Does Not Directly Bind to an Isolated MuSK Ectodomain

[0218] If MuSK is indeed the functional agrin receptor, applicants would expect to be able to demonstrate binding of agrin to MuSK. In an attempt to demonstrate such binding, applicants first constructed an expression construct encoding a fusion protein between the ectodomain of rat MuSK and the Fc portion of human immunoglobulin G1 (designated MuSK-Fc), and then produced and purified the fusion protein. Similar receptor-Fc fusions have previously been used to characterize binding between RTKs and their ligands (Davis, S., et al., 1994, *Science* 266: 816-819; Stitt, T., et al., 1995, *Cell* 80: 661-670).

[0219] Baculovirus expression vectors encoding MuSK-Fc, TrkB-Fc, and Ret-Fc produced fusion proteins in which the ectodomains of rat TrkB, rat Ret, or rat MuSK, respectively, were linked to a spacer with the sequence Gly-Pro-Gly, followed by the hinge, CH2, and CH3 regions of human IgG1, beginning with the residues Glu-Pro-Lys, as described (Davis, S., et al., 1994, *Science* 266: 816-819). Baculovirus infections into *Spodoptera frugiperda* SF-21AE insect cells were performed by standard methods (Stitt, T., et al., 1995,

Cell 80: 661-670). The soluble Fc-containing proteins were purified by protein A-Sepharose (Pharmacia) chromatography.

[0220] The binding of agrin to immobilized MuSK-Fc as compared to a monoclonal antibody specific for agrin was evaluated by use of BIAcore biosensor technology (Pharmacia Biosensor), using approaches previously described (Stitt, T., et al., 1995, *Cell* 80: 661-670). Heparin and CaCl₂ were supplied by Sigma Chemical Co. (St. Louis, Mo.) and used without further purification. The agrin-specific monoclonal antibody (clone AGR131 generated to rat agrin) was purchased from StressGen Biotechnologies Corp. (Victoria, BC, Canada).

[0221] In a first approach, applicants used MuSK-Fc together with BIAcore biosensor technology. The BIAcore technology allows for the direct and quantitative measure of binding of soluble ligands to receptors coupled onto a sensor chip. Recombinant MuSK-Fc was covalently coupled to a surface on the BIAcore sensor chip, and as a control, a monoclonal antibody specific for rat agrin was also coupled to a separate surface on the sensor chip; media containing c-agrin_{4,8} was then passed over the two surfaces. While robust binding of the agrin to the antibody surface was easily detected, no binding of the agrin to the MuSK surface could be seen (FIG. 10A). Furthermore, while binding to the antibody surface was specifically competable by excess soluble antibody added to the agrin-containing media, the binding was not competable by excess soluble MuSK-Fc (FIG. 10A). Since agrin activity requires calcium (Bowe and Fallon, 1995, *Ann. Rev. Neurosci.* 18: 443-462), and because some heparin-binding factors require heparin to bind to their receptors (Goldfarb, M., 1990, *Cell Growth & Differentiation* 1: 439-445), applicants also attempted binding in the presence of calcium or heparin; in neither case was binding to the MuSK surface observed (FIG. 10A).

[0222] Next, applicants tried to demonstrate binding of MuSK and agrin by attempting to use MuSK-Fc to detect agrin immobilized onto nitrocellulose. In contrast to our control experiments, in which immobilized brain-derived neurotrophic factor (BDNF) was easily detected by an Fc fusion of its cognate receptor (TrkB-Fc), and in which immobilized agrin was easily detected by the agrin-specific monoclonal antibody, immobilized agrin could not be detected by MuSK-Fc (FIG. 10B).

[0223] The negative binding results described above demonstrate that the isolated MuSK receptor is not sufficient to bind agrin. Thus, despite the plethora of functional data indicating that agrin acts via MuSK, MuSK may not directly serve as a receptor for agrin. Alternatively, MuSK may require additional components or modifications which are required for it to bind and respond to agrin.

EXAMPLE 12

Agrin Activates MuSK in a Cell-Context-Dependent Fashion: Requirement for a Myotube-Specific Accessory Component

[0224] Based on the results described above, applicants considered the possibility that the agrin-MuSK interaction requires additional components. To further explore this possibility, applicants determined the cell-context dependency for agrin activation of MuSK, reasoning that if an

accessory component was required, it might be specifically expressed only on cells normally responding to agrin. Thus applicants ectopically expressed full-length cDNAs encoding rat, human and chicken MuSK in fibroblasts, and assayed for whether these MuSK receptors could be inducibly phosphorylated by agrin. When expressed in fibroblasts, none of the three species of MuSK could be phosphorylated in response to agrin. While this supported the possibility that MuSK requires an accessory myotube-specific component to respond to agrin, it was also possible that our cDNAs encoded MuSK variants that could not respond to agrin. This was a potentially worrisome possibility since there are multiple differently spliced versions of the MuSK transcript (Valenzuela, D., et al., 1995, *Neuron* 15: 573-584), applicants did not know which of the forms were normally agrin-responsive, and our cDNAs only accounted for a subset of the variant forms. Thus applicants decided to express our cDNAs in myoblasts to verify that they could mediate responses to agrin when expressed in the right context. For this purpose applicants chose to express the chicken MuSK in the mouse C2C12 myoblast cell line, since the chicken MuSK could easily be distinguished from the endogenous mouse MuSK based on size and by using particular antibodies. When expressed in undifferentiated myoblasts, the chicken MuSK did not undergo phosphorylation in response to any isoforms of agrin (**FIG. 11**, see lanes indicated "Undif", upper panel), just as it did not undergo phosphorylation in fibroblasts; undifferentiated C2C12 cells do not express appreciable amounts of endogenous MuSK (**FIG. 11**, lanes indicated "Undif", lower panel and also (Valenzuela, D., et al., 1995, *Neuron* 15: 573-584), so applicants could not compare activation of the endogenous mouse MuSK in myoblasts. Upon differentiation into myotubes, the introduced chicken MuSK was as effectively activated by agrin as was the endogenous mouse MuSK (**FIG. 11**, lanes indicated "Diff", upper panel); both introduced and endogenous MuSK had identical profiles of responsiveness to the various forms of agrins, with activations mediated only by forms having the eight amino acid insert at the Z position. Thus our cDNAs encode MuSK proteins that are perfectly competent to undergo agrin-induced phosphorylation, but they can only be activated by agrin in the context of a differentiated myotube, consistent with the notion that agrin activation of MuSK requires a myotube-specific accessory component that is not expressed in fibroblasts or undifferentiated myoblasts.

EXAMPLE 13

A Receptor Complex Can Be Demonstrated Between Agrin, MuSK and a Myotube-Specific Accessory Component

[0225] Altogether, the above data indicate that agrin requires MuSK to mediate clustering and that agrin activates MuSK very rapidly, but that agrin does not directly bind to a purified MuSK ectodomain and can only activate MuSK in the context of a myotube. These findings are consistent with the possibility that MuSK is a requisite part of an agrin receptor complex, but that although MuSK provides a key signaling function for this complex, it requires another component(s) to bind to agrin. Similar types of receptor complexes have been described for other ligands. Perhaps some of the best characterized examples include the receptor complexes for ciliary neurotrophic factor (CNTF) and its

cytokine relatives (Davis, S., et al., 1993, *Science* 260: 1805-1808; Stahl and Yancopoulos, 1993, *Cell* 74: 587-590). In order to interact with its two signal transducing "b" receptor components, gp130 and LIFRb, CNTF must first bind to its "a" receptor component, known as CNTFRa. CNTFRa serves no signaling role, and is in fact linked to the surface via a glycosylphosphatidylinositol linkage and thus has no cytoplasmic domain. The receptor complex for CNTF is built in step-wise fashion: CNTF first binds to CNTFRa; this initial complex can then bind to and recruit a single "b" component; finally, a complete complex forms that involves "b" component dimerization, which is required for signal initiation (**FIG. 12A**). In the final complex, CNTF seems to make contacts with all three receptor components. Interestingly, receptor complexes for CNTF can be built in solution using just the soluble ectodomains of the various components. Furthermore, if just one of the receptor components is linked to the surface, a receptor complex can be built around it using soluble versions of the other components, but only in a CNTF-dependent fashion (**FIG. 12B**).

[0226] If agrin binds to MuSK in a receptor complex, applicants reasoned that they might be able to manipulate this complex in much the same way the CNTF receptor complex can be manipulated. To explore the possibility that myotubes specifically express an accessory component(s) required for agrin to bind MuSK (**FIG. 12C**), applicants decided to test whether applicants could specifically build a receptor complex on the surface of myotubes, but not on other cells, using agrin together with a soluble version of the MuSK receptor to complex to the putative accessory component(s) on the surface of myotubes. Confirming this possibility, applicants found that the binding of soluble MuSK-Fc to the surface of cells can be increased using agrin, but only on the surface of differentiated myotubes and not on the surface of fibroblasts or myoblasts (**FIG. 13A**). These data demonstrate that complexes can form between agrin and MuSK, but only in the presence of a myotube-specific component(s) (as suggested in **FIG. 12C**). Interestingly, although forms of c-agrin containing the eight amino acid insert at the Z position are best able to promote agrin-dependent MuSK complex formation, forms of c-agrin without this insert can also form these complexes. The ability of all the soluble forms to promote complex formation, including those lacking the eight amino acid insert for activity, may be related to previous findings that matrix-bound forms of agrins lacking the Z insert can activate clustering (Ferns, M., et al., 1992, *Neuron* 8: 1079-1086). Thus although soluble agrins lacking inserts at the Z position do not seem capable of signaling, they may be able to form partial complexes, while matrix-associated forms of these same agrins can proceed to form complete signaling-competent complexes. Interestingly, ligands for the EPH family of RTKs provide an example of ligands that bind but do not activate their receptors when presented in soluble form, but which can act as potent activators when bound to the cell surface (Davis, S., et al., 1994, *Science* 266: 816-819); deliberate clustering of the soluble ligands can allow them to activate as well, suggesting that the role of surface-attachment is to allow for ligand-clustering (Davis, S., et al., 1994, *Science* 266: 816-819).

[0227] In the absence of added agrin, the MuSK-Fc exhibited much higher binding to myotube surfaces than did several control receptor-Fc fusion proteins (**FIG. 13A**, data shown for TrkB-Fc); the MuSK-Fc, however, displayed

similar agrin-independent binding to both myoblast and fibroblasts as did control receptor-Fc proteins (**FIG. 13A**). Specific binding of MuSK-Fc to myotube surfaces, in the absence of exogenously provided agrin, may indicate that MuSK has an affinity for its myotube-specific accessory component in the absence of ligand. Alternatively, since myotubes make muscle forms of agrin (lacking the eight amino acid insert at the Z position), the specific binding of MuSK-Fc to myotubes in the absence of added agrin could be explained by the formation of a complex between the added MuSK-Fc and endogenously expressed muscle agrin along with the accessory component; adding additional exogenous soluble agrin may simply allow for even more MuSK to be recruited into complexes with the myotube-specific accessory component. Although both myoblasts and myotubes make endogenous agrin, myoblasts seemingly cannot form complexes with added MuSK-Fc since they do not express the required accessory component.

[0228] To confirm that MuSK directly interacts with agrin as part of its receptor complex, applicants next demonstrated that radiolabelled agrin could be cross-linked to MuSK receptors on the surface of myotubes.

[0229] Flg-tagged human agrin protein corresponding to the COOH-terminal 50 kD of human agrin 4,8 was expressed in Cos cells and purified by affinity and size-exclusion chromatography to >95% purity. Twenty μ g were iodinated by a modification of the lactoperoxidase method described previously (DiStefano, P., et al, 1992, *Neuron* 8: 983-993). Incorporation of 125I was greater than 80%; 125I-h-agrin 4,8-flg was separated from free 125I on a 1x3 cm Sephadex G-25 column prior to use in cross-linking assays. Specific activity was ~4000 cpm/fmol (~2400 Ci/mmol). Biological activity of 125I-h-agrin 4,8-flg was monitored by tyrosine phosphorylation of MuSK in C2C12 myotubes and was found to be indistinguishable from its unlabeled counterpart. For cross-linking studies, 10 cm plates of differentiated C2C12 myotubes were incubated in 1 nM of [125I]-agrin_{4,8} in 1.5 ml of PBS containing 1% BSA and 1 mg/ml glucose in the presence or absence of 150-fold excess unlabeled agrin_{4,8} for 75 min at 4° C. The cross-linking agent DSS (disuccinimidyl suberate) was added to a final concentration of 0.2 mM and the plates were incubated at room temperature for 30 min, washed 3 times with 50 mM Tris/150 M NaCl pH 7.5, lysed, and subjected to immunoprecipitation with MuSK-specific antibodies. For peptide competition, peptide antigen was included in the immunoprecipitation at a final concentration of 20 μ g/ml. The samples were then electrophoresed and the fixed and dried gels were exposed for autoradiography.

[0230] Immunoprecipitations using a MuSK-specific antibody, from lysates of myotubes chemically cross-linked to radiolabelled recombinant human agrin contained complexes corresponding in size to agrin/MuSK complexes (**FIG. 13B**). These agrin/MuSK complexes were not seen in the presence of excess unlabelled agrin, or if a peptide was used to block MuSK precipitation (**FIG. 13B**). Additional radiolabelled species that immunoprecipitated with the MuSK antibody correspond to forms of agrin that are associated with, but not cross-linked to, MuSK, presumably due to the low efficiency of cross-linking (**FIG. 13B**); low levels of additional agrin complexes, perhaps involving MASC, could also be detected in these immunoprecipitations.

[0231] Finally, if our findings that soluble MuSK could form complexes with its requisite myotube-specific accessory component are correct, then this soluble receptor should also act as an inhibitor of agrin-mediated responses by sequestering the accessory component and preventing it from interacting with the endogenously-expressed, signaling-competent MuSK. Indeed, addition of increasing amounts of MuSK-Fc did inhibit agrin-mediated clustering of AChRs (**FIG. 13C**) as well as agrin-induced MuSK phosphorylation in a dose-dependent manner, while control receptor-Fc proteins had no inhibitory effect.

EXAMPLE 14

Cloning of Human Agrin cDNA

[0232] Probes corresponding to human agrin were prepared by PCR based on partial sequences of human agrin available from the Genbank database.

[0233] Two pairs of PCR primers were synthesized based on human agrin cDNA sequences obtained from Genbank. The sequences of the oligonucleotide primers were as follows:

```
Primer pair 18:
h-agrin 18-5' : 5'-GACGACCTCTCCGGAATTC-3'

h-agrin 18-3' : 5'-GTGCACATCCACAATGGC-3'

Primer pair 35:
h-agrin 35-5' : 5'-GAGCAGAGGGGAAAGTTCCCTG-3'

h-agrin 35-3' : 5'-TCATGTGCCAGTCGCTGG-3'
```

[0234] The oligonucleotide primers were used for PCR amplification of two segments of DNA of approximately 100 nts (primer pair 18) and 85 nts (primer pair 35) using 300 ngs of human genomic DNA as a template. The PCR amplification was carried out as recommended by the manufacturer (Perkin-Elmer) under the following conditions: 35 cycles at 94° C. for 60 sec, 55° C. for 50 sec and 72° C. for 30 sec. The PCR fragments obtained were purified from an agarose gel and re-amplified for 30 cycles using the same PCR conditions described above.

[0235] After amplification, the PCR reactions were electrophoresed in agarose gels, the agarose containing the DNA bands of 100 and 85 nts respectively was excised, purified by QiaEx II (Qiagen), and then cloned into plasmid pCR-script using Stratagene's pCR-Script cloning kit, followed by bacterial transformation and plating onto agar-ampicillin plates as recommended by the manufacturer. Bacterial colonies containing the 100 and 85 nt inserts were identified by PCR using the primers described above. The PCR fragments obtained were radiolabeled for use as probes using a standard PCR reaction (Perkin-Elmer) on 20 ng of DNA template, except that 5 nmoles each of dATP, dGTP and dTTP and 0.2 mCurie of alpha ³²P-dCTP (Du Pont 3000 Ci/mmol) were added to the reaction mixture and then subjected to 7 cycles of PCR. Unincorporated label was separated from the probes on a G50 NICK column (Pharmacia). These probes were used to screen a human fetal brain cDNA library (Stratagene Cat#936206) using standard library screening procedures (Sambrook, Fritsch and Maniatis, *Molecular Cloning, a Laboratory Manual*, (1989) Second Edition, Cold Spring Harbor Laboratory Press). One and a half million

phage plaques were plated in XL-1 Blue bacteria as recommended by Stratagene, and transferred to nitrocellulose filters in duplicate as previously described (Id.). The filters were processed and each filter replica was used for hybridization with one of the above probes as previously described (Id.). Plaques hybridizing to both probes were isolated and purified and a plasmid containing the cDNA insert was excised from the lambda clone according to Stratagene's recommended procedure (EXASSIST/SOLR System). The pBluescript plasmid containing the human Agrin insert was purified and the insert was then sequenced using an automated sequencing kit (Applied Biosystems).

[0236] As a result of this screen, one clone (pBL-hAgrin1) was obtained which contains a nucleotide sequence encoding an amino acid sequence of human agrin. The first amino acid encoded by the cloned nucleotide sequence corresponds approximately to amino acid 424 of rat agrin (See FIG. 14). The nucleotide sequence of the clone ends downstream of the stop codon. Clone pBL-hAgrin1 contains a 4 amino acid insert starting at the position which corresponds to position 1643 of FIG. 14, a point which was previously described for the rat as position "Y" (Stone, D. M. and Nikolics, K., J. Neurosci. 15: 6767-6778 (1995)). The sequence of the 4 amino acid insert both in clone pBL-hAgrin1 and in the rat is KSRK.

[0237] A second clone was obtained from this screen. This second clone (pBL-hAgrin23) also contains a nucleotide sequence encoding an amino acid sequence of human agrin. The first amino acid encoded by the cloned nucleotide sequence corresponds approximately to amino acid 1552 of the rat agrin (See FIG. 14). The nucleotide sequence of the clone ends downstream of the stop codon. Clone pBL-hAgrin23 contains an 8 amino acid insert starting at a position which corresponds to position 1780 of FIG. 14, a point which was previously described for the rat as position "Z" (Stone, D. M. and Nikolics, K., J. Neurosci. 15: 6767-6778 (1995)). The sequence of the eight amino acid insert both in clone pBL-hAgrin23 and in the rat is ELANEIPV. As previously discussed, it has been reported that the 8 amino acid insert plays an important role in regulating the AChR clustering activity of different agrin forms. Therefore, by inserting a nucleotide sequence encoding the eight amino acid sequence ELANEIPV into clone pBL-hAgrin1 at the position corresponding to position Z of rat agrin, a human 4-8 agrin clone may be obtained. The addition of the 8 amino acid insert at position Z should confer a high level of biological activity to the human 4-8 clone.

[0238] Clone pBL-hAgrin23 also contains the 4 amino acid "Y" insert as described above for clone pBL-hAgrin1. However, clone pBL-hAgrin23 contains 17 extra amino acids at the same "Y" position, such that the sequence of the "Y" insert in clone pBL-hAgrin23 is KSRKVLASHP-PLTVSGASTPR. Therefore, in addition to the (4-0) and (4-8) human agrin splice variants described above, human clones corresponding to splice variants containing (Y-Z) inserts of (17-0), (17-8), (21-0), and (21-8) are indicated by these results and are within the scope of the present invention.

EXAMPLE 15

Expression of Human Agrin

[0239] Construction of Human Agrin Expression Vector

[0240] A human agrin Sfi I-A at II fragment containing the 4 amino acid insert at the position corresponding to the Y-site described for rat agrin (see FIG. 14) was excised from clone pBL h agrin-1. A human agrin Aat II-Not I fragment containing the 8 amino acid insert at the position corresponding to the Z-site described for rat agrin (see FIG. 14) was excised from clone pBL h agrin-23. A Xho I-Sfi I fragment was then generated via PCR that contained a preprotrypsin signal peptide, the 8 amino acid flg peptide (from the flag tagging system, IBI/Kodak, Rochester, N.Y.) and the human agrin sequence corresponding to the sequence of amino acids from position 1480 to the Sfi I site located at amino acids 1563-1566 of rat agrin (see FIG. 14). The three fragments were then ligated into a Xho I-Not I digested pMT21 expression vector to form the human agrin 4-8 expression vector pMT21-agrin 4-8. The sequence of human agrin 4-8 that was encoded in the expression vector is shown in FIG. 15. Expression vectors for the human clones corresponding to splice variants containing (Y-Z) inserts of (0-8) and (4-0) were also constructed.

[0241] Expression of Human Agrin (4-8) in *E. coli*

[0242] The gene for human agrin 4-8 was PCR amplified from pMT21-agrin 4-8 with the primer pair AG5' (5'-GAGAGAGGTTTAAACATGAGCCCCCTGC-CAGCCCAACCCCTG-3') and AG3' (5'-CTCTGCGGC-CGCTTATCATGGGGTGGGGCAGGGCCGAG-3'). The PCR product was digested with the restriction enzymes Pme I and Not I and cloned into the Pme I and Not I sites of the vector pRG501, a pMB1 replicon that confers kanamycin resistance and is designed to express cloned genes from the phage T7 promoter. One isolate was characterized and named pRG531. The 1315 base pair Nco I-Nae I fragment internal to agrin in pRG531 was then replaced with the corresponding fragment from pMT21-agrin 4-8. The resulting plasmid, pRG451, was transformed into the expression strain RFJ209 [IN(rrnD-rrn/E)1 lacI^Q lacZpL8 fhuAD322-405 rpoS_(MC4100) ara::lacUV5-T7 gene 1]8]. Cultures of RFJ209/pRG451 induced with IPTG express human agrin to about 5% of total cellular protein and fractionates with soluble protein upon cell disruption. The crude soluble protein fraction containing human agrin 4-8, as well as human agrin 4-8 purified by Q-Sepharose chromatography was determined to be active in phosphorylation of MuSK receptor.

[0243] Expression of Human Agrin (4-8) in *Pichia pastoris*

[0244] The 50 kD active fragment (portion) of human agrin 4-8 was cloned by PCR using a primer containing a portion of the *S. cerevisiae* α mating factor pre-pro secretion signal and the 5' end of the region encoding the 50 kD agrin fragment (GTATCTCTCGAGAAAAGAGAGGCT-GAAGCT AGCCCCTGCCAGCCCAACC), and a primer containing sequences from the region 3' of the agrin coding region and a NotI site (AATAGTGCGGCCCAACACT-CAGGCAAGAAAATCATATC). After PCR the fragment was digested with XhoI, which recognizes sequences in the 5' primer, and NotI, and was cloned into pPIC9 (Invitrogen)

digested with XhoI and NotI. The resulting clone was digested with NotI and partially digested with NcoI to remove most of the PCRred agrin sequences. This region was replaced by a NotI-NcoI fragment of agrin from pRG541. PCRred regions were sequenced and shown to be wild-type. This clone, pRG543 was digested with SalI and transformed into *Pichia pastoris* by electroporation. Transformants were selected for a His⁺ Mut⁺ phenotype. Induction of the AOX1 promoter driving the expression of hAgrin was done by growing the cells in buffered glycerol-complex medium containing 0.5% glycerol, pH=6.0, for 24 hrs until the glycerol was exhausted, at which point methanol was added to a final concentration of 0.5%. The culture was centrifuged and the supernatant was dialyzed against PBS. The concentration of hAgrin was approximately 10 ug/ml and was determined to be active in phosphorylation of MuSK receptor.

[0245] Production of Human Agrin 4,8 from Baculovirus Infected Insect Cells

[0246] Virus Production

[0247] The flg-tagged gene for human agrin 4-8 was engineered into a baculovirus expression plasmid and recombined with viral DNA to generate recombinant baculovirus, amplified and harvested using methods previously described (O'Reilly, D. R., L. K. Miller, and V. A. Luckow, *Baculovirus Expression Vectors—A Laboratory Manual* 1992, New York: W. H. Freeman). SF21 insect cells (*Spodoptera frugiperda*) obtained from Invitrogen were adapted and expanded at 27° C. in Gibco SF900 II serum-free medium. Uninfected cells were grown to a density of 1×10⁷ cells/mL. Cell density was determined by counting viable cells using a hemacytometer. The virus stock for FLAG-agrin was added to the bioreactor at a low multiplicity 0.01-0.1 PFU/cell to begin the infection. The infection process was allowed to continue for 3-4 days allowing maximum virus replication without incurring substantial cell lysis. The cell suspension was aseptically aliquoted into sterile centrifuge bottles and the cells removed by centrifugation (1600 RPM, 30 min). The cell-free supernatant was collected in sterile bottles and stored at 4° C. in the absence of light until further use.

[0248] The virus titer was determined by plaque assay as described by O'Reilly, Miller and Luckow. The method is carried out in 60 mm tissue-culture dishes which are seeded with 1.5×10⁶ cells. Serial dilutions of the virus stock are added to the attached cells and the mixture incubated with rocking to allow the virus to adsorb to individual cells. An agar overlay is added and plates incubated for 5 days at 27° C. Viable cells were stained with neutral red revealing circular plaques which were counted to give the virus titer expressed in plaque forming unit per milliliter (PFU/mL).

[0249] Infection of Cells for Protein Production

[0250] Uninfected SF21 cells were grown in a 60 LABEC bioreactor containing 40 L of Gibco SF900 II medium with gentamicin sulfate (25 mg/L) and amphotericin B (1 mg/L). Temperature was controlled at 27° C. and the dissolved oxygen level was maintained at 50% of saturation by controlling the flowrate of oxygen in the inlet gas stream. When a density of 2×10⁶ cells/mL was reached, the cells were concentrated within the bioreactor to 20 L, using a low shear steam sterilizable pump and a tangential flow filtration

device with Millipore Prostack 0.45 micron membranes. After concentration, fresh sterile growth medium was slowly added to the bioreactor while the filtration system continued to remove the spent growth medium by diafiltration. After two volume exchanges an additional 20 L of fresh medium was added to the bioreactor to resuspend the cells to the original volume of 40 L.

[0251] The amount of virus stock required was calculated based on the cell density, virus titer and the desired multiplicity of infection (MOI). Multiplicity ratios between 1 and 10 pfu/cell have been effectively used. The virus stock was added aseptically to the bioreactor and the infection was allowed to proceed for three to four days.

[0252] Recovery and Chromatographic Purification

[0253] At the conclusion of the infection phase of the bioreactor process the cells were concentrated in the bioreactor using a 30 ft² Millipore Prostack filter (0.45 micron) pore size. The cell-free permeate passing through the filter was collected in a clean process vessel. The protein was diafiltered into a low conductivity buffer (20 mM citrate, pH 5.5) using Millipore Pellicon ultrafiltration membrane cassettes totaling 20 ft² with a nominal 10 kiloDalton cutoff. The protein in the retentate was loaded onto a cation exchange column (Pharmacia SP Sepharose FF) equilibrated with 20 mM citrate buffer, pH 5.5. After loading the protein was washed first with 20 mM citrate, 200 mM sodium chloride, pH 5.5 then with 20 mM Bicine, pH 8.0 to remove contaminating proteins. The protein was eluted with a 0-750 mM sodium chloride linear gradient over 7.5 column volumes. The eluted agrin was buffer exchanged into 20 mM Tris, pH 8.5 buffer to remove salt for subsequent binding to an anion exchange column.

[0254] The agrin was then bound to a Pharmacia Q Sepharose FF column equilibrated with 20 mM Tris, pH 8.5. After loading the column was washed with the same buffer to remove contaminating proteins and the protein eluted with a 0-250 mM sodium chloride gradient. The fractions containing agrin were pooled and concentrated and dialyzed into PBS containing calcium and magnesium.

[0255] Expression of human agrin (4-8) in COS-7 cells Lipofectamine reagent (GIBCO-BRL, Inc.) and recommended protocols were used to transfect COS-7 cells with the human agrin cDNA clone pMT21-agrin 4-8 containing a nucleotide sequence encoding the eight amino acid sequence ELANEIPV at the position corresponding to position Z of rat agrin. COS media containing secreted ligand was harvested after three days and concentrated 20-fold by diafiltration (DIAFLO ultrafiltration membranes, Amicon, Inc.). The quantity of active human agrin present in the media was determined and expressed as the amount (in resonance units, R.U.) of MuSK receptor specific binding activity measured by a BIAcore binding assay.

EXAMPLE 16

Preparation of Truncated Molecules Containing the MuSK Activation Portion of Human Agrin

[0256] It has recently been reported that a 21 kD fragment of chick agrin is sufficient to induce AChR aggregation (Gesemann, M., et al., 1995, *J. Cell. Biol.* 128: 625-636). Applicants therefore decided to investigate the properties of

various portions of human agrin and to test the ability of each to induce phosphorylation of the MuSK receptor.

[0257] As set forth in FIG. 15, the amino acid sequence of the 50 kD active portion of human agrin 4,8 is 492 amino acids long. A preprotrypsin signal sequence (Stevenson et al., 1986. *Nucleic Acids Res.* 21: 8307-8330) precedes a FLAG tag sequence (Hopp et al. 1988. *Bio/Technology* 6: 1204-1210); together, they constitute the first 23 amino acids. Thus the agrin 4,8 sequence begins with amino acid 24. Truncated molecules were created, each of which contained the signal sequence and FLAG tag (23 amino acids) followed by the agrin 4,8 sequence to which N-terminal deletions had been made to create portions of agrin (designated delta 3 through 9) as follows:

[0258] delta 3: agrin sequence starts with amino acid #60: QTAS . . .

[0259] delta 4: agrin sequence starts with amino acid #76: NGFS . . .

[0260] delta 5: agrin sequence starts with amino acid #126: VSLA . . .

[0261] delta 6: agrin sequence starts with amino acid #178: GPRV . . .

[0262] delta 7: agrin sequence starts with amino acid #222: GFDG . . .

[0263] delta 8: agrin sequence starts with amino acid #260: ASGH . . .

[0264] delta 9: agrin sequence starts with amino acid #300: AGDV . . .

[0265] All of the sequences continue to the terminal amino acids PCP/TP, as with the 50 kD agrin.

[0266] The truncated molecules were made as follows: PCR primers were designed consistent with the nucleotide sequences encoding the first and last ten amino acids of each construct. Included in the 5' primer was sequence data to append the preprotrypsin signal sequence and "FLAG-tag" to the amino terminus of each agrin fragment. Thus, the shortest truncated molecule (delta 9) contains the signal sequence and FLAG tag and the human agrin sequence from amino acid 300 to 492 of human c-agrin 4,8. DNA encoding the "delta" forms of truncated c-agrin 4,8 was then cloned into a eukaryotic expression vector, and transient transfections were performed as previously described (Glass, D., et al., 1991, *Cell* 66: 405-413; Ip, N.Y., et al., 1992, *PNAS (USA)* 89: 3060-3064).

[0267] Agrin levels in the COS-transfected supernatants were determined by Western analysis of the conditioned media with an agrin-specific antibody (Stressgen 131), using a purified agrin control of known concentration. Each of the truncated molecules was expressed and shown to be capable of inducing tyrosine phosphorylation of MuSK receptor.

[0268] FIG. 16 shows that the delta 9 truncated molecule can induce phosphorylation of the MuSK receptor, though with less efficiency than the 50 kD agrin 4,8 molecule. Thus, each of the truncated molecules created exhibited the biological activity of human agrin 4,8 with respect to the MuSK receptor.

EXAMPLE 17

PEGylation of Agrin 4,8 and Pharmacokinetics Study

[0269] After intravenous administration, the 50 kD agrin 4,8 was cleared rapidly from the systemic circulation with a half-life of <10 minutes. (See FIG. 17). It was known that the properties of certain proteins can be modulated by attachment of polyethylene glycol (PEG) polymers, which increases the hydrodynamic volume of the protein and thereby slows its clearance by kidney filtration. (See, e.g. Clark, R., et al., 1996, *J. Biol. Chem.* 271: 21969-21977). Therefore, in an attempt to increase its circulating half-life, agrin 4,8 was modified by covalent attachment of a polyethylene glycol molecule and the effect on the protein's serum half-life was studied.

[0270] A solution of 500 mg of human agrin 4,8 at 3.0 mg/mL was added to a reaction vessel and the PEGylation reaction was initiated by addition of monomethoxypolyethylene glycol succinimidyl propionate (PEG) (approximate molecular weight=20,000 daltons). A ratio of 1.75 moles PEG reagent to agrin was used for the reaction which was carried out at a pH of 7.3 to 8.5 in phosphate buffered saline over a period of 2 hours. The reaction was stopped by addition of 50 mM Tris hydrochloride.

[0271] The PEGylated agrin was diluted with buffer at a pH of 8.2 to lower both the conductivity and the concentration of Tris, before loading onto a cation exchange column (Pharmacia SP High Performance). The column was eluted using a gradient from 0 to 600 mM sodium chloride in Tris buffer at a pH of 8.2. Numerous distinct forms of PEGylated agrin eluted along the gradient and unmodified agrin eluted at the high salt end of the gradient. Monopegylated forms were selectively pooled for subsequent in vivo testing.

[0272] Adult Sprague-Dawley rats (male or female) weighing 300-500 g were anesthetized with ketamine/xylazine (50/10 mg/kg) and the right hind limb muscles were denervated by transecting the sciatic nerve at mid thigh level. After 10-14 days (when MuSK expression was substantially elevated in denervated muscle) rats were re-anesthetized and the right jugular vein was exposed by cut down surgery. Rats were then administered doses of agrin 4,8 or PEG-agrin 4,8 ranging from 1-10 mg/kg into the jugular vein with a 27 gauge needle. After injection, the wound was sutured and tail blood samples were taken at 0 (pre-injection), 5, 10, 15, 30 minutes, and at 1, 2, 4, 6, 8, 16, 24, and 48 hours after the injection. Serum samples were harvested from centrifuged blood and assayed using an ELISA. Serum levels are expressed as $\mu\text{g/ml}$ of serum.

[0273] As shown in FIG. 17, at a dose of 10 mg/kg, i.v., agrin 4,8 was rapidly cleared from the blood with a half-life of ~10 minutes. In contrast, the half-life of PEG-agrin 4,8 (also at 10 mg/kg, i.v.) was dramatically increased by ~10-fold. These results show that modification of agrin 4,8 with PEG greatly increases its apparent half-life in the blood. Thus, PEGylated agrin may have prolonged activity on MuSK in denervated skeletal muscle and may thus be a more effective treatment for muscular disorders and conditions such as muscle atrophy. It is expected that the PEGylation of the above-described truncated agrin molecules would similarly increase their apparent half-lives in the blood.

DEPOSIT OF MICROORGANISMS

[0274] A clone designated pBluescript SK-containing dmk was deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852 on Jul. 13, 1993 under ATCC Accession No. 75498. Recombinant *Autographa californica* baculovirus encoding the rat Dmk RB (i.e., rat MuSK-IgG1 receptorbody) was designated "vDmk receptorbody" and deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852 on May 16, 1995 under ATCC Accession No. VR-2507. The cDNA clone pBL-hAgrin1 was deposited

with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852 on Dec. 12, 1995 under ATCC Accession No. 97378.

[0275] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 36

<210> SEQ ID NO 1

<211> LENGTH: 868

<212> TYPE: PRT

<213> ORGANISM: Rattus sp.

<400> SEQUENCE: 1

```

Met Arg Glu Leu Val Asn Ile Pro Leu Leu Gln Met Leu Thr Leu Val
 1           5           10           15

Ala Phe Ser Gly Thr Glu Lys Leu Pro Lys Ala Pro Val Ile Thr Thr
          20           25           30

Pro Leu Glu Thr Val Asp Ala Leu Val Glu Glu Val Ala Thr Phe Met
          35           40           45

Cys Ala Val Glu Ser Tyr Pro Gln Pro Glu Ile Ser Trp Thr Arg Asn
 50           55           60

Lys Ile Leu Ile Lys Leu Phe Asp Thr Arg Tyr Ser Ile Arg Glu Asn
 65           70           75           80

Gly Gln Leu Leu Thr Ile Leu Ser Val Glu Asp Ser Asp Asp Gly Ile
          85           90           95

Tyr Cys Cys Thr Ala Asn Asn Gly Val Gly Gly Ala Val Glu Ser Cys
100           105           110

Gly Ala Leu Gln Val Lys Met Lys Pro Lys Ile Thr Arg Pro Pro Ile
115           120           125

Asn Val Lys Ile Ile Glu Gly Leu Lys Ala Val Leu Pro Cys Thr Thr
130           135           140

Met Gly Asn Pro Lys Pro Ser Val Ser Trp Ile Lys Gly Asp Ser Ala
145           150           155           160

Leu Arg Glu Asn Ser Arg Ile Ala Val Leu Glu Ser Gly Ser Leu Arg
165           170           175

Ile His Asn Val Gln Lys Glu Asp Ala Gly Gln Tyr Arg Cys Val Ala
180           185           190

Lys Asn Ser Leu Gly Thr Ala Tyr Ser Lys Leu Val Lys Leu Glu Val
195           200           205

Glu Val Phe Ala Arg Ile Leu Arg Ala Pro Glu Ser His Asn Val Thr
210           215           220

Phe Gly Ser Phe Val Thr Leu Arg Cys Thr Ala Ile Gly Met Pro Val
225           230           235           240

Pro Thr Ile Ser Trp Ile Glu Asn Gly Asn Ala Val Ser Ser Gly Ser
245           250           255

Ile Gln Glu Asn Val Lys Asp Arg Val Ile Asp Ser Arg Leu Gln Leu

```

-continued

260					265					270					
Phe	Ile	Thr	Lys	Pro	Gly	Leu	Tyr	Thr	Cys	Ile	Ala	Thr	Asn	Lys	His
		275					280					285			
Gly	Glu	Lys	Phe	Ser	Thr	Ala	Lys	Ala	Ala	Ala	Thr	Val	Ser	Ile	Ala
	290					295					300				
Glu	Trp	Ser	Lys	Ser	Gln	Lys	Glu	Ser	Lys	Gly	Tyr	Cys	Ala	Gln	Tyr
305					310					315					320
Arg	Gly	Glu	Val	Cys	Asp	Ala	Val	Leu	Val	Lys	Asp	Ser	Leu	Val	Phe
				325						330					335
Phe	Asn	Thr	Ser	Tyr	Pro	Asp	Pro	Glu	Glu	Ala	Gln	Glu	Leu	Leu	Ile
			340					345						350	
His	Thr	Ala	Trp	Asn	Glu	Leu	Lys	Ala	Val	Ser	Pro	Leu	Cys	Arg	Pro
		355					360					365			
Ala	Ala	Glu	Ala	Leu	Leu	Cys	Asn	His	Leu	Phe	Gln	Glu	Cys	Ser	Pro
	370					375					380				
Gly	Val	Leu	Pro	Thr	Pro	Met	Pro	Ile	Cys	Arg	Glu	Tyr	Cys	Leu	Ala
385						390					395				400
Val	Lys	Glu	Leu	Phe	Cys	Ala	Lys	Glu	Trp	Leu	Ala	Met	Glu	Gly	Lys
				405					410					415	
Thr	His	Arg	Gly	Leu	Tyr	Arg	Ser	Gly	Met	His	Phe	Leu	Pro	Val	Pro
			420					425					430		
Glu	Cys	Ser	Lys	Leu	Pro	Ser	Met	His	Gln	Asp	Pro	Thr	Ala	Cys	Thr
		435					440					445			
Arg	Leu	Pro	Tyr	Leu	Asp	Tyr	Lys	Lys	Glu	Asn	Ile	Thr	Thr	Phe	Pro
	450					455					460				
Ser	Ile	Thr	Ser	Ser	Lys	Pro	Ser	Val	Asp	Ile	Pro	Asn	Leu	Pro	Ala
465						470					475				480
Ser	Thr	Ser	Ser	Phe	Ala	Val	Ser	Pro	Ala	Tyr	Ser	Met	Thr	Val	Ile
				485					490					495	
Ile	Ser	Ile	Met	Ser	Cys	Phe	Ala	Val	Phe	Ala	Leu	Leu	Thr	Ile	Thr
			500					505					510		
Thr	Leu	Tyr	Cys	Cys	Arg	Arg	Arg	Arg	Glu	Trp	Lys	Asn	Lys	Lys	Arg
		515					520					525			
Glu	Ser	Ala	Ala	Val	Thr	Leu	Thr	Thr	Leu	Pro	Ser	Glu	Leu	Leu	Leu
	530					535					540				
Asp	Arg	Leu	His	Pro	Asn	Pro	Met	Tyr	Gln	Arg	Met	Pro	Leu	Leu	Leu
545						550					555				560
Asn	Pro	Lys	Leu	Leu	Ser	Leu	Glu	Tyr	Pro	Arg	Asn	Asn	Ile	Glu	Tyr
				565					570					575	
Val	Arg	Asp	Ile	Gly	Glu	Gly	Ala	Phe	Gly	Arg	Val	Phe	Gln	Ala	Arg
			580					585					590		
Ala	Pro	Gly	Leu	Leu	Pro	Tyr	Glu	Pro	Phe	Thr	Met	Val	Ala	Val	Lys
		595					600					605			
Met	Leu	Lys	Glu	Glu	Ala	Ser	Ala	Asp	Met	Gln	Ala	Asp	Phe	Gln	Arg
	610					615					620				
Glu	Ala	Ala	Leu	Met	Ala	Glu	Phe	Asp	Asn	Pro	Asn	Ile	Val	Lys	Leu
625						630					635				640
Leu	Gly	Val	Cys	Ala	Val	Gly	Lys	Pro	Met	Cys	Leu	Leu	Phe	Glu	Tyr
				645					650					655	
Met	Ala	Tyr	Gly	Asp	Leu	Asn	Glu	Phe	Leu	Arg	Ser	Met	Ser	Pro	His
			660				665						670		

-continued

```

Thr Val Cys Ser Leu Ser His Ser Asp Leu Ser Thr Arg Ala Arg Val
675                               680                               685

Ser Ser Pro Gly Pro Pro Pro Leu Ser Cys Ala Glu Gln Leu Cys Ile
690                               695                               700

Ala Arg Gln Val Ala Ala Gly Met Ala Tyr Leu Ser Glu Arg Lys Phe
705                               710                               715                               720

Val His Arg Asp Leu Ala Thr Arg Asn Cys Leu Val Gly Glu Asn Met
725                               730                               735

Val Val Lys Ile Ala Asp Phe Gly Leu Ser Arg Asn Ile Tyr Ser Ala
740                               745                               750

Asp Tyr Tyr Lys Ala Asp Gly Asn Asp Ala Ile Pro Ile Arg Trp Met
755                               760                               765

Pro Pro Glu Ser Ile Phe Tyr Asn Arg Tyr Thr Thr Glu Ser Asp Val
770                               775                               780

Trp Ala Tyr Gly Val Val Leu Trp Glu Ile Phe Ser Tyr Gly Leu Gln
785                               790                               795                               800

Pro Tyr Tyr Gly Met Ala His Glu Glu Val Ile Tyr Tyr Val Arg Asp
805                               810                               815

Gly Asn Ile Leu Ala Cys Pro Glu Asn Cys Pro Leu Glu Leu Tyr Asn
820                               825                               830

Leu Met Arg Leu Cys Trp Ser Lys Leu Pro Ala Asp Arg Pro Ser Phe
835                               840                               845

Cys Ser Ile His Arg Ile Leu Gln Arg Met Cys Glu Arg Ala Glu Gly
850                               855                               860

Thr Val Gly Val
865
    
```

```

<210> SEQ ID NO 2
<211> LENGTH: 2869
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (2817)
<223> OTHER INFORMATION: n=a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (2823)
<223> OTHER INFORMATION: n=a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (2824)
<223> OTHER INFORMATION: n=a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (2867)
<223> OTHER INFORMATION: n=a, c, g, or t
    
```

```

<400> SEQUENCE: 2
gaattcggca cgagcaaaca gtcattagtg gacgactcta ttgtaataaa ctgtgcttta      60
aaatgtaaac caggagcgt ttttttcct cacattgtcc agaagcaacc tttcttcctg      120
agcctggatt aatcatgaga gagctcgtca acattccact gttacagatg ctcaccctgg      180
ttgccttcag cgggaccgag aaacttccaa aagcccctgt catcaccacg cctcttgaaa      240
ctgtagatgc cttagttaga gaagtggcga ctttcatgtg cgccgtggaa tcctaccctc      300
agcctgaaat ttcttgacc agaaataaaa ttctcatcaa gctgtttgac acccgctaca      360
    
```

-continued

gcatccgaga gaacggtcag ctctcacca tcttgagtgt ggaggacagt gatgatggca	420
tctactgctg cacagccaac aatggagtgg gaggagcggg gaaaagtgtg ggcgccctgc	480
aagtgaagat gaagcctaaa ataactcgtc ctcccatcaa tgtaaaaata attgagggat	540
tgaaagcagt cctaccgtgc actacgatgg gtaaccccaa gccatccgtg tcttgatta	600
agggggacag tgctctcagg gaaaattcca ggattgcagt tcttgaatct gggagttaa	660
ggatccataa tgtgcaaaaag gaagacgcag gacagtaccg atgtgtggca aaaaacagcc	720
tgggcacagc ttactccaaa ctggtgaaagc tggaagtggg ggtttttgca agaactcctgc	780
gtgctcctga atcccacaat gtcaccttg gttcctttgt aacctacgc tgcacagcaa	840
taggcattgc tgtccccacc atcagctgga ttgaaaacgg aaatgctgtt tcttcaggtt	900
ccattcaaga gaatgtgaaa gaccgagtga ttgactcaag actccagctc tttatcacia	960
agccaggact ctacacatgc atagctacca ataagcatgg agagaaattc agtaccgcaa	1020
aggctgcagc cactgtcagt atagcagaat ggagcaaatc acagaaagaa agcaaaggct	1080
actgtgcca gtacagaggg gaggtgtgtg atgccgtcct ggtgaaagac tctctgtct	1140
tcttcaacac ctctatccc gacctgagg aggcccaaga gctgctgac cacactgct	1200
ggaatgaact caaggctgtg agcccactct gccgaccagc tgcogaggct ctgctgtgta	1260
atcacctctt ccaggagtgc agccctggag tgctacctac tcctatgcc atttgcagag	1320
agtactgctt ggcagtaaaag gactcttct gtgcaaaagga atggctggca atggaaggga	1380
agaccaccg cggactctac agatccggga tgcatttct cccggctccg gactgcagca	1440
agcttcccag catgcaccag gaccaccag cctgcacaag actgccgtat ttagattata	1500
aaaaagaaa cataacaaca ttcccgtcca taacgtctc caagccgagc gtggacattc	1560
caaacctgcc tgcctccag tctctctcg ccgtctcgc tgcgtactcc atgactgtoa	1620
tcactccat catgtctgc tttgcgggtg ttgctctcct caccatcact actctctatt	1680
gctgccgaag gaggagagag tgaaaaata agaaaagaga gtcggcagcg gtgacctca	1740
ccacattgcc ttccgagctc ctgctggaca ggctgcatcc caacccatg taccagagga	1800
tgccactcct tctgaatccc aagtgtctca gctggagta tccgaggaat aacatcgagt	1860
atgtcagaga catcggagag ggagcgtttg gaagggtctt tcaagcgagg gcccaggct	1920
tgcttctta tgaaccctc actatgggtg ctgtgaagat gctgaaggag gaggcctccg	1980
cagatatgca ggcagacttt cagagggagg cagccctcat ggcggagttt gacaaccca	2040
acattgtgaa gctcttaggt gtgtgtgctg ttgggaagcc aatgtgctg ctctttgaa	2100
atatggceta tggtagctc aatgagttcc tccgaagcat gtcccctcac actgtgtgca	2160
gcctcagcca cagtgcctg tccacgagg ctggtgtgct cagccctggt cctccacccc	2220
tgtcttgtg ggaacagctc tgtattgcca ggcaagtggc agctggcatg gcctacctgt	2280
cggagcgcaa gtttgcctc cgggacttag ctaccaggaa ctgctgggtt ggagagaaca	2340
tggtgtgaa aattgcagac tttggcctc ctaggaacat ctactccgca gactactaca	2400
aagctgatgg aaacgatgct atacctatcc gctggatgcc acccgagtct atcttctaca	2460
accgctacac cacggagtca gatgtgtggg cttatggcgt ggtcctctgg gagatctct	2520
cctatggact gcagccctac tatggaatgg cccatgagga ggtcatttac tatgtgagag	2580
atggtaacat ccttgctcgc cctgagaact gtcccctgga actgtacaac cttatgcgcc	2640

-continued

```
tatgttggag caagctgct gcagacagac ccagcttctg cagtatccac cggatcctgc 2700
agcgcgatgtg cgagagagca gagggaacgg taggcgtcta aggttgacca tgctcaaaaca 2760
acaccocagga ggatcttttc agactgcgag ctggagggat cctaaagcag agggcgnata 2820
agmncagata ggaagagttt atctcaggca gcacgtncag ttggttgtt 2869
```

```
<210> SEQ ID NO 3
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer
<400> SEQUENCE: 3
```

```
Asp Val Trp Ala Tyr Gly
  1             5
```

```
<210> SEQ ID NO 4
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (18)
<223> OTHER INFORMATION: n=a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)
<223> OTHER INFORMATION: n=a, c, g, or t
<400> SEQUENCE: 4
```

```
gaattcgagc tcccrwangc ccanacrtc 29
```

```
<210> SEQ ID NO 5
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer
<400> SEQUENCE: 5
```

```
Asp Leu Ala Thr Arg Asn
  1             5
```

```
<210> SEQ ID NO 6
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (17)
<223> OTHER INFORMATION: n=a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (20)
<223> OTHER INFORMATION: n=a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (23)
<223> OTHER INFORMATION: n=a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (26)
```

-continued

<223> OTHER INFORMATION: n=a, c, g, or t

<400> SEQUENCE: 6

tcttgactcg agayytngcn acnmgnaa 28

<210> SEQ ID NO 7

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<400> SEQUENCE: 7

Asp Leu Ala Ala Arg Asn

1 5

<210> SEQ ID NO 8

<211> LENGTH: 28

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (17)

<223> OTHER INFORMATION: n=a, c, g, or t

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (20)

<223> OTHER INFORMATION: n=a, c, g, or t

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (23)

<223> OTHER INFORMATION: n=a, c, g, or t

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (26)

<223> OTHER INFORMATION: n=a, c, g, or t

<400> SEQUENCE: 8

tcttgactcg agayytngcn gcnmgnaa 28

<210> SEQ ID NO 9

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<400> SEQUENCE: 9

Asp Val Trp Ser Leu Gly

1 5

<210> SEQ ID NO 10

<211> LENGTH: 29

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (6)

<223> OTHER INFORMATION: n=a, c, g, or t

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (12)

<223> OTHER INFORMATION: n=a, c, g, or t

-continued

<400> SEQUENCE: 10

ctrccanaccw snatrcocctc gagcttaag

29

<210> SEQ ID NO 11

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<400> SEQUENCE: 11

Asp Val Trp Ser Phe Gly

1

5

<210> SEQ ID NO 12

<211> LENGTH: 29

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (6)

<223> OTHER INFORMATION: n=a, c, g, or t

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (11)

<223> OTHER INFORMATION: n=a, c, g, or t

<400> SEQUENCE: 12

ctrccanaccw snaarccocctc gagcttaag

29

<210> SEQ ID NO 13

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<400> SEQUENCE: 13

Asp Val Trp Ser Tyr Gly

1

5

<210> SEQ ID NO 14

<211> LENGTH: 29

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (6)

<223> OTHER INFORMATION: n=a, c, g, or t

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (12)

<223> OTHER INFORMATION: n=a, c, g, or t

<220> FEATURE:

<221> NAME/KEY: modified_base

<222> LOCATION: (15)

<223> OTHER INFORMATION: n=a, c, g, or t

<400> SEQUENCE: 14

ctrccanaccw snranccocctc gagcttaag

29

<210> SEQ ID NO 15

-continued

```

<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (18)
<223> OTHER INFORMATION: n=a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (24)
<223> OTHER INFORMATION: n=a, c, g, or t

<400> SEQUENCE: 15

gaattcgagc tcccransw ccanacrtc                29

<210> SEQ ID NO 16
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Gallus gallus

<400> SEQUENCE: 16

Thr Leu Pro Ser Glu Leu Leu Leu Asp Arg Leu His Pro Asn Pro Met
  1             5             10             15

Tyr Gln

<210> SEQ ID NO 17
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<400> SEQUENCE: 17

gacgacctct tccggaattc                20

<210> SEQ ID NO 18
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<400> SEQUENCE: 18

gtgcacatcc acaatggc                18

<210> SEQ ID NO 19
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<400> SEQUENCE: 19

gagcagaggg aaggttcctt g                21

<210> SEQ ID NO 20
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer

<400> SEQUENCE: 20

```

-continued

tcattgtccc agctgcgtgg 20

<210> SEQ ID NO 21
 <211> LENGTH: 41
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

gagagaggtt taaacatgag cccctgccag cccaaccct g 41

<210> SEQ ID NO 22
 <211> LENGTH: 39
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 22

ctctgcggcc gcttatcatg gggtagggca gggccgcag 39

<210> SEQ ID NO 23
 <211> LENGTH: 49
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: primer

<400> SEQUENCE: 23

gtatctctcg agaaaagaga ggcgaagct agccctgcc agccaacc 49

<210> SEQ ID NO 24
 <211> LENGTH: 40
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: primer

<400> SEQUENCE: 24

aatagtgcgg cgcaccaac tcaggcaaga aatcatatc 40

<210> SEQ ID NO 25
 <211> LENGTH: 456
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
 1 5 10 15

Tyr Lys Asp Asp Asp Lys Gln Thr Ala Ser Gly Gln Asp Gly Ser
 20 25 30

Gly Pro Phe Leu Ala Asp Phe Asn Gly Phe Ser His Leu Glu Leu Arg
 35 40 45

Gly Leu His Thr Phe Ala Arg Asp Leu Gly Glu Lys Met Ala Leu Glu
 50 55 60

Val Val Phe Leu Ala Arg Gly Pro Ser Gly Leu Leu Leu Tyr Asn Gly
 65 70 75 80

Gln Lys Thr Asp Gly Lys Gly Asp Phe Val Ser Leu Ala Leu Arg Asp
 85 90 95

Arg Arg Leu Glu Phe Arg Tyr Asp Leu Gly Lys Gly Ala Ala Val Ile
 100 105 110

-continued

```

Arg Ser Arg Glu Pro Val Thr Leu Gly Ala Trp Thr Arg Val Ser Leu
    115                120                125

Glu Arg Asn Gly Arg Lys Gly Ala Leu Arg Val Gly Asp Gly Pro Arg
    130                135                140

Val Leu Gly Glu Ser Pro Lys Ser Arg Lys Val Pro His Thr Val Leu
    145                150                155                160

Asn Leu Lys Glu Pro Leu Tyr Val Gly Gly Ala Pro Asp Phe Ser Lys
    165                170                175

Leu Ala Arg Ala Ala Ala Val Ser Ser Gly Phe Asp Gly Ala Ile Gln
    180                185                190

Leu Val Ser Leu Gly Gly Arg Gln Leu Leu Thr Pro Glu His Val Leu
    195                200                205

Arg Gln Val Asp Val Thr Ser Phe Ala Gly His Pro Cys Thr Arg Ala
    210                215                220

Ser Gly His Pro Cys Leu Asn Gly Ala Ser Cys Val Pro Arg Glu Ala
    225                230                235                240

Ala Tyr Val Cys Leu Cys Pro Gly Gly Phe Ser Gly Pro His Cys Glu
    245                250                255

Lys Gly Leu Val Glu Lys Ser Ala Gly Asp Val Asp Thr Leu Ala Phe
    260                265                270

Asp Gly Arg Thr Phe Val Glu Tyr Leu Asn Ala Val Thr Glu Ser Glu
    275                280                285

Leu Ala Asn Glu Ile Pro Val Glu Lys Ala Leu Gln Ser Asn His Phe
    290                295                300

Glu Leu Ser Leu Arg Thr Glu Ala Thr Gln Gly Leu Val Leu Trp Ser
    305                310                315                320

Gly Lys Ala Thr Glu Arg Ala Asp Tyr Val Ala Leu Ala Ile Val Asp
    325                330                335

Gly His Leu Gln Leu Ser Tyr Asn Leu Gly Ser Gln Pro Val Val Leu
    340                345                350

Arg Ser Thr Val Pro Val Asn Thr Asn Arg Trp Leu Arg Val Val Ala
    355                360                365

His Arg Glu Gln Arg Glu Gly Ser Leu Gln Val Gly Asn Glu Ala Pro
    370                375                380

Val Thr Gly Ser Ser Pro Leu Gly Ala Thr Gln Leu Asp Thr Asp Gly
    385                390                395                400

Ala Leu Trp Leu Gly Gly Leu Pro Glu Leu Pro Val Gly Pro Ala Leu
    405                410                415

Pro Lys Ala Tyr Gly Thr Gly Phe Val Gly Cys Leu Arg Asp Val Val
    420                425                430

Val Gly Arg His Pro Leu His Leu Leu Glu Asp Ala Val Thr Lys Pro
    435                440                445

Glu Leu Arg Pro Cys Pro Thr Pro
    450                455
    
```

<210> SEQ ID NO 26
 <211> LENGTH: 440
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 26

```

Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
  1           5           10           15
    
```


-continued

Val Gly Arg His Pro Leu His Leu Leu Glu Asp Ala Val Thr Lys Pro
 420 425 430

Glu Leu Arg Pro Cys Pro Thr Pro
 435 440

<210> SEQ ID NO 27
 <211> LENGTH: 390
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 27

Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
 1 5 10 15

Tyr Lys Asp Asp Asp Asp Lys Val Ser Leu Ala Leu Arg Asp Arg Arg
 20 25 30

Leu Glu Phe Arg Tyr Asp Leu Gly Lys Gly Ala Ala Val Ile Arg Ser
 35 40 45

Arg Glu Pro Val Thr Leu Gly Ala Trp Thr Arg Val Ser Leu Glu Arg
 50 55 60

Asn Gly Arg Lys Gly Ala Leu Arg Val Gly Asp Gly Pro Arg Val Leu
 65 70 75 80

Gly Glu Ser Pro Lys Ser Arg Lys Val Pro His Thr Val Leu Asn Leu
 85 90 95

Lys Glu Pro Leu Tyr Val Gly Gly Ala Pro Asp Phe Ser Lys Leu Ala
 100 105 110

Arg Ala Ala Ala Val Ser Ser Gly Phe Asp Gly Ala Ile Gln Leu Val
 115 120 125

Ser Leu Gly Gly Arg Gln Leu Leu Thr Pro Glu His Val Leu Arg Gln
 130 135 140

Val Asp Val Thr Ser Phe Ala Gly His Pro Cys Thr Arg Ala Ser Gly
 145 150 155 160

His Pro Cys Leu Asn Gly Ala Ser Cys Val Pro Arg Glu Ala Ala Tyr
 165 170 175

Val Cys Leu Cys Pro Gly Gly Phe Ser Gly Pro His Cys Glu Lys Gly
 180 185 190

Leu Val Glu Lys Ser Ala Gly Asp Val Asp Thr Leu Ala Phe Asp Gly
 195 200 205

Arg Thr Phe Val Glu Tyr Leu Asn Ala Val Thr Glu Ser Glu Leu Ala
 210 215 220

Asn Glu Ile Pro Val Glu Lys Ala Leu Gln Ser Asn His Phe Glu Leu
 225 230 235 240

Ser Leu Arg Thr Glu Ala Thr Gln Gly Leu Val Leu Trp Ser Gly Lys
 245 250 255

Ala Thr Glu Arg Ala Asp Tyr Val Ala Leu Ala Ile Val Asp Gly His
 260 265 270

Leu Gln Leu Ser Tyr Asn Leu Gly Ser Gln Pro Val Val Leu Arg Ser
 275 280 285

Thr Val Pro Val Asn Thr Asn Arg Trp Leu Arg Val Val Ala His Arg
 290 295 300

Glu Gln Arg Glu Gly Ser Leu Gln Val Gly Asn Glu Ala Pro Val Thr
 305 310 315 320

Gly Ser Ser Pro Leu Gly Ala Thr Gln Leu Asp Thr Asp Gly Ala Leu
 325 330 335

-continued

Trp Leu Gly Gly Leu Pro Glu Leu Pro Val Gly Pro Ala Leu Pro Lys
 340 345 350
 Ala Tyr Gly Thr Gly Phe Val Gly Cys Leu Arg Asp Val Val Val Gly
 355 360 365
 Arg His Pro Leu His Leu Leu Glu Asp Ala Val Thr Lys Pro Glu Leu
 370 375 380
 Arg Pro Cys Pro Thr Pro
 385 390

<210> SEQ ID NO 28
 <211> LENGTH: 338
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 28

Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
 1 5 10 15
 Tyr Lys Asp Asp Asp Lys Gly Pro Arg Val Leu Gly Glu Ser Pro
 20 25 30
 Lys Ser Arg Lys Val Pro His Thr Val Leu Asn Leu Lys Glu Pro Leu
 35 40 45
 Tyr Val Gly Gly Ala Pro Asp Phe Ser Lys Leu Ala Arg Ala Ala Ala
 50 55 60
 Val Ser Ser Gly Phe Asp Gly Ala Ile Gln Leu Val Ser Leu Gly Gly
 65 70 75 80
 Arg Gln Leu Leu Thr Pro Glu His Val Leu Arg Gln Val Asp Val Thr
 85 90 95
 Ser Phe Ala Gly His Pro Cys Thr Arg Ala Ser Gly His Pro Cys Leu
 100 105 110
 Asn Gly Ala Ser Cys Val Pro Arg Glu Ala Ala Tyr Val Cys Leu Cys
 115 120 125
 Pro Gly Gly Phe Ser Gly Pro His Cys Glu Lys Gly Leu Val Glu Lys
 130 135 140
 Ser Ala Gly Asp Val Asp Thr Leu Ala Phe Asp Gly Arg Thr Phe Val
 145 150 155 160
 Glu Tyr Leu Asn Ala Val Thr Glu Ser Glu Leu Ala Asn Glu Ile Pro
 165 170 175
 Val Glu Lys Ala Leu Gln Ser Asn His Phe Glu Leu Ser Leu Arg Thr
 180 185 190
 Glu Ala Thr Gln Gly Leu Val Leu Trp Ser Gly Lys Ala Thr Glu Arg
 195 200 205
 Ala Asp Tyr Val Ala Leu Ala Ile Val Asp Gly His Leu Gln Leu Ser
 210 215 220
 Tyr Asn Leu Gly Ser Gln Pro Val Val Leu Arg Ser Thr Val Pro Val
 225 230 235 240
 Asn Thr Asn Arg Trp Leu Arg Val Val Ala His Arg Glu Gln Arg Glu
 245 250 255
 Gly Ser Leu Gln Val Gly Asn Glu Ala Pro Val Thr Gly Ser Ser Pro
 260 265 270
 Leu Gly Ala Thr Gln Leu Asp Thr Asp Gly Ala Leu Trp Leu Gly Gly
 275 280 285
 Leu Pro Glu Leu Pro Val Gly Pro Ala Leu Pro Lys Ala Tyr Gly Thr

-continued

```

<210> SEQ ID NO 30
<211> LENGTH: 256
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 30

Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
 1           5           10           15
Tyr Lys Asp Asp Asp Asp Lys Ala Ser Gly His Pro Cys Leu Asn Gly
          20           25           30
Ala Ser Cys Val Pro Arg Glu Ala Ala Tyr Val Cys Leu Cys Pro Gly
          35           40           45
Gly Phe Ser Gly Pro His Cys Glu Lys Gly Leu Val Glu Lys Ser Ala
          50           55           60
Gly Asp Val Asp Thr Leu Ala Phe Asp Gly Arg Thr Phe Val Glu Tyr
          65           70           75           80
Leu Asn Ala Val Thr Glu Ser Glu Leu Ala Asn Glu Ile Pro Val Glu
          85           90           95
Lys Ala Leu Gln Ser Asn His Phe Glu Leu Ser Leu Arg Thr Glu Ala
          100          105          110
Thr Gln Gly Leu Val Leu Trp Ser Gly Lys Ala Thr Glu Arg Ala Asp
          115          120          125
Tyr Val Ala Leu Ala Ile Val Asp Gly His Leu Gln Leu Ser Tyr Asn
          130          135          140
Leu Gly Ser Gln Pro Val Val Leu Arg Ser Thr Val Pro Val Asn Thr
          145          150          155          160
Asn Arg Trp Leu Arg Val Val Ala His Arg Glu Gln Arg Glu Gly Ser
          165          170          175
Leu Gln Val Gly Asn Glu Ala Pro Val Thr Gly Ser Ser Pro Leu Gly
          180          185          190
Ala Thr Gln Leu Asp Thr Asp Gly Ala Leu Trp Leu Gly Gly Leu Pro
          195          200          205
Glu Leu Pro Val Gly Pro Ala Leu Pro Lys Ala Tyr Gly Thr Gly Phe
          210          215          220
Val Gly Cys Leu Arg Asp Val Val Val Gly Arg His Pro Leu His Leu
          225          230          235          240
Leu Glu Asp Ala Val Thr Lys Pro Glu Leu Arg Pro Cys Pro Thr Pro
          245          250          255

```

```

<210> SEQ ID NO 31
<211> LENGTH: 216
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 31

Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
 1           5           10           15
Tyr Lys Asp Asp Asp Asp Lys Ala Gly Asp Val Asp Thr Leu Ala Phe
          20           25           30
Asp Gly Arg Thr Phe Val Glu Tyr Leu Asn Ala Val Thr Glu Ser Glu
          35           40           45
Leu Ala Asn Glu Ile Pro Val Glu Lys Ala Leu Gln Ser Asn His Phe
          50           55           60
Glu Leu Ser Leu Arg Thr Glu Ala Thr Gln Gly Leu Val Leu Trp Ser

```

-continued

65	70	75	80
Gly Lys Ala Thr Glu Arg Ala Asp Tyr Val Ala Leu Ala Ile Val Asp	85	90	95
Gly His Leu Gln Leu Ser Tyr Asn Leu Gly Ser Gln Pro Val Val Leu	100	105	110
Arg Ser Thr Val Pro Val Asn Thr Asn Arg Trp Leu Arg Val Val Ala	115	120	125
His Arg Glu Gln Arg Glu Gly Ser Leu Gln Val Gly Asn Glu Ala Pro	130	135	140
Val Thr Gly Ser Ser Pro Leu Gly Ala Thr Gln Leu Asp Thr Asp Gly	145	150	155
Ala Leu Trp Leu Gly Gly Leu Pro Glu Leu Pro Val Gly Pro Ala Leu	165	170	175
Pro Lys Ala Tyr Gly Thr Gly Phe Val Gly Cys Leu Arg Asp Val Val	180	185	190
Val Gly Arg His Pro Leu His Leu Leu Glu Asp Ala Val Thr Lys Pro	195	200	205
Glu Leu Arg Pro Cys Pro Thr Pro	210	215	

<210> SEQ ID NO 32
 <211> LENGTH: 2610
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 32

```

atgagagagc tcgtcaacat tccactggta catattctta ctctggttgc cttcagcgga      60
actgagaaac ttccaaaagc tcctgtcatc accactcctc ttgaaacagt ggatgcctta      120
gttgaagaag tggctacttt catgtgtgca gtggaatcct acccccagcc tgagatttcc      180
tggactagaa ataaaaattct cattaaactc tttgacacc ggtacagcat ccgggagaat      240
gggcagctcc tcaccatcct gagtgtggaa gacagtgatg atggcattta ctgctgcacg      300
gccaaacatg gtgtgggagg agctgtggag agttgtggag ccctgcaagt gaagatgaaa      360
cctaaaataa ctcgccctcc cataaatgtg aaaataatag agggattaaa agcagtccta      420
ccatgtacta caatgggtaa tcccaaacca tcagtgtcct ggataaaggg agacagccct      480
ctcaggghaa attcccgaat tgcagttcct gaatctggga gcttgaggat tcataacgta      540
caaaaggaag atgcaggaca gtatcgatgt gtggcaaaaa acagcctcgg gacagcatat      600
tccaaagtgg tgaagctgga agttgaggtt tttgccagga tcctgcgggc tctgtaatcc      660
cacaatgtca cctttggctc ctttgtgacc ctgcaactgta cagcaacagg cattcctgtc      720
cccaccatca cctggattga aaacggaaat gctgtttcct ctgggtccat tcaagagagt      780
gtgaaagacc gagtgtattg ctcaagactg cagctgttta tcaccaagcc aggactctac      840
acatgcatag ctaccaataa gcatggggag aagttcagta ctgccaaggc tgcagccacc      900
atcagcatag cagaatggag taaaccacag aaagataaca aaggctactg cgcccagtac      960
agaggggagg tgtgtaatgc agtctggca aaagatgctc ttgttttct caacacctcc     1020
tatgcgggacc ctgaggaggc ccaagagcta ctggtccaca cggcctggaa tgaactgaaa     1080
gtagtgagcc cagtctgccg gccagctgct gaggtttgtg tgtgtaacca catcttcag     1140
gagtgcagtc ctggagtagt gcctactcct attcccattt gcagagagta ctgcttggca     1200
    
```

-continued

```

gtaaaggagc tcttctgcbc aaaagaatgg ctggtaatgg aagagaagac ccacagagga 1260
ctctacagat ccgagatgca ttgtctgtcc gtgccagaat gcagcaagct tcccagcatg 1320
cattggggacc ccacggcctg tgccagactg ccacatctag attataacaa agaaaaccta 1380
aaaacattcc caccaatgac gtctctcaaag ccaagtgtgg acattccaaa tctgccttcc 1440
tcctcctctt cttccttctc tgtctcacct acatactcca tgactgtaat aatctccatc 1500
atgtccagct ttgcaatatt tgtgcttctt accataacta ctctctattg ctgccgaaga 1560
agaaaacaat gaaaaataa gaaaagagaa tcagcagcag taaccctcac cacactgcct 1620
tctgagctct tactagatag acttcatccc aaccccatgt accagaggat gccgctcctt 1680
ctgaacccca aattgctcag cctggagtat ccaaggaata acattgaata tgtgagagac 1740
atcggagagg gagcgtttgg aagggtgttt caagcaaggg caccaggctt acttccctat 1800
gaacctttca ctatggtggc agtaaagatg ctcaaagaag aagcctcggc agatatgcaa 1860
gcggaactttc agagggaggc agccctcatg gcagaatttg acaaccctaa cattgtgaag 1920
ctattaggag tgtgtgctgt cgggaagcca atgtgcctgc tctttgaata catggcctat 1980
ggtgacctca atgagttctc ccgagcatg tcccctcaca ccgtgtgag cctcagtcac 2040
agtgacttgt ctatgagggc tcaggctctc agccctgggc cccaccctct ctcctgtgct 2100
gagcagcctt gcattgccag gcaggtggca gctggcatgg cttacctctc agaacgtaag 2160
ttgtttcacc gagatttagc caccaggaac tgctgtgtgg gcgagaacat ggtggtgaaa 2220
attgccgact ttggcctctc caggaacatc tactcagcag actactacaa agctaatagaa 2280
aacgacgcta tccctatccg ttggatgcca ccagagtcca tttttataa ccgctacact 2340
acagagtctg atgtgtgggc ctatggcgtg gtcctctggg agatcttctc ctatggcctg 2400
cagccctact atgggatggc ccatgaggag gtcatttact acgtgcgaga tggcaacatc 2460
ctctcctgcc ctgagaactg ccccggtggag ctgtacaatc tcatgctgtct atgttgagac 2520
aagctgcctg cagacagacc cagtttcacc agtattcacc gaattctgga acgcatgtgt 2580
gagagggcag agggaaactgt gagtgtctaa 2610
    
```

```

<210> SEQ ID NO 33
<211> LENGTH: 869
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
    
```

<400> SEQUENCE: 33

```

Met Arg Glu Leu Val Asn Ile Pro Leu Val His Ile Leu Thr Leu Val
 1           5           10           15
Ala Phe Ser Gly Thr Glu Lys Leu Pro Lys Ala Pro Val Ile Thr Thr
 20           25           30
Pro Leu Glu Thr Val Asp Ala Leu Val Glu Glu Val Ala Thr Phe Met
 35           40           45
Cys Ala Val Glu Ser Tyr Pro Gln Pro Glu Ile Ser Trp Thr Arg Asn
 50           55           60
Lys Ile Leu Ile Lys Leu Phe Asp Thr Arg Tyr Ser Ile Arg Glu Asn
 65           70           75           80
Gly Gln Leu Leu Thr Ile Leu Ser Val Glu Asp Ser Asp Asp Gly Ile
 85           90           95
Tyr Cys Cys Thr Ala Asn Asn Gly Val Gly Gly Ala Val Glu Ser Cys
    
```

-continued

100					105					110					
Gly	Ala	Leu	Gln	Val	Lys	Met	Lys	Pro	Lys	Ile	Thr	Arg	Pro	Pro	Ile
	115						120					125			
Asn	Val	Lys	Ile	Ile	Glu	Gly	Leu	Lys	Ala	Val	Leu	Pro	Cys	Thr	Thr
	130					135					140				
Met	Gly	Asn	Pro	Lys	Pro	Ser	Val	Ser	Trp	Ile	Lys	Gly	Asp	Ser	Pro
145				150						155					160
Leu	Arg	Glu	Asn	Ser	Arg	Ile	Ala	Val	Leu	Glu	Ser	Gly	Ser	Leu	Arg
				165					170					175	
Ile	His	Asn	Val	Gln	Lys	Glu	Asp	Ala	Gly	Gln	Tyr	Arg	Cys	Val	Ala
		180						185					190		
Lys	Asn	Ser	Leu	Gly	Thr	Ala	Tyr	Ser	Lys	Val	Val	Lys	Leu	Glu	Val
		195					200					205			
Glu	Val	Phe	Ala	Arg	Ile	Leu	Arg	Ala	Pro	Glu	Ser	His	Asn	Val	Thr
	210					215						220			
Phe	Gly	Ser	Phe	Val	Thr	Leu	His	Cys	Thr	Ala	Thr	Gly	Ile	Pro	Val
225				230						235					240
Pro	Thr	Ile	Thr	Trp	Ile	Glu	Asn	Gly	Asn	Ala	Val	Ser	Ser	Gly	Ser
				245					250					255	
Ile	Gln	Glu	Ser	Val	Lys	Asp	Arg	Val	Ile	Asp	Ser	Arg	Leu	Gln	Leu
			260					265					270		
Phe	Ile	Thr	Lys	Pro	Gly	Leu	Tyr	Thr	Cys	Ile	Ala	Thr	Asn	Lys	His
		275					280						285		
Gly	Glu	Lys	Phe	Ser	Thr	Ala	Lys	Ala	Ala	Ala	Thr	Ile	Ser	Ile	Ala
	290					295					300				
Glu	Trp	Ser	Lys	Pro	Gln	Lys	Asp	Asn	Lys	Gly	Tyr	Cys	Ala	Gln	Tyr
305				310						315				320	
Arg	Gly	Glu	Val	Cys	Asn	Ala	Val	Leu	Ala	Lys	Asp	Ala	Leu	Val	Phe
				325					330					335	
Leu	Asn	Thr	Ser	Tyr	Ala	Asp	Pro	Glu	Glu	Ala	Gln	Glu	Leu	Leu	Val
			340				345						350		
His	Thr	Ala	Trp	Asn	Glu	Leu	Lys	Val	Val	Ser	Pro	Val	Cys	Arg	Pro
		355					360					365			
Ala	Ala	Glu	Ala	Leu	Leu	Cys	Asn	His	Ile	Phe	Gln	Glu	Cys	Ser	Pro
	370					375					380				
Gly	Val	Val	Pro	Thr	Pro	Ile	Pro	Ile	Cys	Arg	Glu	Tyr	Cys	Leu	Ala
385				390						395					400
Val	Lys	Glu	Leu	Phe	Cys	Ala	Lys	Glu	Trp	Leu	Val	Met	Glu	Glu	Lys
				405					410					415	
Thr	His	Arg	Gly	Leu	Tyr	Arg	Ser	Glu	Met	His	Leu	Leu	Ser	Val	Pro
			420					425						430	
Glu	Cys	Ser	Lys	Leu	Pro	Ser	Met	His	Trp	Asp	Pro	Thr	Ala	Cys	Ala
		435					440					445			
Arg	Leu	Pro	His	Leu	Asp	Tyr	Asn	Lys	Glu	Asn	Leu	Lys	Thr	Phe	Pro
	450					455						460			
Pro	Met	Thr	Ser	Ser	Lys	Pro	Ser	Val	Asp	Ile	Pro	Asn	Leu	Pro	Ser
465				470						475				480	
Ser	Ser	Ser	Ser	Ser	Phe	Ser	Val	Ser	Pro	Thr	Tyr	Ser	Met	Thr	Val
				485					490					495	
Ile	Ile	Ser	Ile	Met	Ser	Ser	Phe	Ala	Ile	Phe	Val	Leu	Leu	Thr	Ile
			500					505						510	

-continued

Thr Thr Leu Tyr Cys Cys Arg Arg Arg Lys Gln Trp Lys Asn Lys Lys
 515 520 525
 Arg Glu Ser Ala Ala Val Thr Leu Thr Thr Leu Pro Ser Glu Leu Leu
 530 535 540
 Leu Asp Arg Leu His Pro Asn Pro Met Tyr Gln Arg Met Pro Leu Leu
 545 550 555 560
 Leu Asn Pro Lys Leu Leu Ser Leu Glu Tyr Pro Arg Asn Asn Ile Glu
 565 570 575
 Tyr Val Arg Asp Ile Gly Glu Gly Ala Phe Gly Arg Val Phe Gln Ala
 580 585 590
 Arg Ala Pro Gly Leu Leu Pro Tyr Glu Pro Phe Thr Met Val Ala Val
 595 600 605
 Lys Met Leu Lys Glu Glu Ala Ser Ala Asp Met Gln Ala Asp Phe Gln
 610 615 620
 Arg Glu Ala Ala Leu Met Ala Glu Phe Asp Asn Pro Asn Ile Val Lys
 625 630 635 640
 Leu Leu Gly Val Cys Ala Val Gly Lys Pro Met Cys Leu Leu Phe Glu
 645 650 655
 Tyr Met Ala Tyr Gly Asp Leu Asn Glu Phe Leu Arg Ser Met Ser Pro
 660 665 670
 His Thr Val Cys Ser Leu Ser His Ser Asp Leu Ser Met Arg Ala Gln
 675 680 685
 Val Ser Ser Pro Gly Pro Pro Leu Ser Cys Ala Glu Gln Leu Cys
 690 695 700
 Ile Ala Arg Gln Val Ala Ala Gly Met Ala Tyr Leu Ser Glu Arg Lys
 705 710 715 720
 Phe Val His Arg Asp Leu Ala Thr Arg Asn Cys Leu Val Gly Glu Asn
 725 730 735
 Met Val Val Lys Ile Ala Asp Phe Gly Leu Ser Arg Asn Ile Tyr Ser
 740 745 750
 Ala Asp Tyr Tyr Lys Ala Asn Glu Asn Asp Ala Ile Pro Ile Arg Trp
 755 760 765
 Met Pro Pro Glu Ser Ile Phe Tyr Asn Arg Tyr Thr Thr Glu Ser Asp
 770 775 780
 Val Trp Ala Tyr Gly Val Val Leu Trp Glu Ile Phe Ser Tyr Gly Leu
 785 790 795 800
 Gln Pro Tyr Tyr Gly Met Ala His Glu Glu Val Ile Tyr Tyr Val Arg
 805 810 815
 Asp Gly Asn Ile Leu Ser Cys Pro Glu Asn Cys Pro Val Glu Leu Tyr
 820 825 830
 Asn Leu Met Arg Leu Cys Trp Ser Lys Leu Pro Ala Asp Arg Pro Ser
 835 840 845
 Phe Thr Ser Ile His Arg Ile Leu Glu Arg Met Cys Glu Arg Ala Glu
 850 855 860
 Gly Thr Val Ser Val
 865

<210> SEQ ID NO 34

<211> LENGTH: 1940

<212> TYPE: PRT

<213> ORGANISM: Rattus sp.

-continued

<400> SEQUENCE: 34

```

Met Pro Pro Leu Pro Leu Glu His Arg Pro Arg Gln Glu Pro Gly Ala
 1          5          10          15
Ser Met Leu Val Arg Tyr Phe Met Ile Pro Cys Asn Ile Cys Leu Ile
      20          25          30
Leu Leu Ala Thr Ser Thr Leu Gly Phe Ala Val Leu Leu Phe Leu Ser
      35          40          45
Asn Tyr Lys Pro Gly Ile His Phe Thr Pro Ala Pro Pro Thr Pro Pro
      50          55          60
Asp Val Cys Arg Gly Met Leu Cys Gly Phe Gly Ala Val Cys Glu Pro
      65          70          75          80
Ser Val Glu Asp Pro Gly Arg Ala Ser Cys Val Cys Lys Lys Asn Ala
      85          90          95
Cys Pro Ala Thr Val Ala Pro Val Cys Gly Ser Asp Ala Ser Thr Tyr
      100          105          110
Ser Asn Glu Cys Glu Leu Gln Arg Ala Gln Cys Asn Gln Gln Arg Arg
      115          120          125
Ile Arg Leu Leu Arg Gln Gly Pro Cys Gly Ser Arg Asp Pro Cys Ala
      130          135          140
Asn Val Thr Cys Ser Phe Gly Ser Thr Cys Val Pro Ser Ala Asp Gly
      145          150          155          160
Gln Thr Ala Ser Cys Leu Cys Pro Thr Thr Cys Phe Gly Ala Pro Asp
      165          170          175
Gly Thr Val Cys Gly Ser Asp Gly Val Asp Tyr Pro Ser Glu Cys Gln
      180          185          190
Leu Leu Ser His Ala Cys Ala Ser Gln Glu His Ile Phe Lys Lys Phe
      195          200          205
Asn Gly Pro Cys Asp Pro Cys Gln Gly Ser Met Ser Asp Leu Asn His
      210          215          220
Ile Cys Arg Val Asn Pro Arg Thr Arg His Pro Glu Met Leu Leu Arg
      225          230          235          240
Pro Glu Asn Cys Pro Ala Gln His Thr Pro Ile Cys Gly Asp Asp Gly
      245          250          255
Val Thr Tyr Glu Asn Asp Cys Val Met Ser Arg Ile Gly Ala Thr Arg
      260          265          270
Gly Leu Leu Leu Gln Lys Val Arg Ser Gly Gln Cys Gln Thr Arg Asp
      275          280          285
Gln Cys Pro Glu Thr Cys Gln Phe Asn Ser Val Cys Leu Ser Arg Arg
      290          295          300
Gly Arg Pro His Cys Ser Cys Asp Arg Val Thr Cys Asp Gly Ser Tyr
      305          310          315          320
Arg Pro Val Cys Ala Gln Asp Gly His Thr Tyr Asn Asn Asp Cys Trp
      325          330          335
Arg Gln Gln Ala Glu Cys Arg Gln Gln Arg Ala Ile Pro Pro Lys His
      340          345          350
Gln Gly Pro Cys Asp Gln Thr Pro Ser Pro Cys His Gly Val Gln Cys
      355          360          365
Ala Phe Gly Ala Val Cys Thr Val Lys Asn Gly Lys Ala Glu Cys Glu
      370          375          380
Cys Gln Arg Val Cys Ser Gly Ile Tyr Asp Pro Val Cys Gly Ser Asp
      385          390          395          400

```

-continued

Gly Val Thr Tyr Gly Ser Val Cys Glu Leu Glu Ser Met Ala Cys Thr
 405 410 415

Leu Gly Arg Glu Ile Gln Val Ala Arg Arg Gly Pro Cys Asp Pro Cys
 420 425 430

Gly Gln Cys Arg Phe Gly Ser Leu Cys Glu Val Glu Thr Gly Arg Cys
 435 440 445

Val Cys Pro Ser Glu Cys Val Glu Ser Ala Gln Pro Val Cys Gly Ser
 450 455 460

Asp Gly His Thr Tyr Ala Ser Glu Cys Glu Leu His Val His Ala Cys
 465 470 475 480

Thr His Gln Ile Ser Leu Tyr Val Ala Ser Ala Gly His Cys Gln Thr
 485 490 495

Cys Gly Glu Lys Val Cys Thr Phe Gly Ala Val Cys Ser Ala Gly Gln
 500 505 510

Cys Val Cys Pro Arg Cys Glu His Pro Pro Pro Gly Pro Val Cys Gly
 515 520 525

Ser Asp Gly Val Thr Tyr Leu Ser Ala Cys Glu Leu Arg Glu Ala Ala
 530 535 540

Cys Gln Gln Gln Val Gln Ile Glu Glu Ala His Ala Gly Pro Cys Glu
 545 550 555 560

Pro Ala Glu Cys Gly Ser Gly Gly Ser Gly Ser Gly Glu Asp Asp Glu
 565 570 575

Cys Glu Gln Glu Leu Cys Arg Gln Arg Gly Gly Ile Trp Asp Glu Asp
 580 585 590

Ser Glu Asp Gly Pro Cys Val Cys Asp Phe Ser Cys Gln Ser Val Pro
 595 600 605

Arg Ser Pro Val Cys Gly Ser Asp Gly Val Thr Tyr Gly Thr Glu Cys
 610 615 620

Asp Leu Lys Lys Ala Arg Cys Glu Ser Gln Gln Glu Leu Tyr Val Ala
 625 630 635 640

Ala Gln Gly Ala Cys Arg Gly Pro Thr Leu Ala Pro Leu Leu Pro Val
 645 650 655

Ala Phe Pro His Cys Ala Gln Thr Pro Tyr Gly Cys Cys Gln Asp Asn
 660 665 670

Phe Thr Ala Ala Gln Gly Val Gly Leu Ala Gly Cys Pro Ser Thr Cys
 675 680 685

His Cys Asn Pro His Gly Ser Tyr Ser Gly Thr Cys Asp Pro Ala Thr
 690 695 700

Gly Gln Cys Ser Cys Arg Pro Gly Val Gly Gly Leu Arg Cys Asp Arg
 705 710 715 720

Cys Glu Pro Gly Phe Trp Asn Phe Arg Gly Ile Val Thr Asp Gly His
 725 730 735

Ser Gly Cys Thr Pro Cys Ser Cys Asp Pro Arg Gly Ala Val Arg Asp
 740 745 750

Asp Cys Glu Gln Met Thr Gly Leu Cys Ser Cys Arg Pro Gly Val Ala
 755 760 765

Gly Pro Lys Cys Gly Gln Cys Pro Asp Gly Gln Val Leu Gly His Leu
 770 775 780

Gly Cys Glu Ala Asp Pro Met Thr Pro Val Thr Cys Val Glu Ile His
 785 790 795 800

-continued

Cys Glu Phe Gly Ala Ser Cys Val Glu Lys Ala Gly Phe Ala Gln Cys
 805 810 815

Ile Cys Pro Thr Leu Thr Cys Pro Glu Ala Asn Ser Thr Lys Val Cys
 820 825 830

Gly Ser Asp Gly Val Thr Tyr Gly Asn Glu Cys Gln Leu Lys Ala Ile
 835 840 845

Ala Cys Arg Gln Arg Leu Asp Ile Ser Thr Gln Ser Leu Gly Pro Cys
 850 855 860

Gln Glu Ser Val Thr Pro Gly Ala Ser Pro Thr Ser Ala Ser Met Thr
 865 870 875 880

Thr Pro Arg His Ile Leu Ser Lys Thr Leu Pro Phe Pro His Asn Ser
 885 890 895

Leu Pro Leu Ser Pro Gly Ser Thr Thr His Asp Trp Pro Thr Pro Leu
 900 905 910

Pro Ile Ser Pro His Thr Thr Val Ser Ile Pro Arg Ser Thr Ala Trp
 915 920 925

Pro Val Leu Thr Val Pro Pro Thr Ala Ala Ala Ser Asp Val Thr Ser
 930 935 940

Leu Ala Thr Ser Ile Phe Ser Glu Ser Gly Ser Ala Asn Gly Ser Gly
 945 950 955 960

Asp Glu Glu Leu Ser Gly Asp Glu Glu Ala Ser Gly Gly Gly Ser Gly
 965 970 975

Gly Leu Glu Pro Pro Val Gly Ser Ile Val Val Thr His Gly Pro Pro
 980 985 990

Ile Glu Arg Ala Ser Cys Tyr Asn Ser Pro Leu Gly Cys Cys Ser Asp
 995 1000 1005

Gly Lys Thr Pro Ser Leu Asp Ser Glu Gly Ser Asn Cys Pro Ala Thr
 1010 1015 1020

Lys Ala Phe Gln Gly Val Leu Glu Leu Glu Gly Val Glu Gly Gln Glu
 1025 1030 1035 1040

Leu Phe Tyr Thr Pro Glu Met Ala Asp Pro Lys Ser Glu Leu Phe Gly
 1045 1050 1055

Glu Thr Ala Arg Ser Ile Glu Ser Thr Leu Asp Asp Leu Phe Arg Asn
 1060 1065 1070

Ser Asp Val Lys Lys Asp Phe Trp Ser Val Arg Leu Arg Glu Leu Gly
 1075 1080 1085

Pro Gly Lys Leu Val Arg Ala Ile Val Asp Val His Phe Asp Pro Thr
 1090 1095 1100

Thr Ala Phe Gln Ala Ser Asp Val Gly Gln Ala Leu Leu Arg Gln Ile
 1105 1110 1115 1120

Gln Val Ser Arg Pro Trp Ala Leu Ala Val Arg Arg Pro Leu Gln Glu
 1125 1130 1135

His Val Arg Phe Leu Asp Phe Asp Trp Phe Pro Thr Phe Phe Thr Gly
 1140 1145 1150

Ala Ala Thr Gly Thr Thr Ala Ala Met Ala Thr Ala Arg Ala Thr Thr
 1155 1160 1165

Val Ser Arg Leu Pro Ala Ser Ser Val Thr Pro Arg Val Tyr Pro Ser
 1170 1175 1180

His Thr Ser Arg Pro Val Gly Arg Thr Thr Ala Pro Pro Thr Thr Arg
 1185 1190 1195 1200

Arg Pro Pro Thr Thr Ala Thr Asn Met Asp Arg Pro Arg Thr Pro Gly

-continued

1205				1210				1215							
His	Gln	Gln	Pro	Ser	Lys	Ser	Cys	Asp	Ser	Gln	Pro	Cys	Leu	His	Gly
		1220						1225					1230		
Gly	Thr	Cys	Gln	Asp	Gln	Asp	Ser	Gly	Lys	Gly	Phe	Thr	Cys	Ser	Cys
		1235						1240				1245			
Thr	Ala	Gly	Arg	Gly	Gly	Ser	Val	Cys	Glu	Lys	Val	Gln	Pro	Pro	Ser
		1250						1255				1260			
Met	Pro	Ala	Phe	Lys	Gly	His	Ser	Phe	Leu	Ala	Phe	Pro	Thr	Leu	Arg
		1265						1270				1275			1280
Ala	Tyr	His	Thr	Leu	Arg	Leu	Ala	Leu	Glu	Phe	Arg	Ala	Leu	Glu	Thr
			1285								1290				1295
Glu	Gly	Leu	Leu	Leu	Tyr	Asn	Gly	Asn	Ala	Arg	Gly	Lys	Asp	Phe	Leu
		1300									1305			1310	
Ala	Leu	Ala	Leu	Leu	Asp	Gly	Arg	Val	Gln	Phe	Arg	Phe	Asp	Thr	Gly
		1315									1320			1325	
Ser	Gly	Pro	Ala	Val	Leu	Thr	Ser	Leu	Val	Pro	Val	Glu	Pro	Gly	Arg
		1330										1340			
Trp	His	Arg	Leu	Glu	Leu	Ser	Arg	His	Trp	Arg	Gln	Gly	Thr	Leu	Ser
			1345								1355				1360
Val	Asp	Gly	Glu	Thr	Pro	Val	Val	Gly	Glu	Ser	Pro	Ser	Gly	Thr	Asp
			1365								1370				1375
Gly	Leu	Asn	Leu	Asp	Thr	Asn	Leu	Tyr	Val	Gly	Gly	Ile	Pro	Glu	Glu
			1380								1385				1390
Gln	Val	Ala	Met	Val	Leu	Asp	Arg	Thr	Ser	Val	Gly	Val	Gly	Leu	Lys
			1395									1400			1405
Gly	Cys	Ile	Arg	Met	Leu	Asp	Ile	Asn	Asn	Gln	Gln	Leu	Glu	Leu	Ser
			1410									1420			
Asp	Trp	Gln	Arg	Ala	Ala	Val	Gln	Ser	Ser	Gly	Val	Gly	Glu	Cys	Gly
			1425								1435				1440
Asp	His	Pro	Cys	Leu	Pro	Asn	Pro	Cys	His	Gly	Gly	Ala	Leu	Cys	Gln
			1445								1450				1455
Ala	Leu	Glu	Ala	Gly	Met	Phe	Leu	Cys	Gln	Cys	Pro	Pro	Gly	Arg	Phe
			1460								1465				1470
Gly	Pro	Thr	Cys	Ala	Asp	Glu	Lys	Ser	Pro	Cys	Gln	Pro	Asn	Pro	Cys
			1475								1480				1485
His	Gly	Ala	Ala	Pro	Cys	Arg	Val	Leu	Ser	Ser	Gly	Gly	Ala	Lys	Cys
			1490								1495				1500
Glu	Cys	Pro	Leu	Gly	Arg	Ser	Gly	Thr	Phe	Cys	Gln	Thr	Val	Leu	Glu
			1505								1515				1520
Thr	Ala	Gly	Ser	Arg	Pro	Phe	Leu	Ala	Asp	Phe	Asn	Gly	Phe	Ser	Tyr
			1525								1530				1535
Leu	Glu	Leu	Lys	Gly	Leu	His	Thr	Phe	Glu	Arg	Asp	Leu	Gly	Glu	Lys
			1540								1545				1550
Met	Ala	Leu	Glu	Met	Val	Phe	Leu	Ala	Arg	Gly	Pro	Ser	Gly	Leu	Leu
			1555								1560				1565
Leu	Tyr	Asn	Gly	Gln	Lys	Thr	Asp	Gly	Lys	Gly	Asp	Phe	Val	Ser	Leu
			1570								1575				1580
Ala	Leu	His	Asn	Arg	His	Leu	Glu	Phe	Cys	Tyr	Asp	Leu	Gly	Lys	Gly
			1585								1595				1600
Ala	Ala	Val	Ile	Arg	Ser	Lys	Glu	Pro	Ile	Ala	Leu	Gly	Thr	Trp	Val
			1605								1610				1615

-continued

```

Arg Val Phe Leu Glu Arg Asn Gly Arg Lys Gly Ala Leu Gln Val Gly
      1620                               1625                1630

Asp Gly Pro Arg Val Leu Gly Glu Ser Pro Lys Ser Arg Lys Val Pro
      1635                               1640                1645

His Thr Met Leu Asn Leu Lys Glu Pro Leu Tyr Ile Gly Gly Ala Pro
      1650                               1655                1660

Asp Phe Ser Lys Leu Ala Arg Gly Ala Ala Val Ser Ser Gly Phe Ser
      1665                               1670                1675                1680

Gly Val Ile Gln Leu Val Ser Leu Arg Gly His Gln Leu Leu Thr Gln
      1685                               1690                1695

Glu His Val Leu Arg Ala Val Asp Val Ser Pro Phe Ala Asp His Pro
      1700                               1705                1710

Cys Thr Gln Ala Leu Gly Asn Pro Cys Leu Asn Gly Gly Ser Cys Val
      1715                               1720                1725

Pro Arg Glu Ala Thr Tyr Glu Cys Leu Cys Pro Gly Gly Phe Ser Gly
      1730                               1735                1740

Leu His Cys Glu Lys Gly Leu Val Glu Lys Ser Val Gly Asp Leu Glu
      1745                               1750                1755                1760

Thr Leu Ala Phe Asp Gly Arg Thr Tyr Ile Glu Tyr Leu Asn Ala Val
      1765                               1770                1775

Ile Glu Ser Glu Lys Ala Leu Gln Ser Asn His Phe Glu Leu Ser Leu
      1780                               1785                1790

Arg Thr Glu Ala Thr Gln Gly Leu Val Leu Trp Ile Gly Lys Ala Ala
      1795                               1800                1805

Glu Arg Ala Asp Tyr Met Ala Leu Ala Ile Val Asp Gly His Leu Gln
      1810                               1815                1820

Leu Ser Tyr Asp Leu Gly Ser Gln Pro Val Val Leu Arg Ser Thr Val
      1825                               1830                1835                1840

Lys Val Asn Thr Asn Arg Trp Leu Arg Ile Arg Ala His Arg Glu His
      1845                               1850                1855

Arg Glu Gly Ser Leu Gln Val Gly Asn Glu Ala Pro Val Thr Gly Ser
      1860                               1865                1870

Ser Pro Leu Gly Ala Thr Gln Leu Asp Thr Asp Gly Ala Leu Trp Leu
      1875                               1880                1885

Gly Gly Leu Gln Lys Leu Pro Val Gly Gln Ala Leu Pro Lys Ala Tyr
      1890                               1895                1900

Gly Thr Gly Phe Val Gly Cys Leu Arg Asp Val Val Val Gly His Arg
      1905                               1910                1915                1920

Gln Leu His Leu Leu Glu Asp Ala Val Thr Lys Pro Glu Leu Arg Pro
      1925                               1930                1935

Cys Pro Thr Pro
      1940
    
```

```

<210> SEQ ID NO 35
<211> LENGTH: 1479
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
    
```

<400> SEQUENCE: 35

```

atgtctgcac ttctgatcct agctcttgtt ggagctgcag ttgctgacta caaagacgat      60
gacgacaaga agagcccctg ccagcccaac ccttgccatg gggcggcgcc ctgccgtgtg      120
    
```

-continued

```

ctgcccgagg gtggtgctca gtgcgagtgc cccctggggc gtgagggcac cttctgccag 180
acagcctcgg ggcaggacgg ctctggggccc ttcctggctg acttcaacgg cttctcccac 240
ctggagctga gaggcctgca cacctttgca cgggacctgg gggagaagat ggcgctggag 300
gtcgtgttcc tggcacgagg ccccaggggc ctcctgctct acaacgggca gaagacggac 360
ggcaaggggg acttcgtgtc gctggcactg cgggaccgcc gcctggagtt cgcctacgac 420
ctgggcaagg gggcagcggc catcaggagc agggagccag tcaccctggg agcctggacc 480
agggtctcac tggagcgaaa cggccgcaag ggtgccctgc gtgtgggcca cggccccctg 540
gtgttggggg agtccccgaa atcccgcaag gttccgcaca ccgtcctcaa cctgaaggag 600
ccgctctacg tagggggcgc tcccgacttc agcaagctgg cccgtgctgc tgccgtgtcc 660
tctggcttcg acggcgccat ccagctggtc tccctcgag gccgccagct gctgaccccg 720
gagcacgtgc tgcggcaggt ggacgtcacg tcctttgag gtcaccctg caccggggcc 780
tcaggccacc cctgcctcaa tggggcctcc tgcgtcccga gggaggctgc ctatgtgtgc 840
ctgtgtcccg ggggattctc aggaccgcac tgcgagaagg ggtggtgga gaagtacgg 900
ggggacgtgg ataccttggc ctttgacggg cggacctttg tgcagtacct caacgctgtg 960
accgagagcg aactggccaa tgagatcccc gtcgagaagg cactgcagag caaccacttt 1020
gaactgagcc tgcgcactga ggccacgag gggctggtgc tctggagtgg caaggccacg 1080
gagcgggcag actatgtggc actggccatt gtggacgggc acctgcaact gagctacaac 1140
ctgggctccc agcccgtggt gctgcgttcc accgtgcccg tcaacaccaa ccgctggtg 1200
cgggtcgtgg cacatagggg gcagagggaa ggttccctgc aggtgggcaa tgaggcccct 1260
gtgaccggct cctccccgct gggcgccacg cagctggaca ctgatggagc cctgtggctt 1320
gggggcctgc cggagctgcc cgtgggocca gcaactgcca aggcctacgg cacaggcttt 1380
gtgggctgct tgcgggacgt ggtggtgggc cggcaccocg tgcacctgct ggaggacgcc 1440
gtcaccaagc cagagctgcg gcctgcccc accccatga 1479
    
```

```

<210> SEQ ID NO 36
<211> LENGTH: 492
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
    
```

<400> SEQUENCE: 36

```

Met Ser Ala Leu Leu Ile Leu Ala Leu Val Gly Ala Ala Val Ala Asp
 1           5           10          15
Tyr Lys Asp Asp Asp Lys Lys Ser Pro Cys Gln Pro Asn Pro Cys
 20          25          30
His Gly Ala Ala Pro Cys Arg Val Leu Pro Glu Gly Gly Ala Gln Cys
 35          40          45
Glu Cys Pro Leu Gly Arg Glu Gly Thr Phe Cys Gln Thr Ala Ser Gly
 50          55          60
Gln Asp Gly Ser Gly Pro Phe Leu Ala Asp Phe Asn Gly Phe Ser His
 65          70          75          80
Leu Glu Leu Arg Gly Leu His Thr Phe Ala Arg Asp Leu Gly Glu Lys
 85          90          95
Met Ala Leu Glu Val Val Phe Leu Ala Arg Gly Pro Ser Gly Leu Leu
 100         105         110
Leu Tyr Asn Gly Gln Lys Thr Asp Gly Lys Gly Asp Phe Val Ser Leu
    
```


What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the active portion of human agrin, wherein the nucleotide sequence is selected from the group consisting of:

- (a) the nucleotide sequence comprising the coding region of the active portion of human agrin contained in the vector designated as pBL-hAgrin 1 (ATCC Accession No. 97378);
- (b) a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of (a) and which encodes the active portion of human agrin; and
- (c) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from the nucleotide sequence of (a) or (b) and which encodes the active portion of human agrin.

2. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the active portion of human agrin, wherein the nucleotide sequence is selected from the group consisting of:

- (a) the nucleotide sequence as set forth in **FIG. 15**;
- (b) the nucleotide sequence encoding amino acids 24 to 492 as set forth in **FIG. 15**;
- (c) the nucleotide sequence encoding amino acids 60 to 492 as set forth in **FIG. 15**;
- (d) the nucleotide sequence encoding amino acids 76 to 492 as set forth in **FIG. 15**;
- (e) the nucleotide sequence encoding amino acids 126 to 492 as set forth in **FIG. 15**;
- (f) the nucleotide sequence encoding amino acids 178 to 492 as set forth in **FIG. 15**;
- (g) the nucleotide sequence encoding amino acids 222 to 492 as set forth in **FIG. 15**;
- (h) the nucleotide sequence encoding amino acids 260 to 492 as set forth in **FIG. 15**;
- (i) the nucleotide sequence encoding amino acids 300 to 492 as set forth in **FIG. 15**;
- (j) a nucleotide sequence that hybridizes under stringent conditions to any of the nucleotide sequences of (a) through (i) and which encodes the active portion of human agrin; and
- (k) a nucleotide sequence that, as a result of the degeneracy of the genetic code, differs from any of the nucleotide sequences of (a) through (j) and which encodes the active portion of human agrin.

3. An isolated nucleic acid molecule of claim 1 or 2, which is lacking an insert at position Y.

4. An isolated nucleic acid molecule of claim 1 or 2, which is lacking an insert at position Z.

5. An isolated polypeptide encoded by the nucleic acid molecule of claim 1, 2, 3 or 4.

6. A polypeptide of claim 5, modified by covalent attachment of a polyethylene glycol molecule.

7. A vector which comprises the isolated nucleic acid molecule of claim 1, 2, 3 or 4.

8. An expression vector comprising a nucleic acid molecule of claim 1, 2, 3 or 4 wherein the nucleic acid molecule is operatively linked to an expression control sequence.

9. A host-vector system for the production of a polypeptide having the biological activity of human agrin which comprises the vector of claim 8, in a suitable host cell.

10. The host-vector system of claim 9, wherein the suitable host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell.

11. A method of producing a polypeptide having the biological activity of human agrin which comprises growing cells of the host-vector system of claim 9 or 10, under conditions permitting production of the polypeptide and recovering the polypeptide so produced.

12. A method of promoting the growth, differentiation or survival of a MuSK receptor expressing cell comprising administering to the cell an effective amount of agrin.

13. The method of claim 12, wherein the MuSK receptor expressing cell is a cell which is normally found in muscle, heart, spleen, ovary or retina.

14. The method of claim 12 or 13, wherein the MuSK receptor expressing cell is a cell which has been genetically engineered to express the MuSK receptor.

15. An antibody capable of specifically binding the polypeptide of claim 5 or 6.

16. A monoclonal antibody of claim 15.

17. A polyclonal antibody of claim 15.

18. A method of detecting the presence of human agrin in a sample comprising:

a) reacting the sample with an antibody of claim 15, under conditions whereby the antibody binds to human agrin present in the sample; and

b) detecting the bound antibody, thereby detecting the presence of human agrin in the sample.

19. The method of claim 18, wherein the antibody is a polyclonal antibody.

20. The method of claim 18, wherein the antibody is a monoclonal antibody.

21. The method of claim 18, wherein the sample is a biological tissue.

22. The method of claim 18, wherein the sample is a body fluid.

23. The method of claim 22, wherein the body fluid is selected from the group consisting of cerebrospinal fluid, blood, serum, plasma, urine and saliva.

24. The method of claim 18, wherein the sample is a cell extract.

25. The host-vector system of claim 10, wherein the bacterial cell is *E. coli*.

26. The host-vector system of claim 10, wherein the yeast cell is *Pichia pastoris*.

27. The host-vector system of claim 10, wherein the insect cell is *Spodoptera frugiperda*.

28. The host-vector system of claim 10, wherein the mammalian cell is a COS cell.

29. The host-vector system of claim 10, wherein the mammalian cell is a CHO cell.

30. A method of treating a patient suffering from a disease or disorder affecting muscle comprising administering to the patient an effective amount of the polypeptide of claim 5 or 6, or a derivative thereof.

31. The method of claim 30, wherein the disease or disorder is muscle atrophy resulting from denervation due to

nerve trauma, degenerative, metabolic or inflammatory neuropathy, peripheral neuropathy, or damage to nerves caused by environmental toxins or drugs.

32. The method of claim 30, wherein the disease or disorder is muscle atrophy due to a motor neuropathy.

33. The method of claim 30, wherein the disease or disorder is muscle atrophy due to chronic disuse.

34. The method of claim 30, wherein the disease or disorder is muscle atrophy due to metabolic stress or nutritional insufficiency.

35. The method of claim 30, wherein the disease or disorder is muscle atrophy due to a muscular dystrophy syndrome.

36. The method of claim 30, wherein the disease or disorder is muscle atrophy due to a congenital myopathy.

37. The method of claim 30, wherein the disease or disorder is an acquired (toxic or inflammatory) myopathy.

38. A polypeptide as defined in claim 5 or 6, for use in a method of treatment of the human or animal body by therapy or in a method of diagnosis.

39. A polypeptide according to claim 38, for use in a method of treatment of the human or animal body of a disease or disorder that affects muscle.

40. A polypeptide according to claim 39, wherein the disease or disorder is muscle atrophy resulting from denervation due to nerve trauma, degenerative, metabolic or inflammatory neuropathy, peripheral neuropathy, or damage to nerves caused by environmental toxins or drugs.

41. A polypeptide according to claim 39, wherein the disease or disorder is muscle atrophy due to a motor neuropathy.

42. A polypeptide according to claim 39, wherein the disease or disorder is muscle atrophy due to chronic disuse.

43. A polypeptide according to claim 39, wherein the disease or disorder is muscle atrophy due to metabolic stress or nutritional insufficiency.

44. A polypeptide according to claim 39, wherein the disease or disorder is muscle atrophy due to a muscular dystrophy syndrome.

45. A polypeptide according to claim 39, wherein the disease or disorder is muscle atrophy due to a congenital myopathy.

46. A polypeptide according to claim 39, wherein the disease or disorder is an acquired (toxic or inflammatory) myopathy.

47. Use of a polypeptide as defined in claim 5 or 6 in the manufacture of a medicament for the treatment of a disease or disorder affecting muscle.

48. A pharmaceutical composition comprising a polypeptide as defined in claim 5 or 6 and a pharmaceutically acceptable carrier.

49. A diagnostic test kit for detecting the presence of human agrin in a sample, said kit comprising an antibody as defined in any of claims 15 to 17, and means for determining whether or not the antibody binds to human agrin, thereby allowing detection of the presence of human agrin in the sample.

50. A method of treating a patient suffering from a disease or disorder affecting muscle comprising administering to the patient an effective amount of the nucleic acid molecule of claim 1, 2, 3 or 4, or a derivative thereof.

51. A nucleic acid molecule as defined in claim 1, 2, 3 or 4, or a derivative thereof, for use in a method of treatment of the human or animal body by therapy or in a method of diagnosis.

52. A nucleic acid molecule according to claim 51, for use in a method of treatment of the human or animal body of a disease or disorder that affects muscle.

53. Use of a nucleic acid molecule as defined in claim 1, 2, 3 or 4, or a derivative thereof, in the manufacture of a medicament for the treatment of a disease or disorder affecting muscle.

54. A pharmaceutical composition comprising a nucleic acid molecule as defined in claim 1, 2, 3 or 4, or a derivative thereof, and a pharmaceutically acceptable carrier.

55. A nucleic acid molecule according to claim 1, 2, 3 or 4, or a derivative thereof, substantially as hereinbefore described.

56. A vector according to claim 7 or an expression vector according to claim 8, substantially as hereinbefore described.

57. A host vector system according to claim 9, substantially as hereinbefore described.

58. A method according to claim 11, 12, 18, 30 or 50 substantially as hereinbefore described.

59. An antibody according to claim 15 substantially as hereinbefore described.

60. A polypeptide according to claim 39 substantially as hereinbefore described.

61. Use according to claim 47 or 53 substantially as hereinbefore described.

62. A pharmaceutical composition according to claim 48 or 54 substantially as hereinbefore described.

63. A kit according to claim 49 substantially as hereinbefore described.

* * * * *

专利名称(译)	新型酪氨酸激酶受体和配体		
公开(公告)号	US20020164702A1	公开(公告)日	2002-11-07
申请号	US10/016283	申请日	2001-11-30
[标]申请(专利权)人(译)	VALENZUELA DAVID中号 玻璃大卫· BOWEN DAVIDÇ YANCOPOULOS GEORGEĐ		
申请(专利权)人(译)	VALENZUELA DAVID M. 玻璃DAVID J. BOWEN DAVID C. YANCOPOULOS GEORGE D.		
当前申请(专利权)人(译)	VALENZUELA DAVID M. 玻璃DAVID J. BOWEN DAVID C. YANCOPOULOS GEORGE D.		
[标]发明人	VALENZUELA DAVID M GLASS DAVID J BOWEN DAVID C YANCOPOULOS GEORGE D		
发明人	VALENZUELA, DAVID M. GLASS, DAVID J. BOWEN, DAVID C. YANCOPOULOS, GEORGE D.		
IPC分类号	C12N15/09 A61K31/00 A61K38/00 A61K39/00 A61K48/00 A61P21/00 C07K14/705 C07K14/71 C07K14/78 C07K14/81 C07K16/38 C07K16/40 C12N1/19 C12N1/21 C12N5/10 C12N9/12 C12N15/12 C12P21/08 C12R1/19 C12R1/84 G01N33/53 G01N33/566 C12P21/02 C12N5/06 C07H21/04 C12N9/00		
CPC分类号	A61K38/00 A61K39/00 A61K48/00 C07K14/70567 C07K16/38 C07K14/71 C07K14/78 C07K14/811 C07K14/70571 A61P21/00		
优先权	09/077955 1998-09-10 US		
其他公开文献	US6852838		
外部链接	Espacenet USPTO		

摘要(译)

本发明提供了一种称为麝香的基因，其编码在去神经肌肉中以高水平表达的新型酪氨酸激酶受体。本发明还提供了活化MuSK受体的分离的多肽。本发明进一步提供了与MuSK活化多肽功能等同的多肽。本发明还提供了可用于检测和/或测量结合麝香基因产物的配体的测定系统。本发明还提供基于激活MuSK的分子的诊断和治疗方法。

ATG	TCT	GCA	CTT	CTG	ATC	CTA	GCT	CTT	CTT	GGA	GCT	GCA	GTT	GCT	GAC
M	S	A	L	L	I	L	A	L	L	V	A	A	A	V	D
TAC	AAA	GAC	GAT	GAC	GAC	AAG	AAG	AGC	CCC	TGC	CAG	CCC	AAC	CCC	TGC
Y	R	D	D	D	D	K	K	S	P	C	Q	P	N	P	C
CAT	GGG	GGG	GGG	CCC	TGC	GCT	GTC	CGG	CCC	GAG	GCT	GCT	GCT	GAG	TGC
H	G	A	A	P	C	R	V	L	E	E	G	G	G	C	C
GAG	TGC	CCC	CTG	GGG	GCT	GAG	GGC	ACC	TTC	TGC	CAG	ACA	GCC	TGC	GGG
E	C	F	L	G	R	E	G	T	C	Q	O	T	A	S	G
CAG	GAC	GCC	TCT	GGG	CCC	TTC	CTG	GCT	AAC	TTC	AAC	GGC	TTC	TCC	CAC
Q	D	G	S	G	E	F	L	A	D	F	N	G	F	S	H
CTG	GAG	CTG	AGA	GGC	CTG	CAC	ACC	TTT	GCA	CGG	GAC	CTG	GGG	GAG	AAG
L	E	L	R	G	L	H	T	F	A	R	D	L	G	B	K
ATG	GGG	CTG	GAG	GTC	GTC	TTC	CTG	GCA	GGA	GGC	CCC	ACC	GGC	CTC	CTG
M	A	L	E	V	V	F	L	A	R	G	E	S	G	L	L
CTC	TAC	AAC	GGG	CAG	AAG	ACG	GAC	GGC	AAG	GGG	GAC	TTC	GTG	TCC	CTG
L	Y	N	G	Q	K	T	D	G	K	G	D	F	V	S	L
GCA	CTG	GGG	GAC	CGC	GGC	CTG	GAG	TTC	CGC	TAC	GAC	CTG	GGC	AAG	GGG
A	L	R	D	R	R	L	E	F	R	Y	D	L	G	K	G
GCA	GGG	GTC	ATC	AGG	AGC	AGG	GAG	CCA	GTC	ACC	CTG	GGA	GCC	TGG	ACC
A	A	V	T	R	S	R	E	F	V	T	L	G	A	W	T
AGG	GTC	TCA	CTG	GAG	GGA	AAC	GGC	CGC	AAG	GGT	GCC	CTG	GCT	GTG	GGC
D	G	S	L	E	R	N	G	R	K	G	A	L	R	G	V
GAC	GGC	CCC	GCT	GTC	TTG	GGG	GAG	TCC	CCG	AAA	TCC	CGC	AAG	GTT	CCG
D	G	P	R	V	L	G	E	S	P	K	S	E	K	V	P
CAC	ACC	GTC	CTC	AAC	CTG	AAG	GAG	CCG	CTC	TAC	GTA	GGG	GGC	GCT	CCC
H	T	V	L	N	L	A	K	E	P	L	Y	V	G	G	A
GAC	TTC	AGC	AAG	CTG	GGC	GCT	GCT	GCT	GCC	GTG	TCC	TCT	GGC	TTC	GAC
D	F	S	K	L	A	R	A	A	A	A	V	S	S	S	F
GGC	GCC	ATC	CAG	CTG	GTC	TCC	CTC	GGA	GCC	CGC	CAG	CTG	CTG	ACC	CCG
P	A	I	O	L	V	S	C	L	G	R	Q	L	L	T	P
GAG	CAC	CTG	CTG	CGG	CAG	GTG	GAC	GTC	ACG	TCC	TTT	GCA	GCT	TCC	CCC
E	H	V	L	R	S	V	D	V	T	S	F	A	G	H	F
TGC	ACC	CGG	GCC	TCA	GGC	CAC	CCC	TGC	CTC	AAT	GGG	GCC	TCC	TGC	GTG
C	T	R	A	S	G	H	F	C	L	N	G	A	S	C	V
CCG	AGG	GAG	GCT	GCC	TAT	GTG	TGC	CTG	TGT	CCC	GGG	GGA	TTC	TCA	GGA
F	R	E	R	A	Y	V	C	L	C	P	G	G	F	S	C
CCG	CAC	TGC	GAG	AAG	GGG	CTG	GTG	GAG	AAG	TCA	GGG	GGG	GAC	GTG	GAT
P	H	C	E	R	G	L	V	E	K	S	A	G	D	V	D